Acceptor specificity studies of fucosyl- and sialyltransferases by Toivonen, Suvi
Acceptor Specificity Studies of Fucosyl- and Sialyltransferases
Suvi Toivonen
Institute of Biotechnology and
Department of Biosciences, Division of Biochemistry
Faculty of Science
University of Helsinki
Finland
Academic dissertation
To be presented for public criticism, with the permission of the Faculty of Science, University of Helsinki,
 in the auditorium 1041 at Viikki Biocenter, Viikinkaari 5, Helsinki, on June 13th, 2002, at 12 oclock noon
Helsinki 2002
Supervised by
Professor Emeritus Ossi Renkonen
Department of Biosciences
University of Helsinki, Finland
Reviewed by
Professor Ilkka Mononen
Department of Clinical Chemistry
University of Turku, Finland
and
Docent Jaakko Parkkinen
Finnish Red Cross Blood Transfusion Service
Helsinki, Finland
Opponent
Professor Jukka Finne
Department of Medical Biochemistry and Molecular Biology
University of Turku, Finland
ISBN 952-10-0305-7
ISBN (ethesis) 952-10-0306-5
ISSN 1239-9469
Contents
ORIGINAL PUBLICATIONS... 5
ABBREVIATIONS...... 6
1. INTRODUCTION... 7
2. REVIEW OF THE LITERATURE... 8
2.1 Glycan structure... 8
2.1.1 Core structures.. 8
2.1.2 Capping group structures.. 8
2.2 Glycan biosynthesis. 9
2.2.1 Fucosyltransferases... 11
2.2.2 Sialyltransferases.. 15
2.3 Glycan function18
2.3.1 Functions of fucosylated glycans.. 18
2.3.2 Functions of sialylated glycans. 22
3. AIMS OF THE STUDY.. 27
4. MATERIALS AND METHODS 28
4.1 Acceptor oligosaccharides... 28
4.2 Glycosyltransferase reactions.. 29
4.2.1 Fucosyltransferase reactions. 29
4.2.2 Sialyltransferase reactions 29
4.3 Glycosidase reactions.. 30
4.3.1 β-Galactosidase reactions. 30
4.3.2 β-N-Acetylhexosaminidase reactions... 30
4.3.3 Endo-β-galactosidase reactions 30
4.3.4 Sialidase reactions.30
4.4 Chromatographic methods... 30
4.4.1 Paper chromatography.. 30
4.4.2 Gel filtration chromatography.. 30
4.4.3 Ion exchange chromatography. 31
4.5 NMR spectroscopy.. 31
4.6 Mass spectrometry... 31
5. RESULTS............................................................................................................. 32
5.1 The acceptor specificity of Fuc-TV (I) 32
5.2 The acceptor specificity of Fuc-TIX (II). 32
5.3 The site-specificity of Fuc-TV on polylactosamines (I).. 33
5.4 The site-specificity of Fuc-TIX on polylactosamines (II)... 35
5.5 Sialylation of GalNAcβ1-3Gal determinants by ST3Gal II (III). 35
5.6 The Neu5Acα2-3GalNAc linkage is resistant to Newcastle disease
virus and Streptococcus pneumoniae sialidases (III). 36
6. DISCUSSION... 37
6.1 The acceptor- and site-specificity profiles of the α1,3-fucosyltransferases 37
6.1.1 The acceptor- and site-specificity of Fuc-TV (I).. 37
6.1.2 The acceptor- and site-specificity of Fuc-TIX (II).... 37
6.2 ST3Gal II is a multifunctional sialyltransferase (III)... 39
6.3 Possible significance of α2,3-sialylation of GalNAc (III)... 40
6.4 Resistance towards Newcastle disease virus sialidase is not necessarily
indicative of α2,6-linked Neu5Ac (III).. 40
7. SUMMARY.. 41
8. ACKNOWLEDGEMENTS 43
9. REFERENCES.44
5ORIGINAL PUBLICATIONS
This thesis is based on the following original publications which are referred to in the text by
their roman numerals:
I Pykäri, M.*, Toivonen, S.*, Natunen, J.*, Niemelä, R., Salminen, H., Aitio, O., Ekström,
M., Parmanne, P., Välimäki, M., Alais, J., Augé, C., Lowe, J. B., Renkonen, O., and
Renkonen, R. (2000) The acceptor and site specificity of human α3-fucosyltransferase
V. High reactivity of the proximal and low of the distal Galβ1-4GlcNAc unit in i-type
polylactosamines J. Biol. Chem. 275, 40057-40063 (* equal contribution)a
II Toivonen, S., Nishihara, S., Narimatsu, H., Renkonen, O., and Renkonen, R. (2002)
Fuc-TIX: a versatile α1,3-fucosyltransferase with a distinct acceptor- and site-specific-
ity profile. Glycobiology, in pressb
III Toivonen, S., Aitio, O., and Renkonen, O. (2001) α2,3-Sialylation of terminal GalNAcβ1-
3Gal determinants by ST3Gal II reveals the multifunctionality of the enzyme. The result-
ing Neu5Acα2-3GalNAc linkage is resistant to sialidases from Newcastle Disease Virus
and Streptococcus pneumoniae. J. Biol. Chem. 276, 37141-37148a
aReprinted from Journal of Biological Chemistry by permission of American Society for Bio-
chemistry and Molecular Biology
bReprinted from Glycobiology by permission of Oxford University Press and Society for
Glycobiology
6ABBREVIATIONS
bFGF basic fibroblast growth factor
CD cluster of differentiation
Cer ceramide
CHO Chinese hamster ovary
DQFCOSY double-quantum-filtered correlated spectroscopy
EGF epidermal growth factor
ESL-1 E-selectin ligand 1
Fuc L-fucose
Fuc-T fucosyltransferase
Gal D-galactose
GalNAc N-acetyl-D-galactosamine
Glc D-glucose
GlcNAc N-acetyl-D-glucosamine
GlyCAM-1 glycosylated cell adhesion molecule 1
Hex hexose
HexNAc N-acetylhexosamine
HMBC heteronuclear multiple bond correlation
HMQC heteronuclear multiple quantum coherence
Lac lactose
LacdiNAc GalNAcβ1-4GlcNAc
Lea Lewis a, Galβ1-3(Fucα1-4)GlcNAc
Leb Lewis b, Fucα1-2Galβ1-3(Fucα1-4)GlcNAc
Lex Lewis x, Galβ1-4(Fucα1-3)GlcNAc
Ley Lewis y, Fucα1-2Galβ1-4(Fucα1-3)GlcNAc
LN N-acetyllactosamine (type 2), Galβ1-4GlcNAc
LNB lacto-N-biose, type 1 N-acetyllactosamine, Galβ1-3GlcNAc
MAG myelin associated glycoprotein
MALDI-TOF matrix-assisted laser desorption/ionization time-of-flight
Man D-mannose
Me methyl
MHC major histocompability complex
MOPS 3-(N-morpholino)propanesulfonic acid
NCAM neuronal cell adhesion molecule
Neu5Ac N-acetylneuraminic acid
NGF nerve growth factor
NK natural killer
NMR nuclear magnetic resonance
PDGF platelet-derived growth factor
PNA peanut agglutinin
PSGL-1 P-selectin glycoprotein ligand 1
sLex sialyl Lewis x, Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAc
sLea sialyl Lewis a, Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAc
ST sialyltransferase
TOCSY total correlation spectroscopy
TrkA tyrosine kinase A
VEGF vascular endothelial growth factor
VIM-2 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc
WEFT water-eliminated Fourier transformation
Xyl D-xylose
X2 GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc
71. INTRODUCTION
The surfaces of eukaryotic cells are covered with carbohydrates which show an enormous diver-
sity of structure. The glycans mediate a wide variety of cellular recognition events, for example
in the recruitment of leukocytes to sites of infection and their homing to lymph nodes, tumour
metastasis, neural development, angiogenesis, fertilization, signal transduction and bacterial
adhesion.
The biological functions of oligosaccharides are often carried out by the terminal elements of the
glycans. Sialylation and fucosylation are typical terminal modifications that mediate specific
functions. Both sialic acid and fucose contain structural features which distinguish them from
the monosaccharides that make up the common core structures. These structural characteristics
may be the reason why sialylated and fucosylated capping group structures are often specifically
recognized by both endogenous and exogenous lectins that mediate their functions.
Glycan biosynthesis occurs primarily through the action of glycosyltransferases. Glycan struc-
ture is determined by the sequential action of glycosyltransferases, which add one monosaccha-
ride at a time to a specific position on specific precursors. The precision of oligosaccharide
biosynthesis is achieved by the strict acceptor substrate specificity of glycosyltransferases. One
glycosyltransferase - one glycosidic linkage is an old paradigm in the field of oligosaccharide
biosynthesis. However, more recently this view has been broadened to encompass the findings
that many glycosyltransferases form redundant families, with more subtle differences in accep-
tor specificity between the members: some transferases can make two different linkages; and
some have relaxed substrate specificities, being able to transfer two different monosaccharides
or to two different monosaccharides. The clarification of the detailed specificities of the indi-
vidual members of glycosyltransferase families will eventually help us understand the different
biological roles of the various isoenzymes. The present study clarifies the detailed acceptor
specificities of the α1,3-fucosyltransferases Fuc-TV and Fuc-TIX, and the α2,3-sialyltransferase
ST3Gal II.
82. REVIEW OF THE LITERATURE
2.1 Glycan structure
Carbohydrate chains are attached to proteins and lipids on cell surfaces. Glycoproteins and  free
oligosaccharides are found in body fluids and secretions. A basic principle of glycan structure is
that each class of glycans has a limited number of common core structures, to which a diversity
of capping groups is attached to a more terminal location. The terminal capping groups are often
responsible for the biological functions of carbohydrates. This review will deal mainly with
mammalian glycosylation. For reviews of the structures described below, see (1,2).
2.1.1 Core structures
Glycoprotein glycans are N-linked to asparagine (N-glycans), or O-linked to serine or threonine
(O-glycans). Mammalian N-glycans share a common pentasaccharide core Manα1-3(Manα1-
6)Manβ1-4GlcNAcβ1-4GlcNAcβ1-Asn. On the basis of the structure that is assembled on the
core they are divided into high-mannose, hybrid and complex types. The innermost GlcNAc of
complex type N-glycans can be α1,6-fucosylated. O-glycans have four common core structures:
core 1 (Galβ1-3GalNAcα1-Ser/Thr), core 2 (Galβ1-3(GlcNAcβ1-6)GalNAcα1-Ser/Thr), core
3 (GlcNAcβ1-3GalNAcα1-Ser/Thr) and core 4  (GlcNAcβ1-3(GlcNAcβ1-6)GalNAcα1-Ser/
Thr), and some less rare GalNAc-linked cores. Less common types of O-glycosylation include
N-acetylglucosamine (3), fucose (4), or mannose (5) O-linked to serine or threonine. Of these,
O-GlcNAc has only been characterized as a monosaccharide, but O-Fuc and O-Man can be
further elongated. Heparan sulphate and chondroitin sulphate glycosaminoglycans are O-linked
to their core proteins via a Galβ1-3Galβ1-4Xyl core. Lipid-linked glycans are divided into five
families according to their core structures: ganglio- (GalNAcβ1-4Galβ1-4Glcβ1-Cer), globo-
(Galα1-4Galβ1-4Glcβ1-Cer), isoglobo- (Galα1-3Galβ1-4Glcβ1-Cer), lacto- (Galβ1-
3GlcNAcβ1-3Galβ1-4Glcβ1-Cer), and neolactoseries (Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-Cer).
In addition, the GPI-anchors of certain proteins contain a lipid-linked glycan as well.
2.1.2 Capping group structures
The core structures are often elongated by repeating Galβ1-4GlcNAcβ1-3 units called
polylactosamines. Polylactosamine chains are either linear or branched at the C6 hydroxyl of the
galactose residue. Polylactosamines on glycoproteins were first characterized in 1978 from hu-
man erythrocyte membranes by Roger Laine (6) and Heikki Rauvala (7) and their co-workers.
Subsequently polylactosamines have emerged as common oligosaccharide structures on both
glycoproteins and glycolipids (1,2).  Polylactosamine backbones carry bioactive terminal epitopes,
like the sialylated and fucosylated structures described here.
Fucosylated structures
Fucose is found α1,3-, α1,4- or α1,6-linked to N-acetylglucosamine and α1,2-linked to galac-
tose in mammalian glycans (Figure 1). α1,3-linked fucose has been characterized on type 2 N-
acetyllactosamine (Galβ1-4GlcNAc) forming the Lewis x structure (Galβ1-4(Fucα1-3)GlcNAc;
Lex), and on the so-called LacdiNAc structure (GalNAcβ1-4GlcNAc). The Lewis a structure
(Galβ1-3(Fucα1-4)GlcNAc) contains an α1,4-linked fucose on a type 1 N-acetyllactosamine.
Both Lewis x and Lewis a also occur in sialylated and sulfated forms. Lewis x epitopes are also
found as polyfucosylated sequences on polylactosamines. Lewis y (Fucα1-2Galβ1-4(Fucα1-
3)GlcNAc) and Lewis b (Fucα1-2Galβ1-3(Fucα1-4)GlcNAc) are doubly fucosylated
derivatives of Lewis x and Lewis a. In addition to Lewis y and Lewis b, α1,2-fucosylation occurs
9in the ABO-blood group determinants A, B and H, and for example in the so called fucosyl-GM1
structure. Fucose also occurs α1,6-linked to the innermost core GlcNAc of complex N-glycans,
and directly O-linked to Ser or Thr in certain proteins, where it can be elongated into an oli-
gosaccharide such as Neu5Acα2-3Galβ1-4GlcNAcβ1-3Fucα1-Ser/Thr.
Figure 1. Examples of fucosylated glycan structures
Sialylated structures
Sialic acid is a common terminal monosaccharide in a variety of glycans. Due to its negative
charge, it dramatically changes the physical and chemical properties of the glycan, which ren-
ders it capable of mediating a wide array of biological functions. Sialic acid occurs in mamma-
lian systems mainly α2,3-linked or α2,6-linked to galactose or N-acetylgalactosamine, and α2,8-
linked to another sialic acid. Sialylated glycolipids are called gangliosides. The Svennerholm
nomenclature for ganglioseries gangliosides (8) is used throughout this text. Examples of sialylated
glycan structures are presented in Figure 2.
2.2 Glycan biosynthesis
Glycan biosynthesis occurs primarily through the action of glycosyltransferases, although some
glycosidases are involved as well. The precursor oligosaccharide of N-glycans is assembled on a
dolichol lipid, and then transferred en bloc to the polypeptide by the oligosaccharyltransferase.
O-glycan biosynthesis is initiated by a polypeptide GalNAc-transferase, and glycolipid biosyn-
thesis by a glucosyl- or galactosyltransferase acting on ceramide. Glycan structure is determined
by the sequential action of glycosyltransferases, which add one monosaccharide at a time to a
specific position on specific precursors. Glycosyltransferases transfer monosaccharides from
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activated donor sugars (e.g. CMP-Neu5Ac, GDP-Fuc) to the growing glycan. The precision of
glycan biosynthesis is achieved through the strict acceptor substrate specificity of
glycosyltransferases. This review will concentrate on the acceptor specificities of the cloned
human glycosyltransferases that are responsible for the generation of fucosylated and sialylated
capping groups on various backbone structures.
Figure 2. Examples of sialylated glycan structures
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2.2.1 Fucosyltransferases
The cloned human fucosyltransferases have been designated Fuc-TI-IX. Fucosyltransferases I
and II are α1,2-fucosyltransferases, III-VII and IX α1,3/4 fucosyltransferases, and Fuc-TVIII is
an α1,6-fucosyltransferase that fucosylates the chitobiose core of N-glycans. In addition, the
protein O-fucosyltransferase I, O-FucT-I, transfers fucose directly to serine or threonine in EGF-
like repeats of certain proteins (9).
α1,3-Fucosyltransferases
Table I shows the relative reactivities of different acceptors with the cloned human α1,3-
fucosyltransferases. The data have been compiled from a set of different studies that have been
referred to in Table I. Some discrepancies exist between them. These differences may be due to
differences in enzyme constructs, the exact structure of the acceptor (e.g. the nature of a possible
aglycon), or reaction conditions such as the acceptor concentration, or the presence and nature of
detergent. When experiments are performed with cell lysates rather than with purified enzymes,
unexpected endogenous glycosyltransferase activities may occur (10,11).
Table I. The relative reactivities of different acceptor oligosaccharides with the α1,3-
fucosyltransferases.
Acceptor Fuc-TIII Fuc-TIV Fuc-TV Fuc-TVI Fuc-TVII Fuc-TIX
LN + +++ +++ +++ - +++
Neu5Acα2,3LN + + +++ +++ +++ -
Neu5Acα2,6LN - - - - -
Fucα1,2LN ++ +++ +++ +++ - +++
Galα1,3LN + +++ +++
6-sulfo-LN - ++ ++
6'-sulfo-LN - - -
3'-sulfo-LN + ++ +++ +++ + +
Lac + - + - - -
Fucα1,2Lac ++ + ++ + -
Neu5Acα2,3Lac + - - -
LNB +++ - + - - -
Neu5Acα2,3LNB ++ - + -
Fucα1,2LNB +++ + ++ - -
Galα1,3LNB +++ - ++
LacdiNAc + +++ - ++
Galβ1-3GalNAc - - - - - -
references (12,14-19, (14-16,33, (14-16,36, (32,35,36, (33,50,51, (58-60)
36,60) 36,60) 60) 38,60) 60)
+++: the best acceptor for the transferase in question, or having reactivity close to the best reactivity, ++: reactiv-
ity about half of that of the best acceptor, +: weak reactivity, -: no or very weak reactivity, blank: no information
available
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Fuc-TIII
Fuc-TIII was the first human α1,3-fucosyltransferase to be cloned in 1990 (12). Fuc-TIII is
thought to correspond to the purified fucosyltransferase known as the Lewis enzyme (13),
since it has both α1,3- and α1,4-fucosyltransferase activities, being able to fucosylate both Galβ1-
4GlcNAc (type 2 lactosamine, LN) and Galβ1-3GlcNAc (type 1 lactosamine, LNB) (12). Fuc-
TIII strongly prefers type 1 lactosamine acceptors to type 2 acceptors (12,14,15). In some sys-
tems Fuc-TIII has been reported to be completely inactive towards Galβ1-4GlcNAc (16-18).
α1,2-fucosylated lactosamines are better acceptors for Fuc-TIII than the corresponding
unsubstituted ones, whereas α2,3-sialylated lactosamines are slightly less effective acceptors
(14,15,17-19). Additionally, Fuc-TIII transfers to Glc in lactose (12,15,16), α1,2-fucosyllactose
(15,16) and α2,3-sialyllactose (16), and to the reducing end glucose of Galβ1-4GlcNAcβ1-
3Galβ1-4Glc and Galβ1-3GlcNAcβ1-3Galβ1-4Glc; a bifucosylated product is formed from the
latter acceptor (19).
Analysis of glycolipids from Fuc-TIII transfected cells has shown that Fuc-TIII is able to make
both Lex and sLex in vivo as well (20). Fuc-TIII synthesizes sLex and Lex in the ratio 14:1 on the
N-glycans of β-trace protein in vivo, transferring preponderantly one fucose per diantennary N-
glycan (21). Fuc-TIII has also been shown to be able to generate the VIM-2 epitope, that is to
fucosylate the penultimate N-acetyllactosamine unit in a sialylated polylactosamine (22). When
LNβ1-3LNβ1-3LN-2AB is used as the acceptor, Fuc-TIII strongly prefers the middle LN unit
as the acceptor site (the reducing end GlcNAc is not likely to be available for fucosylation in this
kind of acceptor, as it has been reductively aminated) (23).
Fuc-TIII is expressed at high levels in colon, stomach, small intestine, lung and kidney (24).
Inactivating point mutations in the Fuc-TIII gene account for the Lewis negative (Le(a-b-)) phe-
notype on erythrocytes and secretions observed in 10% of Caucasians (25,26). An increased risk
of atherosclerotic disease has been associated with Le(a-b-) phenotype, but the mechanism of
this effect is unclear (27,28).
Fuc-TIV
Fuc-TIV has been independently cloned by three groups (29-31). It corresponds to the my-
eloid type of fucosyltransferase activity (13). Fuc-TIV fucosylates preferentially neutral type 2
N-acetyllactosamine (30,31). It does not react with type 1 acceptors (16,31,32), and reacts very
weakly if at all with Neu5Acα2-3Galβ1-4GlcNAc (16,30,31,33). Fuc-TIV reacts very effec-
tively with Fucα1-2Galβ1-4GlcNAc, generating the Lewis y epitope (14). Galα1-3Galβ1-
4GlcNAc is a good acceptor, and N-acetyllactosamines sulfated at the 3-position of Gal or at the
6-position of GlcNAc show moderate reactivity (14). The analysis of glycolipids from Fuc-TIV
transfected cells supports the view that Fuc-TIV synthesizes Lex rather than sLex (20). In the
analysis of β-trace protein N-glycans, Fuc-TIV shows a sLex/Lex ratio 1:7 (21).
Like Fuc-TIII, Fuc-TIV fucosylates inner LN units within a polylactosamine chain. Fuc-TIV-
transfected cells synthesize the VIM-2 epitope (Neu5Acα2-3LNβ1-3Lex)  (30,31). It has been
shown that Fuc-TIV prefers the inner LN units to the non-reducing end LN unit in both sialylated
and non-sialylated polylactosamine acceptors (34). In sialylated polylactosamine acceptors the
sialylated LN unit is virtually non-reactive, whereas in neutral polylactosamines the differences
between the reactivities of the different LN units are less dramatic (34).
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Fuc-TV
Fuc-TV is highly homologous to Fuc-TIII, but has a slightly different acceptor specificity profile
(15). Fuc-TV reacts with both sialylated and non-sialylated type 2 N-acetyllactosamine, and
weakly with type 1 N-acetyllactosamine and lactose (15). In in vivo studies Fuc-TV has been
shown to synthesize both Lex and sLex on both glycolipids (20) and glycoproteins (21), with a
slight preference towards sialylated structures. In addition, α1,2'-fucosylated, α1,3'-galactosylated,
3'-sulfated and 6-sulfated derivatives of LN serve as acceptors in vitro (14-16,35,36). (3 de-
notes modification at the 3-hydroxyl of the second monosaccharide residue from the reducing
end, in this case Gal, whereas 3 would  refer to modification at the reducing end monosaccharide
residue, in this case GlcNAc.) Fuc-TV is able to react with chito-oligosaccharides, forming a
terminal GlcNAcβ1-4(Fucα1-3)GlcNAc determinant (37). Like Fuc-TIII and Fuc-TIV, Fuc-TV
preferentially fucosylates the inner LN unit in a polylactosamine chain (23). Fuc-TV expression
is restricted to liver, colon and testicle (24). The detailed acceptor- and site-specificity of Fuc-
TV has been studied in the present thesis (part I).
Fuc-TVI
The enzymatic properties of cloned Fuc-TVI correspond to the fucosyltransferase previously
known as plasma type (13,35,38). Fuc-TVI reacts with sialylated and non-sialylated type 2 N-
acetyllactosamine (32,35,36,38). The reactivities of type 1 lactosamine (32,36,38) and lactose
(36,38) are very weak or non-existent. α1,2'-Fucosylated or 3'-sulfated type 2 lactosamines react
efficiently (32,36). Additionally, Fuc-TVI has been shown to be able to fucosylate GlcNAcβ1-
4GlcNAc (37).
Fuc-TVI makes both Lex and sLex on glycolipids in vivo (20). Fuc-TVI prefers longer glycolip-
ids as acceptors than Fuc-TIII, -IV, -V and -VII, but the structures of the products have not been
analyzed in detail (20). Fuc-TVI makes equal amounts of Lex and sLex on a glycoprotein sub-
strate in vivo, and efficiently fucosylates both branches of a biantennary N-glycan, unlike Fuc-
TIII, -IV, -V and -VII, which predominantly make monofucosylated N-glycans (21).
The site-specificity of Fuc-TVI seems to be different on sialylated and non-sialylated
polylactosamines. Fuc-TVI preferentially fucosylates the inner LN unit in LNβ1-3LNβ1-3LN-
2AB, and virtually no difucosylated product is formed (23). However, Fuc-TVI transfected CHO
cells do not stain with anti-VIM-2 antibodies, but do stain with anti-difucosyl-sLex (Neu5Acα2-
3Lexβ1-3Lex) antibodies (35). The clarification of the site-specificity of Fuc-TVI on sialylated
and non-sialylated polylactosamines will require experiments where both types of acceptors are
analyzed under the same experimental setup.
Fuc-TVI is expressed in liver, kidney, small intestine, colon, salivary gland, bladder, and uterus
(24). Fuc-TVI in liver has been found to be essential for the fucosylation of acute phase proteins
(39). Liver Fuc-TVI is also the major source of the α1,3-fucosyltransferase activity in plasma
(39,40). In addition to the Golgi, Fuc-TVI has rather surprisingly been shown to be localized in
the Weibel-Palade bodies of human endothelial cells (41). Individuals having a missense muta-
tion in the Fuc-TVI gene show no obvious pathologies, indicating that Fuc-TVI function is
dispensable in humans, or that other fucosyltransferases can compensate for the lack of Fuc-TVI
(40).
Fuc-TIII, Fuc-TV and Fuc-TVI genes are highly homologous to each other (12,15,35,38). They
form a cluster on human chromosome 19p13.3 (42). Fuc-TIII, -V and -VI are thought to have
originated by duplication events in human evolution, since only one homologue has been found
from the bovine genomic library (43). This bovine gene is thought to be an orthologous
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homologue of the ancestor of the human Fuc-TIII, -V and -VI genes (43). The bovine α1,3-
fucosyltransferase shows an acceptor specificity profile similar to human Fuc-TVI, consistent
with the finding that bovine tissues do not express α1,4-fucosylated structures (43). Despite
their high sequence homology, human Fuc-TIII, -V and -VI have different acceptor specificity
profiles, as discussed above. Domain swapping experiments, sequence alignment of α1,3- and
α1,3/4-fucosyltransferases, and site-directed mutagenesis experiments have demonstrated that
only a few amino acids determine whether or not the fucosyltransferases can use type 1
lactosamines as substrates, and thus conform to their distinct acceptor specificity profiles (44-
48).
Fuc-TVII
Fuc-TVII exhibits strict specificity towards α2,3-sialylated type 2 lactosamines (49,50). The
reactivity of non-sialylated and type 1 acceptors is very weak or non-existent, depending on the
assay conditions (33,50,51). Fuc-TVII prefers sialylated N-acetyllactosamines to non-sialylated
ones also when studied in vivo with glycoprotein (21) and glycolipid (20) acceptors. Fuc-TVII is
able to react with Neu5Acα2-3Galβ1-4(SO3-6)-GlcNAc, generating the L-selectin ligand 6-
sulfo sLex (52).
The site-specificity of Fuc-TVII is also strict. Fuc-TVII has been shown to fucosylate Neu5Acα2-
3LNβ1-3LNβ1-3Lacβ1-Cer glycolipid only at the non-reducing end, sialylated LN unit (53).
Similar results have been obtained by using oligosaccharide acceptors: Fuc-TVII transfers pref-
erentially to the non-reducing end, sialylated LN unit of both Neu5Acα2-3LNβ1-3LNβ1-
3Galβ1-OMe and Neu5Acα2-3LNβ1-3LNβ1-3LN (34). Fuc-TVII prefers the non-reducing
end site also on prefucosylated polylactosamines: Neu5Acα2-3LNβ1-3Lexβ1-R type accep-
tors react efficiently, whereas Neu5Acα2-3Lexβ1-3LNβ1-R type acceptors react only weakly
(34,51).
Fuc-TIV and Fuc-TVII are expressed on leukocytes, and they are thought to collaborate in the
biosynthesis of selectin ligands (for discussion on selectins and selectin ligands, see section
2.3.1). They seem to be at least partially specialized in the way that Fuc-TVII directs the expres-
sion of P-selectin binding glycoforms of P-selectin glycoprotein ligand 1 (PSGL-1) and controls
the rolling frequency of leukocytes, whereas Fuc-TIV directs the expression of E-selectin bind-
ing glycoforms of E-selectin ligand 1 (ESL-1) and dictates rolling velocity (54,55). Fuc-TVII-
deficient mice show defects in their selectin ligand activity and leukocyte recruitment in inflam-
mation (52). However, prominent selectin ligand activities remain in these mice, whereas in
mice deficient in both Fuc-TIV and Fuc-TVII nearly all selectin ligand activity and leukocyte
recruitment is absent (56). In the light of the complementary site-specificities of Fuc-TIV and
Fuc-TVII (34), it seems likely that the biosynthesis of the complete repertoire of optimal ligands
for all three of the selectins involves both internal and distal fucosylation of polylactosamine
chains.
An individual having an inactivating missense mutation in his Fuc-TVII gene has been diag-
nosed with ulcer disease, non-insulin-dependent diabetes, osteoporosis, spondylarthrosis, and
Sjögrens syndrome, but does not have a history of recurrent bacterial infections or leukocytosis
(57).
Fuc-TIX
Fuc-TIX transfers fucose to non-sialylated type 2 lactosamine, but not to α2,3-sialylated type 2
lactosamine, or to type 1 lactosamine (58). 3'-sulfated type 2 lactosamine reacts weakly (59).
α1,2'-fucosylated type 2 lactosamine is a good acceptor, but α1,2-fucosylated type 1 lactosamine
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does not react (60). Lactose is non-reactive as well (60). LacdiNAc (GalNAcβ1-4GlcNAc) shows
moderate reactivity (60). Fuc-TIX shows unique site-specificity on LNβ1-3LNβ1-3LN-2AB:
it preferentially fucosylates the non-reducing end LN unit (23). The acceptor and site-specificity
of Fuc-TIX has been studied in detail in this thesis (part II).
Fuc-TIX has a low degree of homology to the other α1,3/4 fucosyltransferases, and is phyloge-
netically quite distant from them (58). In contrast, the Fuc-TIX gene sequence is highly con-
served between human, mouse, rat and hamster (58,61-63), indicating that it has been under
strong selective pressure during evolution, and thus suggesting that it has an essential role in the
organisms.
Fuc-TIX has a more restricted expression pattern than the other α1,3/4-fucosyltransferases. It is
expressed as transcripts of different lengths in different tissues and developmental stages (58,60).
Notably, Fuc-TIX is abundantly expressed in both the developing and mature brain (58,60). The
expression of the Fuc-TIX product, the Lewis x epitope, is developmentally regulated in the
brain, and it is thought to be involved in brain morphogenesis, as discussed in section 2.3.1.
Pax6, a transcription factor involved in brain patterning and neurogenesis, controls the spatially
and temporally restricted expression of the Lewis x epitope in the developing rat brain by regu-
lating Fuc-TIX gene expression (64). A concomitantly occurring increase in the amounts of
Lewis x bearing glycolipids and increased expression of Fuc-TIX has been observed during
neural differentiation of PC19 embryonal carcinoma cells induced by retinoic acid (65).
Fuc-TIX has been shown to direct the synthesis of CD15 (non-sialylated Lewis x) on mature
granulocytes (66), but its possible role in the selectin ligand biosynthesis remains to be eluci-
dated. It is possible that Fuc-TIX accounts for the residual neutrophil infiltration in experimen-
tally induced inflammation seen in mice that lack both Fuc-TIV and Fuc-TVII (56).
α1,2- and α1,6-Fucosyltransferases
Fuc-TI and Fuc-TII are α1,2-fucosyltransferases. Fuc-TI (H-enzyme) regulates the expression
of the H antigen (Fucα1-2Gal) on erythrocyte membranes (67). Fuc-TII (Secretor enzyme) regu-
lates the expression of the H antigen in the secretory fluids and digestive mucosa (68). Fuc-
TVIII is an α1,6-fucosyltransferase, that fucosylates the chitobiose (GlcNAcβ1-4GlcNAc) core
of N-glycans (69). Phylogenetic analysis indicates that the vertebrate α1,2-, α1,3/4- and α1,6-
fucosyltransferase gene families have evolved by duplications, translocations, and divergent
evolution from a single ancestral gene (70,71).
2.2.2 Sialyltransferases
Sialyltransferases transfer sialic acid from CPM-Neu5Ac to glycolipids and glycoproteins. To
date, six α2,3-sialyltransferases, seven α2,6-sialyltransferases and five α2,8-sialyltransferases
have been cloned. All sialyltransferases cloned to date contain a conserved region called a
sialylmotif, which is involved in binding the donor substrate CMP-Neu5Ac (72). Conserved
cysteines in the sialylmotif form a disulfide linkage that seems to be essential for proper confor-
mation and activity of the enzymes (73).
Nomenclature of sialyltransferases
The naming of sialyltransferases used to be rather confusing. Multiple names were given to the
same enzyme, and even the same name was given to different enzymes. The names did not give
sufficient information for distinguishing the different transferases. In 1996 a systematic nomen-
clature was proposed (74), and since then it has become universally used. This system comprises
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four elements, for example the CMP-Neu5Ac: Galβ1-4GlcNAc α2,6-sialyltransferase is abbre-
viated ST6Gal I, where ST denotes sialyltransferase, 6 means that it is an α2,6-sialyltransferase,
Gal is the acceptor sugar to which sialic acid is transferred, and I is the numeral assigned con-
secutively to each new gene in the subgroup. In the following sections the older names for the
sialyltransferases are indicated in parenthesis following the current denotation. Unless other-
wise stated, the data refer to human sialyltransferases.
α2,3-Sialyltransferases
ST3Gal I (ST3O, ST3GalA.1, SiaT-4a, SAT-4, ST-2, ST3Gal-Ia)
ST3Gal I transfers sialic acid to Galβ1-3GalNAc, but not to Galβ1-3GlcNAc or Galβ1-4GlcNAc
(75-77). Mouse ST3Gal I has been shown to prefer glycoprotein acceptors (asialofetuin) to gly-
colipid acceptors (GM1 and asialo GM1) in vitro (78). The acceptor specificities of α2,3-
sialyltransferases are summarized in Table II.
Table II. Relative reactivities of different acceptors with the α2,3-sialyltransferases
Acceptor ST3Gal I  ST3Gal II ST3Gal III  ST3Gal IV  ST3Gal V  ST3Gal VI
Galβ1-4GlcNAc - - ++ ++ +++
Galβ1-3GlcNAc - - +++ + +
Galβ1-3GalNAc +++ +++ + +++ -
Galβ1-4Glc - + +
lactosylceramide - - + +++ -
asialo GM1 ++ +++ - +++ - -
asialofetuin +++ ++ +++ +++ - ++
references (76,77) (83,84) (77,87) (77,92) (98,101) (100)
+++: the best acceptor for the transferase in question, or having reactivity close to the best reactivity, ++: reactiv-
ity about the half of that of the best acceptor, +: weak reactivity, -: no or very weak reactivity, blank: information
not available
ST3Gal I is expressed in many tissues. High levels are found in heart, placenta, lung, liver,
skeletal muscle, kidney, pancreas, spleen and peripheral blood leukocytes (76). Expression of
ST3Gal I is elevated in breast cancer cells, associated with the synthesis of the cancer-associated
epitope sialyl T (Neu5Acα2-3Galβ1-3GalNAcα1-Ser/Thr) (79,80).
ST3Gal I-deficient mice show increased apoptosis of CD8+ T-cells (81). Activation of T-cells is
associated with desialylation of core 1 O-glycans and concomitant increase in core 2 biosynthe-
sis (82). The activated T-cells bearing core 2 O-glycans are destined for either apoptosis, or
differentiation into memory cells, which is accompanied by the reappearance of sialylated core 1
O-glycans as the predominant O-glycan structure (81). Therefore it can be assumed that ST3Gal
I is involved in the regulation of T-cell homeostasis.
ST3Gal II (ST3O-II, ST3GalA.2, SiaT-4b, ST3Gal-Ib)
Like ST3Gal I, ST3Gal II uses Galβ1-3GalNAc as an acceptor determinant (83,84). Galβ1-
4GlcNAc and Galβ1-3GlcNAc are not sialylated by ST3Gal II (83). Mouse ST3Gal II prefers
glycolipid acceptors to glycoprotein acceptors in vitro (78). Species-specific differences exist in
the tissue expression patterns of ST3Gal II. Human ST3Gal II is expressed in heart, liver, skel-
etal muscle and lymphoid tissues, but not in brain or kidney (83), whereas in mouse and rat the
expression of ST3Gal II is restricted to the brain and liver (85). ST3Gal II-deficient mice
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accumulate ST3Gal II substrates GM1a and GD1b, but yet have significant amounts of the prod-
ucts GD1a and GT1b, possibly due to the action of ST3Gal I (86). The acceptor specificity of
ST3Gal II was further studied in this thesis (part III).
ST3Gal III (ST3N, ST3GalB, ST-3, ST3Gal II)
ST3Gal III sialylates both Galβ1-3GlcNAc and Galβ1-4GlcNAc, the type 1 lactosamine being
the preferred acceptor (87). Lactose and Galβ1-3GalNAc are poor acceptors (77,87). A com-
mercial cloned α2,3-sialyltransferase, supposedly ST3Gal III, has been reported to be able to
sialylate Galβ1-3GlcNAc where the 6-hydroxyl of GlcNAc has been substituted by sulphate or
sialic acid (88). Rat ST3Gal III has been shown to prefer tri- and tetra-antennary N-glycans to
biantennary N-glycans, and intact glycoproteins to glycopeptides (89), suggesting that it recog-
nizes larger structures than the acceptor disaccharide determinant.
ST3Gal III is strongly expressed in liver, skeletal muscle, testis, and many fetal tissues (76,87).
ST3Gal III expression level in the female rat pituitary gland has been shown to be regulated by
oestrogens, and to be associated with the changes in the sialylation status of follicle-stimulating
hormone, affecting its charge-isoform distribution and biological activity (90). An unexpected
post-Golgi localization of ST3Gal III on the apical membrane of rat kidney tubule cells has been
demonstrated (91).
ST3Gal IV (ST3O/N, ST3GalC, SiaT-4c, SAT-3, ST-4, STZ, ST3Gal III)
ST3Gal IV sialylates Galβ1-3GalNAc, Galβ1-4GlcNAc and it poorly sialylates Galβ1-3GlcNAc
and lactose (77,92). ST3Gal IV has been shown to sialylate both glycolipids and glycoproteins
presenting Galβ1-3GalNAc or Galβ1-4GlcNAc determinants (77). ST3Gal IV is strongly ex-
pressed in the placenta, testis and ovary (76). Cell type-specific transcriptional regulation has
been described for ST3Gal IV in epithelial and leukemia cell lines (93,94). Transfection with
ST3Gal IV has been shown to confer increased expression of sialyl Lewis x in Namalwa cells
(92), suggesting a possible role in the selectin ligand biosynthesis. ST3Gal IV, together with
Fuc-TVII, is rapidly upregulated upon activation of CD4+ T-cells, resulting in the synthesis of P-
selectin ligands and migration into inflamed tissue (95) (for selectins and selectin ligands see
section 2.3.1). ST3Gal IV is upregulated in the hippocampus of the mouse following kindled
seizures, suggesting that it may be involved in neural plasticity (96). ST3Gal IV-deficient mice
have a markedly reduced number of platelets and have a significant increase in bleeding time,
but the exact role of ST3Gal IV in hematopoiesis and hemostasis remains to be studied (97).
ST3Gal V (GM3 synthase)
GM3 synthase initiates the biosynthesis of the ganglio-series gangliosides by converting
lactosylceramide into GM3 (Neu5Acα2-3Galβ1-4Glcβ1-Cer) (98). ST3Gal V is expressed tis-
sue specifically, predominantly in the brain, skeletal muscle and testis (98). ST3Gal V has been
shown to localize to axons in addition to the Golgi in mouse and rat neurons (99).
ST3Gal VI
ST3Gal VI shows a strict acceptor specificity towards type 2 lactosamines (100). Both glycopro-
teins and glycolipids containing Galβ1-4GlcNAc serve as acceptors for ST3Gal VI, but those
containing Galβ1-3GlcNAc or Galβ1-3GalNAc do not. Free Galβ1-4GlcNAc oligosaccharide
reacts readily with ST3Gal VI, Galβ1-3GlcNAc reacts weakly and Galβ1-3GalNAc not at all.
Lactosylceramide is not an acceptor for ST3Gal VI (100).
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α2,6-Sialyltransferases
ST6Gal I is the only known sialyltransferase that sialylates the 6-position of galactose (102,103).
ST6GalNAc I and ST6GalNAc II sialylate the GalNAc in GalNAcα1-Ser/Thr, Galβ1-
3GalNAcα1-Ser/Thr and Neu5Acα2-3Galβ1-3GalNAcα1-Ser/Thr (104-107). ST6GalNAc I and
ST6GalNAc II require glycopeptide acceptors; they are inactive towards oligosaccharides and
glycolipids containing the appropriate acceptor determinants (104,107). ST6GalNAc III has only
been cloned from the mouse and rat so far (108,109). ST6GalNAc III and ST6GalNAc IV sialylate
Neu5Acα2-3Galβ1-3GalNAc determinants in glycoprotein and glycolipid acceptors, but are
inactive towards non-sialylated Galβ1-3GalNAc (108,110). ST6GalNAc V seems to be specific
for GM1b (Neu5Acα2-3Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-Cer): it does not react with other
glycolipids, or glycoproteins containing the Neu5Acα2-3Galβ1-3GalNAc determinant.
ST6GalNAc V has only been cloned from the mouse so far, and it is expressed specifically in the
brain (111,112). Mouse ST6GalNAc VI sialylates GM1b, GT1b and GD1a, but not glycopro-
teins (113).
α2,8-Sialyltransferases
ST8Sia I (GD3 synthase) is specific for GM3 (114-116). ST8Sia II (STX) and ST8Sia IV (PST)
are α2,8-sialyltransferases capable of synthesizing polysialic acid (117,118). Polysialic acid is
an α2,8-linked sialic acid polymer that occurs specifically on the embryonic form of the neural
cell adhesion molecule and a limited number of other proteins, as discussed in section 2.3.2.
ST8Sia III sialylates the sialic acid in Neu5Acα2-3Galβ1-4GlcNAc (119), and ST8Sia V sialylates
the α2,3-sialylated gangliosides GM1b, GD1a, GT1b and GD3, but not GM3 (120).
2.3. Glycan Function
Since sialylated and fucosylated epitopes are usually situated terminally in glycan structures,
they are in a position which is easily accessible to lectins. Moreover, sialic acid and fucose have
distinct structural characteristics that make them different from the monosaccharides that make
up the common core structures. Therefore it is not surprising that a large proportion of the known
glycan functions are associated with the sialylated and fucosylated structures. The next sections
describe some examples of these, concentrating on the best-characterized phenomena and recent
findings.
2.3.1. Functions of fucosylated glycans
The importance of fucosylated glycan structures is highlighted by the clinical manifestations of
LAD II (leukocyte adhesion deficiency II; also known as CDG-IIc, congenital disorder of
glycosylation IIc), a disorder where the GDP-fucose transporter, that provides the donor GDP-
fucose for all fucosyltransferases, is defective (121). LAD II patients are deficient in all fucosylated
glycans. Children suffering from LAD II have distorted facial features and frontal cerebral atro-
phy leading to severe psychomotor retardation. They suffer from growth retardation, general
failure to thrive, and immunodeficiency leading to recurrent infections (122-124).
The selectins and their fucosylated ligands mediate vascular cell adhesion
The selectins mediate the primary adhesion and rolling step of the leukocyte extravasation cas-
cade leading to leukocyte infiltration into inflamed tissue and homing to lymph nodes, reviewed
in (125,126). Three selectins are known: L-selectin that is constitutively expressed by most
leukocytes, P-selectin that is transported from storage vesicles to cell surface of endothelial cells
and platelets as a response to inflammatory mediators, and E-selectin whose expression is in-
duced on inflamed endothelium. All selectins bind to the sialyl Lewis x tetrasaccharide (127),
19
Figure 3. Selectin ligand oligosaccharides
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but their high-affinity biological ligands are more complex structures carried by specific pro-
teins, and for a large part they are yet uncharacterized.
Several putative L-selectin glycoprotein ligands that carry sialylated and fucosylated oligosac-
charides have been characterized (126,128). The best known oligosaccharide structures occur-
ring on a L-selectin ligand are the O-glycans of mouse glycosylated cell adhesion molecule 1
(GlyCAM-1); the core 2 structures carrying 6- and 6-sulfated sialyl Lewis x (Figure 3) (129).
However, mice that lack a core 2 GlcNAc-transferase show normal lymphocyte homing (130).
L-selectin ligands in these mice carry 6-sulfated sialyl Lewis x on an extended core 1 structure
(Figure 3) (131). These observations indicate that the core 2 structure is not indispensable for L-
selectin binding. CD34 is another L-selectin ligand glycoprotein. CD34 from human tonsillar
high endothelial venules carries a sialylated, sulfated and fucosylated O-glycan, with a proposed
structure where 6-sulfated sLex is β1,3-linked to the core 1 galactose (Figure 3) (132).
The best-characterized selectin-glycoprotein interaction is that between P-selectin and P-selectin
glycoprotein ligand 1 (PSGL-1). PSGL-1 glycosylation has been characterized from the human
promyelocytic cell line HL-60. PSGL-1 carries sialyl Lewis x on sialylated core 2, and a larger
structure containing trivalent Lex (Figure 3) (133). Sulfation at specific tyrosines of the protein
backbone is needed for binding to P-selectin (134). Binding studies and X-ray crystallography
using a glycopeptide model containing the tyrosine sulfations and the O-glycan indicate that
there is a stereospecific interaction between P-selectin and PSGL-1, to which each of the three
tyrosine sulfates, the peptide backbone, and fucose/sialic acid on an optimally positioned core 2
O-glycan each contribute distinctly (135,136). E-selectin has been shown to bind sialylated,
multiply fucosylated polylactosamines on glycoproteins such as ESL-1 (137,138), and glycolip-
ids (139).
Many fucosylated glycans are tumour-associated antigens
Elevated expression of several fucosylated antigens is associated with malignant transforma-
tion. These include Lex (140), dimeric Lex (141), sLex (142), sialyl dimeric Lex (140,143), Ley
(144), Lea (145), sLea (146), Leb (145), fucosyl GM1 (Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-
3)Galβ1-4Glcβ1-Cer) (147) and globo H (Fucα1-2Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-
Cer) (148). sLex, sialyl dimeric sLex and sLea have been proposed to have a role in hematogeneous
metastasis of cancer, where malignant cells would adhere to the endothelial lining via E or P-
selectin in a manner analogous to leukocyte adhesion (149,150). The expression of these anti-
gens has been correlated with increased the metastatic potential of tumours and poor prognosis
for cancer patients (151-153).
Fucosylated glycans play roles in fertilization and embryonic development
The molecular details of mammalian gamete adhesion remain for the large part unresolved.
There is, however, substantial evidence that mammalian gamete adhesion is carbohydrate-medi-
ated (154). Fucosylated glycans, such as Lewis x and sialyl Lewis x, have been proposed to be
involved in high affinity sperm-egg adhesion (155,156).
The expression of many fucosylated oligosaccharide antigens is tightly regulated both spatially
and temporally during development (157). The Lewis x epitope first appears at the 8-16 cell
stage, thus correlating with the onset of compaction of the embryo (158). It has been proposed
that homotypic interaction between Lewis x epitopes is involved in embryonal compaction
(159,160).
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The expression of Lewis x is thought to have a role in neural development. Lewis x is transiently
expressed at defined regions of the developing brain, and often appears during critical stages of
development (161-163). The amount of Lewis x bearing glycolipids has been shown to dramati-
cally increase during the course of neural differentiation of PC19 embryonal carcinoma cells
induced by retinoic acid (65). Lewis x has been implicated in glial-neuronal cell adhesion (164),
and the segregation of cells to form different regions (165). It has not been established whether
these adhesion events are mediated by homotypic Lex-Lex adhesion, or by a yet uncharacterized
lectin with Lewis x binding activity. A glycoprotein bearing the Lewis x determinant is ex-
pressed in cell-cell contact- and the differentiation state-dependent fashion by corneal epithelial
cells during development (166). The Lewis x epitope is also selectively expressed by cell popu-
lations undergoing important morphogenetic steps during the development of the pancreas (167),
kidney (168) and lung (169).
Fuc-TI and its product the type 2 H-antigen define a unique expression pattern in the developing
prostate and regulate epithelial cell proliferation during prostatic branching morphogenesis (170).
O-linked fucose is involved in the regulation of cell signalling
The EGF modules of certain proteins are glycosylated by fucose directly O-linked to serine or
threonine (5). The Notch receptors function in cell-fate decisions, proliferation and apoptosis
during development (171). The Fringe family of glycosyltransferases modify the ability of Notch
to respond to its ligands by transferring a β1,3-linked GlcNAc to O-linked fucose on Notch
(172). This structure is then elongated into Neu5Acα2-3Galβ1-4GlcNAcβ1-3Fucα1-O-Ser/Thr
(172). O-linked fucose has also been shown to be essential for the growth factor activity of
urokinase-type plasminogen activator (173) and signalling activity of Cripto (174).
Bacteria use fucosylated glycans on host cell surface for adhesion
Many bacteria, viruses and toxins adhere to host cell surface carbohydrates. It has been sug-
gested that the evolutionary selection pressures of external origin, mediated by pathogens that
recognize glycans, are an important factor driving the diversification of glycans (175). A Lewis
bbinding adhesin has been characterized from Helicobacter pylori, a human pathogen that
causes gastric ulcers and cancer (176). The intracellular parasite that causes granulocytic erlichiosis
in humans specifically adheres to fucosylated PSGL-1 in a manner that mimics P-selectin bind-
ing (177). Fucosylated oligosaccharides of human milk inhibit the binding of various gastric
pathogenic agents such as enteropathogenic Escherichia coli (EPEC), Campylobacter jejuni,
and the heat stable enterotoxin of E. coli to their host cells (178). It has been postulated that the
great diversity of free oligosaccharides found in human milk serves to protect the infant from
bacterial infection.
Fucosylated glycans mediate angiogenesis
Fucosylated carbohydrate structures have been implicated to have a role in the induction of
angiogenesis. Selectins and their carbohydrate ligands seem to have a versatile role in the mul-
tiple events that occur during inflammatory responses. Monoclonal antibodies against sialyl
Lewis x and sialyl Lewis a inhibit capillary morphogenesis in a bovine in vitro model (179).
Furthermore, soluble E-selectin has been shown to induce chemotaxis of human endothelial
cells, and induce angiogenesis in rat cornea (180). On the basis of these observations it has been
proposed that after the binding of leukocytes to endothelial cells, E-selectin expressed on the
cell surface is cleaved and shed, and then recruits and activates endothelial cells (181). A selectin-
independent carbohydrate-mediated signalling system may also contribute to angiogenesis. A
carbohydrate structure that is recognized by an antibody against Lewis y and H-antigens is rap-
idly up-regulated on human endothelial cells by several cytokines and its amount is increased in
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rheumatoid arthritis synovial fluid. Glucose analogues of Lewis y and H trisaccharides are chemo-
tactic to human endothelial cells and induce angiogenesis in rat cornea (182).
2.3.2 Functions of sialylated glycans
The sialic acid-binding immunoglobulin superfamily lectins (Siglecs) mediate many dif-
ferent recognition and signalling phenomena
The Siglecs, sialic acid-binding immunoglobulin superfamily lectins, are a family of sialic-acid
binding lectins that have sequence homology and share structural similarities (183). Ten Siglecs
have been characterized to date (184). Their tissue expression, sialic acid recognition specifici-
ties and functions vary (Table III). The CD33-related Siglecs (Siglecs 3 and 5-10) contain con-
served immunoreceptor tyrosine-based inhibition motifs (ITIMs) in their cytoplasmic tails, sug-
gesting that they may be regulatory receptors in the immune system (184).
Siglecs 1-3 are expressed by different subsets of hematopoietic cells: Siglec 1 (sialoadhesin) by
subsets of macrophages (185), Siglec 2 (CD22) by mature resting B-cells (186,187), and Siglec
3 by (CD33) by myeloid progenitors, monocytes and macrophages (188). Sialoadhesin binds to
gangliosides and glycoproteins containing terminal α2,3-linked sialic acid (189), whereas CD22
binds specifically to Neu5Acα2-6Galβ1-4GlcNAc on N-glycans (190). Siglecs 1-3 are thought
to be involved in the regulation of the immune system. Sialoadhesin is thought to mediate inter-
actions of developing myeloid cells in the bone marrow (191) and lymphocyte trafficking (192).
CD22 is proposed to have roles in the regulation of B-cell signalling (193), and B-cell homing to
bone marrow (194). CD22-deficient mice show evidence of dysregulation of B-cell responses
and expanded numbers of peritoneal B-cells (195,196). Mice that lack ST6Gal I, and therefore
lack CD22 ligands, present a phenotype that partially overlaps with that of CD22 knock out
mice, including a severe immunodeficiency (197). CD33 has been proposed to have a regulatory
role in hematopoiesis and the myeloid cell maturation, since mAb-mediated crosslinking of
CD33 inhibits the proliferation of myelomonocytic cell precursors (198) and generation of den-
dritic cells from monocytes (199).
Siglec 4, also called myelin associated glycoprotein (MAG), is expressed by myelin forming
oligodendrocytes and Schwann cells (200,201). Various neuronal gangliosides bearing a termi-
nal Neu5Acα2-3Galβ1-3GalNAc determinant have been proposed to be ligands for Siglec 4
(202). Additional sialic acid residues linked to the inner core, especially Neu5Acα2,6 on the
GalNAc, enhance binding affinity (203). However, there is also evidence of glycoprotein ligands
(204,205). Siglec 4 participates in myelin-axon interactions. Siglec 4 deficient mice have altered
periaxonal architecture (206,207), and they exhibit demyelination and axonal degeneration when
they get older than 8 months (208). In addition to its apparent role in myelin organization, Siglec
4 has been shown to promote neurite outgrowth from neonatal neurons, but inhibit axonal growth
from adult neurons (209). The inhibition of neurite outgrowth is mediated by Siglec 4 binding to
ganglioside GT1b with subsequent activation of Rho-kinase (210).
The newly cloned Siglecs 5-10 are less well characterized when it comes to their binding speci-
ficity and function. Siglec 5 is expressed by neutrophils and monocytes (211). Siglec 6 is ex-
pressed at high levels in placenta, and at moderate levels in B-cells, spleen and small intestine
(212). Siglec 6 binds specifically to Neu5Acα2-6GalNAc (sialyl-Tn antigen) (212), whereas
Siglec 5 exhibits the least specificity of the Siglecs for sialic acid linkage: it binds to α2,8-linked
as well as to α2,3- and α2,6-linked Neu5Ac (189). Siglec 7 is a putative inhibitory receptor on
NK-cells (213,214). It recognizes gangliosides containing the disialyl sequence Neu5Acα2-
8Neu5Ac or an internal Neu5Acα2,6-branch (215,216). Siglecs 8-10 are specifically expressed
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by different subsets of hematopoietic cells and bind to both α2,3- and α2,6-sialyllactose (217-
219).
An eleventh Siglec has recently been cloned and named human Siglec-like molecule (Siglec-L1)
(220) and S2V (221). Interestingly, in this Siglec a conserved arginine known to be essential for
sialic acid binding has been mutated (220). The chimpanzee orthologue of Siglec-L1 retains the
arginine and is fully functional, showing a binding preference toward N-glycolylneuraminic
acid (220). It has been postulated that the mutation in human Siglec-L1 is evolutionarily related
to the loss of N-glycolylneuraminic acid in human evolution (see the discussion about modified
sialic acids below).
Table III. The Siglecs.
Siglec other names expression binding specificity function
Siglec 1 sialoadhesin macrophages Neu5Acα2,3 myeloid cell development?,
lymphocyte traffic?
Siglec 2 CD22 B-cells Neu5Acα2-3Galβ1-4 regulation of B-cell signaling
GlcNAc
Siglec 3 CD33 myeloid Neu5Acα2-3/6Gal hematopoeisis, myeloid cell
progenitors, maturation?
monocytes,
macrophages
Siglec 4 MAG myelin forming Neu5Acα2-3Galβ1-3 myelin stability, regulation of
cells (Neu5Acα2-6)GalNAc neurite outgrowth
Siglec 5 OB-BP2 neutrophils, Neu5Acα2,3/6/8 ?
monocytes,
macrophages,
B-cells
Siglec 6 OB-BP1, placenta, B-cells Neu5Acα2-6GalNAc ?
CD33L
Siglec 7 p75/AIRM1 NK cells, Neu5Acα2-8Neu5Ac
monocytes, or internal Neu5Acα2,6 regulation of NK cell activa-
dendritic cells tion?
Siglec 8 eosinophils Neu5Acα2,3/6 ?
Siglec 9 neutrophils, terminal Neu5Acα2,3/6 ?
monocytes,
NK cells, B-cells
Siglec 10 eosinophils, Neu5Acα2,3/6 ?
dendritic cells,
NK cells, B-cells
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Gangliosides modulate signal transduction
Gangliosides are thought to have roles in cell-cell recognition, cell-matrix interactions, and growth
and differentiation of cells, especially neurons, but most of these events are poorly characterized
at the molecular level, reviewed in (222,223). The functions of gangliosides as Siglec ligands
were discussed in the previous section. An emerging theme of ganglioside function is their roles
as receptor modulators. Gangliosides and tyrosine kinase receptors associate with each other in
specialized microdomains of the cell membrane (224). Many of the experiments described be-
low involve incubation of cells with exogenous gangliosides. The results obtained this way
should be interpreted with caution, as culture conditions may affect the incorporation of ganglio-
sides, and depending on the cell line, many exogenously added gangliosides become rapidly
metabolized into others. Therefore it is not uncommon that conflicting results about the effect of
gangliosides on growth factor receptors are obtained (225,226)
Exogenously added ganglioside GM1 has neurotrophic and neuritogenic effects both in vivo and
in vitro (227-229). These effects are mediated by potentiation of the action of nerve growth
factor (NGF): GM1 facilitates the dimerization and autophosphorylation of the NGF receptor
tyrosine kinase A (TrkA) (230). Depletion of PC12 cells of glycosphingolipids inhibits the ac-
tion NGF and abolishes TrkA autophosphorylation. These effects can be reversed by addition of
GM1 to the culture medium, but not by other gangliosides (231). GM3 inhibits epidermal growth
factor (EGF) -stimulated phosphorylation of the EGF receptor (232). The role of GM3 in the
negative regulation of EGF signalling is supported by studies showing that cells with decreased
amounts of gangliosides, especially GM3, either because of a metabolic defect in ganglioside
biosynthesis (233) or overexpression of a specific sialidase (234) show increased EGF receptor
autophosphorylation. Specific gangliosides have also been proposed to modulate signalling
mediated by PDGF (235), interleukin-2 (236), bFGF (237), insulin (238), and VEGF (239).
Sialylation influences the activity and survival of T-cells
CD8 on immature T-cells binds the PNA lectin, which is specific for the core 1 (Galβ1-3GalNAc)
structure (240). When T-cells mature, PNA-binding is lost due to sialylation of Galβ1-3GalNAc
by ST3Gal I (82,241). Mature T-cells show a diminished ability to bind soluble class I MHC
tetramers as compared to immature T-cells. This switch has been attributed to the Neu5Acα2-
3Galβ1-3GalNAc structure on mature T-cells (242,243). Alteration in the domain-domain asso-
ciation or orientation of the CD8αβ coreceptor stalk by the carbohydrate have been proposed as
a possible mechanism for the change in avidity (243). Activation of T-cells is associated with
desialylation of core 1 O-glycans and concomitant increase in core 2 biosynthesis (82). The
activated T-cells bearing core 2 O-glycans are destined for either apoptosis mediated by galectin-
1 (244,245), or differentiation into memory cells, which is accompanied by the reappearance of
sialylated core 1 O-glycans as the predominant O-glycan structure (81). ST3Gal I-deficient mice
show increased apoptosis of CD8+ T-cells (81). These observations show that the Neu5Acα2-
3Galβ1-3GalNAc structure generated by ST3Gal I has an important role in the regulation of T-
cell activity and homeostasis.
A sialylated glycan regulates cell adhesion mediated by α-dystroglycan binding to laminin
α-Dystroglycan carries an unusual mannose-linked O-glycan, which is elaborated by a sialylated
N-acetyllactosamine: Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-Ser/Thr (246,247). This struc-
ture is essential for the binding of α-dystroglycan to laminin (246). Mutation of the β1,2-N-
acetylglucosaminyltransferase involved in the biosynthesis of this structure causes muscular
dystrophy and neuronal migration disorder (248).
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Sialylated glycans and microbial pathogenesis
The attachment of bacteria, their toxins, and viruses to host tissue is considered to be essential
for the pathogenic processes elicited by these agents. Many bacteria, toxins and viruses use
sialylated glycans on host cell surface as receptors (249-251). Some examples are presented
below.
Bacterial adhesins
In addition to binding to Lewis b, as mentioned in section 2.3.1, Helicobacter pylori has at least
two different sialic acid-binding specificities, but the identity of the sialic acid-binding adhesins
and their detailed specificities remain obscure. The first binding specificity is towards Neu5Acα2-
3Gal and it is expressed when bacteria are grown on agar (252,253). The second binding speci-
ficity remains, when the bacteria are grown in broth and it is associated with Neu5Acα2-3Gal on
complex polyglycosylceramides (254,255). The specific binding of H. pylori to sialylneolacto-
hexaosylceramide and sialylneolacto-octaosylceramide isolated from human gastric adenocar-
cinoma has been demonstrated (256). S-fimbriated E. coli which cause meningitis in infants
bind to glycoproteins carrying Neu5Acα2-3Gal on O-glycans (257). Interestingly, certain strains
of Streptococcus suis which cause meningitis in piglets, similarly bind to terminal Neu5Acα2-
3Gal, but in the context of a polylactosamine chain (258). Other sialic acid-binding bacteria
include Mycoplasma pneumoniae, which binds to gangliosides (259), and Haemophilus
influenzae, which binds to sialylated polylactosamines (260).
Bacterial toxins
Cholera toxin and the heat-labile enterotoxin from Escherichia coli bind to GM1 ganglioside,
whereas tetanus toxin requires the internal disialyl sequence found in the GT1b series of gan-
gliosides (261). Clostridium botulinum neurotoxins use gangliosides such as GT1b and GD1a as
coreceptors together with synaptotagmin (262). Pertussis toxin from Bordetella pertussis binds
to sialic acid on glycoproteins (263,264).
Viruses
The binding specificity of influenza virus hemagglutinin is dependent on the species of origin of
the virus; most human influenza virus isolates preferentially bind to Neu5Acα2-6Gal (265,266).
Influenza pandemics have been accompanied by the evolution of the receptor binding site from
the narrower type found in avian viruses, that preferentially accommodates the α2,3-linkage, to
the wider type with the preference to α2,6-linkage, found in human isolates (267). Specific
recognition of larger ganglioside structures by influenza viruses has been implicated, although
the detailed structure of the receptor remains unclear (268). Sendai virus binds to gangliosides
containing the Neu5Acα2-3Galβ1-3GalNAc sequence, and shows highest affinity towards GQ1b
(269). Mouse polyomavirus binds to α2,3-linked sialic acid (270), whereas the human
polyomavirus JC binds to α2,6-linked sialic acid (271).
Molecular mimicry
Sialic acid is also used by pathogens as a means of evading host immune response. Some bacte-
ria make polysaccharides that resemble or are identical to host glycoconjugates, which makes
them poorly immunogenic. Examples include the polysialic acid containing capsule of certain
strains of Neisseria meningitidis and E. coli (272), and the α2,3-sialylated lipo-oligosaccharide
of N. meningitidis and N. gonorrhoeae (273).
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Sialylated glycans as tumour-associated antigens
As mentioned earlier in the context of fucosylated oligosaccharides, aberrant glycosylation is a
feature often associated with malignant transformation. A general increase in cell surface
sialylation has been shown to correlate with metastatic potential (274,275).
An altered ganglioside profile is a common feature of many types of tumours. For example, GD3
expression is often enhanced in tumours as compared to normal tissue (276), and high level of
GD3 has been associated with malignancy of the tumour (277) and poor survival of patients
(278). Suppression of GD3 synthesis reduces cell migration, tumour growth, metastasis, angio-
genesis, and vascular endothelial growth factor production of rat neuroblastoma cells (279,280).
This indicates that gangliosides, specifically GD3, are involved in the regulation of tumour
growth, possibly by stimulating angiogenesis. Other cancer-associated gangliosides include GD2
(281), GM2 (282,283), GT3 (282), and α2,6- and α2,3-sialylated lacto- and neolactoseries gan-
gliosides (284-286). Tumour cells have been observed to shed gangliosides (287,288), which
may have immunosuppressive activity (289-291).
In addition to gangliosides, the expression of many protein-associated carbohydrate antigens is
altered in cancer. Enhanced expression of the sialyl T (292) and sialyl Tn (293,294) antigens,
resulting from underprocessing of O-glycans (295), is a common feature of many cancer cells.
Re-expression of polysialic acid on neuronal cell adhesion molecule (NCAM) has been reported
in some tumours (296,297) (normally NCAM is polysialylated only in fetal tissues, as discussed
below). Sialylated glycoconjugates bearing N-glycolylneuraminic acid are found on some hu-
man tumours (298). This is rather unexpected, since as discussed in the section modified sialic
acids, the human CMP-Neu5Ac hydroxylase gene has an exon deletion.
Polysialic acid modulates the function of the neuronal cell adhesion molecule
Polysialic acid, a linear homopolymer of α2,8-linked sialic acid, occurs in mammals almost
exclusively on one protein, the embryonic form of NCAM (272). Polysialic acid modulates cell
adhesion mediated by NCAM during cell migration, axon pathfinding and synaptogenesis, and
thus has important functions in the development of the nervous system (299). NCAM is the
major polysialic acid carrying protein in mammals, but this modification also occurs on the
sodium channel α-subunit (300), on the polysialyltransferases that are responsible for its biosyn-
thesis (301), and on integrin α5 subunit, where it mediates binding to fibronectin (302).
Modified sialic acids
The term sialic acid is commonly used to refer to N-acetylneuraminic acid (Neu5Ac), al-
though in fact the sialic acids are a family of 9-carbon acidic sugars (303). The most common
sialic acids in mammals are N-acetylneuraminic acid (Neu5Ac), 9-O-acetylated N-
acetylneuraminic acid (Neu5,9Ac) and N-glycolylneuraminic acid (Neu5Gc). Humans are ex-
ceptional, because a mutation in CMP-sialic hydroxylase has resulted in the loss of Neu5Gc,
making Neu5Ac the predominant sialic acid in humans (304). The sialic acid modifications
affect the biological functions of the molecules carrying them. For example, 9-O-acetylation is
developmentally regulated, and also regarded as an onco-developmental antigen - it has been
shown to reappear in cancer tissue (305,306). The presence of 9-O-acetylated N-acetylneuraminic
acid or N-glycolylneuraminic acid also affects sialic acid recognition by pathogens (307,308)
and endogenous lectins like Siglecs (189,220,309,310)
27
 3. AIMS OF THE STUDY
The aim of this study was to study the function of fucosyl- and sialyltransferases by
1. Determining the detailed acceptor specificity profiles of Fuc-TV (I) and Fuc-TIX (II), as well
as their site-specificities on polylactosamine acceptors.
2. Studying enzymatic synthesis of the Neu5Acα2-3GalNAc linkage (III).
and additionally to use the oligosaccharide containing Neu5Acα2-3GalNAc generated by ST3Gal
II to study its susceptibility to sialidases (III).
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4. MATERIALS AND METHODS
4.1 Acceptor oligosaccharides
LN (I,II), Galβ1-3GlcNAc (I,II), chitobiose (I,II) and Galβ1-4LN (II) were from Sigma. Manβ1-
4GlcNAc (I), Fucα1-2LN (II) Neu5Acα2-6LN (II) and GalNAcβ1-3Gal (III) were from Dextra
(Reading, UK). Chitotriose (I) and chitotetraose (I) were from Seikagaku (Tokyo, Japan). Lac-
tose (II) was from BDH Chemicals (Poole, UK). 2'-Fucosyllactose (II) was from Biocarb (Lund,
Sweden). Neu5Acα2-3LN (I,II) was from Oxford Glycosystems (Abingdon, UK). Globo-N-
tetraose (III) was from Accurate Chemical and Scientific Corporation (Westbury, NY).
LNβ1-OMe (I), LNβ1-2Man (I,II), LNβ1-6Gal (I,II), LNβ1-3Galβ1-OMe (I,II), LNβ1-6Manα1-
OMe (I, II), LNβ1-4GlcNAc (I) and 6-SO3-LN (II) were synthesized by using bovine milk β1,4-
galactosyltransferase (Sigma) from GlcNAcβ1-OMe (Sigma), GlcNAcβ1-2Man (Glyko, Novato,
CA), GlcNAcβ1-6Gal (Sigma), GlcNAcβ1-3Galβ1-OMe (Sigma), GlcNAcβ1-6Manα1-OMe
(Sigma), chitobiose and 6-SO3-GlcNAc (Sigma), respectively, essentially as described in (311).
GalNAcβ1-4GlcNAc (I) and GalNAcβ1-4GlcNAcβ1-OMe (I, II) were synthesized from GlcNAc
(Sigma) and GlcNAcβ1-OMe, respectively, by bovine milk β1,4-galactosyltransferase using
UDP-GalNAc as a donor, as described in (312).
GlcNAcβ1-3LN (I,II), LNβ1-3LN (I,II), LNβ1-3LNβ1-OMe (I), LNβ1-3LNβ1-3Galβ1-OMe
(I), GlcNAcβ1-3LNβ1-3LN (II) and LNβ1-3LNβ1-3LN (I) were synthesized by consecutive
β1,4-galactosyltransferase and β1,3-GlcNAc-transferase (human serum) reactions as described
in (313).
Galβ1-3(LNβ1-6)GalNAc (I,II) was synthesized from Galβ1-3GalNAc (Sigma) by using β1,6-
GlcNAc-transferase (hog gastric mucosa) and bovine milk β1,4-galactosyltransferase as described
in (314). LNβ1-3'(LNβ1-6')LN (I,II) was synthesized from LN by using human serum β1,3-
GlcNAc transferase, hog gastric β1,6-GlcNAc transferase and bovine milk β1,4-galactosyl-
transferase as described in (315).
Galβ1-3GlcNAcβ1-3LNβ1-3Galβ1-OMe (I) was prepared by galactosylating GlcNAcβ1-
3LNβ1-3Galβ1-OMe with β1,3/4-galactosyltransferase activity present in Colo 205 cells, treat-
ing the resulting mixture with β1,4-galactosidase from Diplococcus pneumoniae to remove se-
lectively the β1,4-linked galactose from LNβ1-3LNβ1-Galβ1-OMe, and purifying the intact
Galβ1-3GlcNAcβ1-3LNβ1-3Galβ1-OMe from the mixture by gel filtration chromatography.
Lexβ1-3LN (I) was obtained from LNβ1-3LN by successive β1,6-GlcNAc-transferase (hog
gastric mucosa), α1,3-fucosyltransferase (recombinant human Fuc-TVI, Calbiochem, La Jolla,
CA) and β-N-acetylhexosaminidase (jack bean, Sigma) reactions, as described in (316). LNβ1-
3Lexβ1-3Galβ1-OMe (I) and LNβ1-3LNβ1-3Lex (I) were synthesized from GlcNAcβ1-
3LNβ1-3Galβ1-OMe and GlcNAcβ1-3LN, respectively, by first fucosylating with α1,3-
fucosyltransferase (recombinant human Fuc-TVI) and then elongating the chains to their full
length with β1,4-galactosyltransferase (bovine milk) and β1,3-GlcNAc-transferase (human se-
rum) reactions, essentially as described in (317,318). Lexβ1-3LNβ1-3LN (I) was synthesized
by first protecting the two most reducing end LN units by β1,6-GlcNAc transferase present in
rat serum, then fucosylating the free non-reducing end LN unit with recombinant human Fuc-
TVI, and finally removing the β1,6-linked GlcNAc:s by β-N-acetylhexosaminidase (jack bean).
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LNβ1-3LNβ1-3LNβ1-3LN (I,II) was chemically synthesized as described in (319).
LNβ1-2Manα1-3(LNβ1-2Manα1-6)Manβ1-4GlcNAc (I,II) and LNβ1-2(LNβ1-4)Manα1-
3[LNβ1-2(LNβ1-6)Manα1-6]Manβ1-4GlcNAc (I) were a gift from Prof. G. Strecker (Université
des Sciences et Technologies de Lille, Villeneuve DAscq, France). LNβ1-2(LNβ1-4)Manα1-
3(LNβ1-2Manα1-6)Manβ1-4GlcNAc (I) was prepared from the corresponding α2,6-sialylated
oligosaccharide (also from Prof. Strecker) by desialylation with Arthrobacter ureafaciens sialidase.
All the α2,3-sialylated acceptors in parts I and II were synthesized from the corresponding neu-
tral oligosaccharides by using recombinant rat ST3Gal III (Calbiochem). Neu5Acα2-3Lexβ1-
3LN (II) was synthesized in the same way as Lexβ1-3LN, but with a sialylation step preceding
fucosylation, as described in (318).
GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc (III) was synthesized from Galβ1-4GlcNAcβ1-
3Galβ1-4Glc (a gift from Prof. R. Cummings, University of Oklahoma) essentially as described
in (320), by using ammonium sulphate precipitate of human serum as the enzyme source (321),
and UDP-GalNAc as the donor.
4.2 Glycosyltransferase reactions
4.2.1 Fucosyltransferase assays (I, II)
GDP-[14C]fucose (100 000 cpm, Amersham Pharmacia Biotech), GDP-fucose (1 nmol, Sigma)
and the individual acceptors (50 nmol) were incubated for 1 h at 37 °C in 10 µl of 50 mM MOPS
pH 7.2, 10 mM fucose, 5 mM ATP and 0.5% Triton X-100 and lysates of transfected cells (30-
50 µg protein). Fuc-TV transfected CHO cells (I) were prepared as described in (15), and they
contained 17-25 µU fucosyltransferase activity per mg lysate protein (1 U = 1 µmol/min).  Fuc-
TIX transfected Namalwa cells (II) were prepared as described in (58), and they contained 53-
100 µU fucosyltransferase activity per mg lysate protein. The Fuc-TV reaction mixtures, but not
the Fuc-TIX reaction mixtures, also contained 10 mM MnCl2. The reactions were terminated by
adding 10 µl of ethanol followed by 100 µl of ice cold water. To rule out possible activation of
endogenous fucosyltransferase activity the substrate specificity of each batch of Fuc-TV trans-
fected CHO cell lysates was tested with LN, LNB and Neu5Acα2-3LN before the actual ex-
periments to ascertain that the reactivity profile with these acceptors conformed to the unique
specificity of Fuc-TV. Fuc-TIX experiments were carried out with a single batch of Namalwa
cells lysates. The specificity profile was indicative of Fuc-TIX and no other known α1,3-
fucosyltransferase. In both series of experiments the acceptors were monitored by gel filtration
chromatography with UV-detection after incubation. No significant acceptor degradation by
glycosidases was observed.
4.2.2 Sialyltransferase reactions (III)
ST3Gal II reactions. 600 nmol of acceptor oligosaccharide and 2.4 µmol of CMP-Neu5Ac were
incubated with 40 mU of rat recombinant ST3Gal II (α2,3-(O)-sialyltransferase, Calbiochem) in
50 mM sodium cacodylate pH 6.0, 0.02% NaN3, 0.05% BSA and 8 mM MnCl2 in a reaction
volume of 600 µl for 6 days at room temperature. 20 mU of fresh enzyme was added on day 3.
The reactions were terminated by boiling for 3 minutes.
ST3Gal III reactions. 49 nmol of acceptor oligosaccharide and 100 nmol of CMP-Neu5Ac were
incubated with 3.2 mU of rat recombinant ST3Gal III (α2,3-(N)-sialyltransferase, Calbiochem)
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in 100 mM MOPS-NaOH pH 7.5, 0.02% NaN3, and 8 mM MnCl2 in a reaction volume of 12.5
µl for 6 days at room temperature.
4.3 Glycosidase reactions
4.3.1 β-Galactosidase reactions (I, II)
Jack bean β-galactosidase (Sigma or Seikagaku) reactions were carried out as described in (322).
4.3.2 β-N-Acetylhexosaminidase reactions
Jack bean β-N-acetylhexosaminidase (Sigma) reactions used in the structural analysis of α1,3-
fucosyltransferase products (I, II) were carried out as described in (322). Jack bean β-N-
acetylhexosaminidase reactions used to characterize the GalNAc-terminating oligosaccharides
in part II were carried out in a similar manner but in the exhaustive conditions described in
(323).
4.3.3 Endo-β-galactosidase reactions (I, III)
Endo-β-galactosidase digestions with Bacteroides fragilis (Roche Molecular Biochemicals, Basel
Switzerland) and Escherichia freundii (Seikagaku) endo-β-galactosidases were performed as
described in (324).
4.3.4 Sialidase reactions
Sialidase reactions in part III were performed in 40 µl reaction volume and 75 µM substrate
concentration. The reactions were incubated for 20 h at 37°C and terminated by boiling for 3
minutes. Clostridium perfringens sialidase (New England Biolabs, Beverly, MA) reactions
were carried out in 50 mM Na-phosphate buffer pH 4.5 with 167 mU of enzyme; Newcastle
disease virus sialidase (Roche molecular biochemicals) reactions in 50 mM Na-phosphate
buffer pH 5.5 with 8 mU of enzyme; and Streptococcus pneumoniae sialidase (Calbiochem)
reactions in 50 mM Na-phosphate buffer pH 4.5 with 20 mU of enzyme.
Arthrobacter ureafaciens sialidase (Glyko) (I, II, III) reactions were carried out as described
in (325).
4.4 Chromatographic methods
4.4.1. Paper chromatography (I, II)
Descending paper chromatography of radiolabelled oligosaccharides was carried out as described
in (326), using the upper phase of n-butanol:acetic acid:water (4:1:5) (solvent A) as the eluant.
4.4.2 Gel filtration chromatography
Gel filtration in a Superdex Peptide HR 10/30 column (Amersham Pharmacia Biotech) was
carried out as described in (34).
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4.4.3 Ion exchange chromatography
The acceptors and reaction products of fucosyltransferase assays (I, II) were desalted and sepa-
rated from unreacted donor in a mixed bed of ion exchange resins (Dowex AG-50 and Dowex
AG-1 from Bio-Rad). The neutral oligosaccharides were eluted with water and the anionic oli-
gosaccharides were eluted with 0.5 mM acetic acid as described in (38).
Anion exchange chromatography in a MonoQ (5/5) column (Amersham Pharmacia Biotech) (I,
II, III) was carried out essentially as described in (314).
4.5 NMR spectroscopy (III)
Prior to the NMR experiments the saccharides (400-600 nmol) were lyophilized twice from D2O
and then dissolved in 40 µL of D2O (99.996 atom %). The NMR experiments were carried out
on a Varian Unity 500 spectrometer at 23°C using a gHX nano-NMR probe (Varian). A spinning
rate of 2000 Hz was used. In recording 1D proton spectra a modification of the WEFT sequence
(327) was used. The DQFCOSY and TOCSY experiments were carried out essentially as in
(328).
For the gradient HMQC (329) and gradient HMBC experiments (330,331) (32 and 128 scans
per t1 value, respectively), matrices of 2k*256 and 2k*128 points were recorded and zero-filled
to 2k*512 and 2k*256 points, respectively and a shifted sine-bell function was used. The aver-
age 1H-13C coupling constant was estimated to be 140 Hz and ∆2 was 63.5 ms. The spectral
widths F1 and F2 were 11250 Hz and 2400 Hz respectively.
4.6 Mass spectrometry
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry of
reaction products was performed with a BIFLEX mass spectrometer (Bruker-Franzen Analytik,
Bremen, Germany). The neutral oligosaccharides were analyzed essentially as in (318) and the
sialylated oligosaccharides as in (332,333).
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5. RESULTS
5.1 The acceptor specificity of Fuc-TV (I)
Lysates of CHO cells transfected with full-length human Fuc-TV reacted efficiently with N-
acetyllactosamine (LN). The transfer rate was 1.0-1.5 nmol fucose per hour per mg lysate pro-
tein at 5 mM acceptor concentration (33-50 µg lysate protein, 0.55-1.3 µU fucosyltransferase
activity). The relative Fuc-TV reactivities of various oligosaccharides, together with their Fuc-
TIX reactivities, are shown in Table IV. It can be noted that Fuc-TV reacted efficiently with N-
acetyllactosamine and GalNAcβ1-4GlcNAc (LacdiNAc). The reactivity of the type I lactosamine,
Galβ1-3GlcNAc, with Fuc-TV was 13% of the reactivity of the type 2 lactosamine. Chitobiose
and Manβ1-4GlcNAc were very poor acceptors.
The addition of a β1,3-linked GlcNAc on the non-reducing side of LN greatly enhanced its
reactivity. Sialylation tended to enhance the reactivity as well: most α2,3-sialylated acceptors
reacted better than the corresponding neutral ones.
The O-glycan analogue Galβ1-3(LNβ1-6)GalNAc was a good acceptor for Fuc-TV. LNβ1-2Man
was quite an inefficient acceptor, whereas LNβ1-6Manα1-OMe reacted much more efficiently.
The relative reactivities of LNβ1-6Gal and LNβ1-3Galβ1-OMe further supported the idea that
LN units linked to the 6-position of the adjacent monosaccharide are favoured as acceptors. The
Fuc-TV reactivities of the N-glycan analogs LNβ1-2(LNβ1-4)Manα1-3[LNβ1-2(LNβ1-
6)Manα1-6]Manβ1-4GlcNAc and LNβ1-2(LNβ1-4)Manα1-3(LNβ1-2Manα1-6)Manβ1-
4GlcNAc were 130% and 140% respectively of the reactivity of a single unconjugated LN.
5.2 The acceptor specificity of Fuc-TIX (II)
The relative reactivities of various oligosaccharide acceptors with Fuc-TIX are shown in Table
IV. Lysates of Namalwa cells transfected with full-length human Fuc-TIX reacted efficiently
with N-acetyllactosamine (LN). The transfer rate was 3.2-6.0 nmol fucose per hour per mg
lysate protein at 5 mM acceptor concentration  (28 µg lysate protein, 1.5-2.8 µU fucosyltransferase
activity). In addition to LN, GalNAcβ1-4GlcNAcβ1-OMe, 6-SO3-LN and Fucα1-2LN reacted
well, and chitobiose (GlcNAcβ1-4GlcNAc) appreciably well. Type 1 N-acetyllactosamine (Galβ1-
3GlcNAc), lactose, Fucα1-2Lac, Galβ1-4LN, Neu5Acα2-6LN and Neu5Acα2-3LN were
virtually unreactive.
The addition of β1,3-linked GlcNAc to the non-reducing end of the acceptor LN unit reduced its
reactivity slightly, as did the addition of Gal to the reducing end as could be seen with LNβ1-
6Gal and LNβ1-3Galβ1-OMe. In contrast to Fuc-TV, Fuc-TIX preferred LNβ1-3Galβ1-OMe to
LNβ1-6Gal.
The N-glycan analogue LNβ1-6Manα1-OMe showed the highest reactivity of all the tested gly-
cans. LNβ1-2Man and LNβ1-2Manα1-3(LNβ1-2Manα1-6)Manβ1-4GlcNAc reacted moder-
ately well. LNβ1-2Man was a better acceptor for Fuc-TIX than for Fuc-TV. The O-glycan ana-
logue Galβ1-3(LNβ1-6)GalNAc also had a high reactivity.
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Table IV. Comparison of the relative reactivities of small oligosaccharide acceptors with Fuc-
TV and Fuc-TIX.
Acceptor Relative Fuc-TV Relative Fuc-TIX
reactivity reactivity
Galβ1-4GlcNAc (LN) 1.0 1.0
Galβ1-4GlcNAcβ1-OMe 1.0 n.d.
Galβ1-3GlcNAc (LNB) 0.13 0.04
Galβ1-4Glc n.d. 0.01
GlcNAcβ1-4GlcNAc 0.04 0.20
GalNAcβ1-4GlcNAc 0.82 n.d.
GalNAcβ1-4GlcNAcβ1-OMe 1.2 0.84
Manβ1-4GlcNAc 0.03 n.d.
6-SO3-LN n.d. 0.40
Neu5Acα2-3LN 1.7 0.05
Neu5Acα2-6LN n.d. 0.02
Fucα1-2Lac n.d. 0.03
Fucα1-2LN n.d. 0.51
GlcNAcβ1-3LN 3.5 0.71
Galβ1-4LN n.d. 0.18
Galβ1-4GlcNAcβ1-4GlcNAc 0.9 n.d.
LNβ1-6Gal 1.4 0.50
LNβ1-3Galβ1-OMe 0.39 0.81
LNβ1-2Man 0.2 0.46
LNβ1-6Manα1-OMe 1.6 1.1
LNβ1-2Manα1-3(LNβ1-2Manα1-6)
Manβ1-4GlcNAc 0.37 0.71
LNβ1-2(LNβ1-4)Manα1-3[LNβ1-2
(LNβ1-6)Manα1-6]Manβ1-4GlcNAc 1.3 n.d.
LNβ1-2(LNβ1-4)Manα1-3(LNβ1-2
Manα1-6)Manβ1-4GlcNAc 1.4 n.d.
Galβ1-3(LNβ1-6)GalNAc 3.0 0.87
Neu5Acα2-3LNβ1-6Gal 3.8 n.d.
Neu5Acα2-3LNβ1-3Galβ1-OMe 1.1 n.d.
Neu5Acα2-3LNβ1-2Man 0.6 n.d.
Neu5Acα2-3LNβ1-6Manα1-OMe 3.7 n.d.
Neu5Acα2-3Galβ1-3(LNβ1-6)GalNAc 2.5 n.d.
The figures represent the mean values of at least two experiments.
n.d. not determined
5.3 The site-specificity of Fuc-TV on polylactosamines (I)
The Fuc-TV products were degraded by sialidase (only the sialylated saccharides) and then by a
mixture of β-galactosidase and β-N-acetylhexosaminidase to determine which GlcNAc residue
was fucosylated in the multisite acceptors. The latter digestion removes all fucose-free LN units
from the non-reducing end of the desialylated polylactosamines, but is unable to act on α1,3-
fucosylated LN units. Thus, the desialylated chains were shortened in a way that established the
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positions of the α1,3-fucosylated LN units. Products of these digestions were analyzed by paper
chromatography to derive the site-specificity data shown in Figure 4.
Fuc-TV clearly preferred the most reducing end LN unit in all the polylactosamine acceptors. It
is noteworthy that while the reactivities of the LN units at the non-reducing ends of the
polylactosamine acceptors were significantly lower than that of free LN, the reactivity of the
LNB unit (Galβ1-3GlcNAc) in LNBβ1-3LNβ1-3Galβ1-OMe was essentially the same as that
of free LNB. As was the case with the smaller acceptors, α2,3-sialylated acceptors reacted better
than corresponding neutral ones.
Figure 4. The site-specificity of Fuc-TV on polylactosamine acceptors. The bars and the values
above them represent the relative reactivities of the individual acceptor sites as compared to that
of free LN (1.0). The site-specificity analyses were carried out by treating the fucosyltransferase
reaction products with β-N-acetylhexosaminidase and β-galactosidase, and analyzing the di-
gests by paper chromatography as described in sections 4.3 and 4.4.
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When prefucosylated polylactosamines were used as acceptors, it was noted that the Lewis x
determinant reduces the reactivity of the LN unit adjacent to it on the reducing end side, but
enhances the reactivity of the LN unit adjacent to it on the non-reducing end side. In the branched
N-acetyllactosamines Fuc-TV showed a preference towards the β1,3-linked branch.
5.4 The site-specificity of Fuc-TIX on polylactosamines (II)
The site-specificity of Fuc-TIX was analyzed as described for Fuc-TV above (Figure 5). When
multiple LN units were available, as in LNβ1-3LN and LNβ1-3LNβ1-3LNβ1-3LN, Fuc-
TIX strongly preferred the terminal, non-reducing end site. Interestingly, both LN units of
GlcNAcβ1-3LNβ1-3LN reacted equally well. Sialylation partially reversed the site-specificity
of Fuc-TIX, as demonstrated by the good reactivity of the two most reducing end LN units in
Neu5Acα2-3LNβ1-3LNβ1-3LNβ1-3LN, as compared to the poor reactivity of the two LN
units adjacent to Neu5Ac. Fuc-TIX showed a preference for the β1,3-linked arm over the β1,6-
linked arm of the branched acceptor. The LN unit at the branch point did not react at all.
5.5 Sialylation of GalNAcβ1-3Gal determinants by ST3Gal II (III)
The X2 pentasaccharide (GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc), globo-N-tetraose
(GalNAcβ1-3Galα1-4Galβ1-4Glc) and the disaccharide GalNAcβ1-3Gal were incubated indi-
vidually with CMP-Neu5Ac and ST3Gal II. Purified sialylation products were initially analyzed
by MALDI-TOF mass spectrometry, where they gave peaks at m/z 1200.44, 997.28 and 673.06,
respectively, which were assigned to the [M-H] - of Neu5Ac1HexNAc2Hex3,
Neu5Ac1HexNAc1Hex3 and Neu5Ac1HexNAc1Hex1, respectively.
The sialylation product of GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc was not cleaved by β-
N-acetylhexosaminidase, suggesting a non-reducing end location of the sialic acid. Endo-β-
galactosidase cleaved the sialylated product of GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc
into Neu5Ac1HexNAc1Hex1 and HexNAc1Hex1, as analyzed by mass spectrometry.
Figure 5. The site-specificity of Fuc-TIX on
polylactosamine acceptors. The bars and the val-
ues above them represent the relative reactivities
of the individual acceptor sites as compared to that
of free LN (1.0). The site-specificity analyses were
carried out by treating the fucosyltransferase reac-
tion products with β-N-acetylhexosaminidase and
β-galactosidase, and analyzing the digests by pa-
per chromatography as described in sections 4.3 and
4.4.
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The structures of the sialylated reaction products were analyzed in detail by NMR spectroscopy.
The positions of the glycosidic linkages were identified by the correlations in the HMBC spec-
tra, which were indicative of the structures Neu5Acα2-3GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-
4Glc, Neu5Acα2-3GalNAcβ1-3Galα1-4Galβ1-4Glc and Neu5Acα2-3GalNAcβ1-3Gal.
ST3Gal III was inactive towards GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc.
5.6 The Neu5Acα2-3GalNAc linkage is resistant to Newcastle disease virus and Streptococ-
cus pneumoniae sialidases (III)
Neu5Acα2-3GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc was incubated with different
sialidases in conditions that completely cleaved off the sialic acid from Neu5Acα2-3Galβ1-
4GlcNAcβ1-3Galβ1-4GlcNAc. The reaction products were analyzed by gel filtration chroma-
tography and MALDI-TOF mass spectrometry. Clostridium perfringens and Arthrobacter
ureafaciens sialidases completely desialylated Neu5Acα2-3GalNAcβ1-3Galβ1-4GlcNAcβ1-
3Galβ1-4Glc. By contrast, Newcastle disease virus and Streptococcus pneumoniae sialidases
were able to desialylate only less than 10% of Neu5Acα2-3GalNAcβ1-3Galβ1-4GlcNAcβ1-
3Galβ1-4Glc.
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6. DISCUSSION
6.1 The acceptor- and site-specificity profiles of the α1,3-fucosyltransferases
The α1,3-fucosyltransferases, like many other glycosyltransferases, form a redundant family.
They all catalyze the same reaction, that is the transfer of fucose in α1,3-linkage to the GlcNAc
in Galβ1-4GlcNAc. One reason for the existence of at least six human α1,3-fucosyltransferase
isoenzymes may be the subtle differences in their acceptor specificities.
The differences in the acceptor profiles could reflect the various biological roles of the different
α1,3-fucosyltransferases. For example, the leukocyte fucosyltransferases Fuc-TVII and Fuc-
TIV have complementary acceptor- and site-specificity profiles: Fuc-TVII preferentially reacts
with sialylated LN units at the non-reducing ends of polylactosamines, whereas Fuc-TIV prefer-
entially fucosylates the inner LN units (34). Fuc-TIV and Fuc-TVII collaborate in the generation
of functional selectin ligands (56). They seem to be at least partly specialized in the way that
Fuc-TVII directs the expression of P-selectin binding glycoforms of PSGL-1 and controls the
rolling frequency of leukocytes, whereas Fuc-TIV directs the expression of E-selectin binding
glycoforms of ESL-1 and dictates rolling velocity (54,55).
6.1.1 The acceptor- and site-specificity Fuc-TV (I)
Fuc-TV is known to be quite flexible in its requirements for acceptor structure: it reacts with
both sialylated and non-sialylated type 2 N-acetyllactosamine, and also weakly with type 1 N-
acetyllactosamine and lactose (16). The data presented in paper I further expands the acceptor
repertoire of Fuc-TV by showing that it can react with LacdiNAc (GalNAcβ1-4GlcNAc) nearly
as efficiently as with LN, and also weakly with GlcNAcβ1-4GlcNAc and Manβ1-4GlcNAc.
Fuc-TV strongly preferred the most reducing end LN unit in all the polylactosamine acceptors
tested. This is in accordance with earlier studies showing that Fuc-TV prefers the inner LN unit
in LNβ1-3LNβ1-3LNβ1-R (23), where the reducing end LN unit is probably not available for
fucosylation because of derivatisation. Fuc-TIII and Fuc-TVI similarly fucosylate the inner LN
units of short neutral polylactosamines (23), but their site-specificity on longer and/or sialylated
polylactosamines has not yet been studied.
While the reactivity of the non-reducing end LN unit in LNβ1-3R type structures with Fuc-TV
was significantly lower than that of free LN, the reactivity of LNBβ1-3R was essentially the
same as that of free LNB. These different reactivity patterns suggest that Fuc-TV may have two
distinct adjacent acceptor substrate binding sites, one that preferably binds LN, and another that
preferably binds LNB.
When prefucosylated polylactosamines were used as acceptors for Fuc-TV, it was noted that the
Lewis x determinant enhances the reactivity of the LN unit adjacent to it on the non-reducing
end side. This suggests that Fuc-TV may generate polyfucosylated lactosamines in a stepwise
manner starting from the reducing end.
6.1.2 The acceptor- and site-specificity of Fuc-TIX (II)
Fuc-TIX reacted well with N-acetyllactosamine, Fucα1-2LN, and GalNAcβ1-4GlcNAc con-
firming previous observations (60). Other N-acetyllactosamine analogues that were good accep-
tors to Fuc-TIX were LN sulfated at the 6-position of GlcNAc and chitobiose. Sulfated Lewis x
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structures occur in L-selectin ligand glycoproteins (129), and on keratan sulfate (334,335), where
they form polyfucosylated sequences. Very poor or nonexistent reactivity was observed for lacto-
N-biose, lactose and Neu5Acα2-3LN confirming earlier observations (58,60), and for Fucα1-
2Lac, Galβ1-4LN, and Neu5Acα2-6LN. The inability to use α2,3-sialylated N-
acetyllactosamine as an acceptor is a property shared between Fuc-TIV (29,31) and Fuc-TIX,
whereas none of the fucosyltransferases studied so far can react with α2,6-sialylated N-
acetyllactosamine.
The present experiments confirmed the observation that Fuc-TIX preferentially fucosylates the
non-reducing end LN unit of neutral polylactosamines (23). The modification of this LN unit at
the 3-position of galactose with LN, Neu5Ac or sulphate significantly reduces the reactivity
(23,59,62). However, the addition of a single β1,3-linked GlcNAc residue did not significantly
reduce the reactivity of LN in the experiments described in part II. The high reactivities of
GlcNAcβ1-3LN and GlcNAcβ1-3LNβ1-3LN suggest that the enzyme can specifically recog-
nize these type of structures. Therefore Fuc-TIX may participate in the biosynthesis of internally
fucosylated polylactosamines, if the GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc product serves as
an acceptor for subsequent galactosylation and elongation.
The site-specificity of Fuc-TIX was reversed on sialylated polylactosamines: the two most re-
ducing end LN units of Neu5Acα2-3LNβ1-3LNβ1-3LNβ1-3LN were the most reactive. In
fine detail the site-specificity of Fuc-TIX on sialylated polylactosamines seems to be intermedi-
ate between Fuc-TIV and Fuc-TV. Fuc-TIV prefers middle LN units (34), and Fuc-TV shows a
strong preference towards the most reducing end LN unit as described above, whereas Fuc-TIX
reacts equally well with the two most reducing end LN units. The site-specificities of α1,3-
fucosyltransferases IV, V, VII and IX are summarized in Figure 6.
Fuc-TIX efficiently fucosylated the N- and O-glycan analogues LNβ1-6Manα1-OMe, LNβ1-
2Man, LNβ1-2Manα1-3(LNβ1-2Manα1-6)Manβ1-4GlcNAc and Galβ1-3(LNβ1-6)GalNAc.
LNβ1-6Manα1-OMe was the best of all the studied acceptors for Fuc-TIX. LNβ1-2Man was a
much better acceptor for Fuc-TIX than for Fuc-TV. In addition to being N-glycan branches,
LNβ1-2Man and LNβ1-2(LNβ1-6)Man structures occur in the brain also O-linked to serine or
threonine (246,247,336). α2,3-Sialylated LNβ1-2Manα1-Ser/Thr on dystroglycan is required
for its binding to laminin (246). Disturbances in the synthesis of this structure lead to muscular
dystrophy and neuronal migration disorder (248). Since sialylation and fucosylation of LNβ1-
2Manα1-Ser/Thr seem to be mutually exclusive (246,247,336), it is possible that fucosylation
regulates the binding of dystroglycan to laminin, and therefore cell adhesion. The brain expres-
sion and specificity pattern of Fuc-TIX make it a likely candidate for the synthesis of Lexβ1-
2Manα1-Ser/Thr. The presentation of the Lewis x epitope on mannose-linked O-glycans, as
Figure 6. Comparison of the preferred accep-
tor sites within polylactosamine acceptors for
α1,3-fucosyltransferases IV (34), V (present
study), VII (34) and IX (present study).
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opposed to GalNAc-linked, may be a factor that affects its function and detectability. Fuc-TIX
has been shown to synthesize the spatially and temporally regulated Lewis x epitope in the
developing rat brain (64). However, the detailed structure that carries the epitope has not been
solved.
The capability of Fuc-TV and Fuc-TIX to fucosylate the inner LN units of a polylactosamine
chain suggests that they may have a role in the generation of the sialylated, multiply fucosylated
polylactosamine selectin counterreceptors (133,139). However, further studies are needed to
clarify the contribution of Fuc-TV and Fuc-TIX to the biosynthesis of multiply fucosylated
polylactosamine chains. Mice that lack both Fuc-TIV and Fuc-TVII show some residual neutro-
phil infiltration in experimentally induced inflammation (56). This could be due to E- or P-
selectin ligands generated by Fuc-TIX.
6.2 ST3Gal II is a multifunctional sialyltransferase (III)
The known mammalian α2,3-sialyltransferases, ST3Gal I-VI, transfer sialic acid to the galac-
tose residue in Galβ1-4GlcNAc, Galβ1-3GlcNAc or Galβ1-3GalNAc, and show some promis-
cuity among the three acceptor types, as well as overlapping acceptor specificities with each
other (77,100,101,337). Enzymatic α2,3-sialylation of GalNAc has not been described previ-
ously, although structures containing Neu5Acα2-3GalNAc have been reported (338-340).
ST3Gal II has been shown to act on glycoproteins and glycolipids containing terminal Galβ1-
3GalNAcβ1-OR sequence (85). Results in part III show that ST3Gal II can also sialylate GalNAc
in terminal GalNAcβ1-3Gal determinants in reaction conditions commonly used in enzymatic
in vitro synthesis. This makes it one of the few glycosyltransferases reported to date which are
capable of transferring to different acceptor monosaccharide residues. The clarification of the
actual contribution of ST3Gal II to the biosynthesis of α2,3-sialylated GalNAc determinants
will need further experiments such as comparison of the efficacy of GalNAcβ1-3Gal and Galβ1-
3GalNAc as acceptor determinants, and the analysis of glycoconjugates from transgenic mice
lacking ST3Gal II.
ST3Gal II emerges as yet another glycosyltransferase that challenges the dogma one
glycosyltransferase - one glycosidic linkage. The best known of these is β1,4-galactosyl-
transferase that is induced by α-lactalbumin to transfer to glucose instead of N-acetylglucosamine
(311). Glycosyltransferases that transfer to different monosaccharide residues without requiring
an additional modifier molecule include the β1,3-galactosyltransferase β3GalT-V that transfers
to both the terminal GalNAc of GalNAcβ1-3Galα1-4Galβ1-4Glc and the terminal GlcNAc of
GlcNAcβ1-3Galβ1-4Glc (341), and the core 2/I β1,6-GlcNAc transferase that transfers to the
GalNAc of Galβ1-3GalNAcα1-R and GlcNAcβ1-3GalNAcα1-R, as well as to the Gal of
GlcNAcβ1-3Galβ1-R (342,343). Other examples include α1,3/4-fucosyltransferases III and V
that transfer to the Glc of lactose as well as to the GlcNAc of N-acetyllactosamine, generating
Galβ1-4(Fucα1-3)Glc and Galβ1-4(Fucα1-3)GlcNAc respectively (12,15). Finally, the bovine
colostrum α2,6-sialyltransferase sialylates both the Gal of Galβ1-4GlcNAc-R and the GalNAc
of GalNAcβ1-4GlcNAc-R (344), suggesting an acceptor recognition mechanism similar to that
of ST3Gal II. Fuc-TIII and Fuc-TV are exceptional in their ability to make both Fucα1-3GlcNAc
and Fucα1-4GlcNAc linkages (12,15).
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6.3 Possible significance of α2,3-sialylation of GalNAc (III)
α2,3-sialylation of the X2 structure (GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc) may play a
role in bacteria-host interactions. It has been suggested that the X2 epitope found on intestinal
epithelium is the human receptor for Clostridium difficile toxin A. The X2 structure shares struc-
tural features with Galα1-3Galβ1-4GlcNAc, which is considered to be the receptor for toxin A
in animals, but does not occur in humans (345). The X2 glycosphingolipid binds toxin A, but
α2,3-sialylated X2 does not bind (345). Therefore sialylation of X2-like structures might be a
protective measure against adhesion, and thus internalization and cytotoxic effects of Clostridium
difficile toxin A.
The X2 epitope is an example of molecular mimicry between human glycoconjugates and sac-
charides of pathogenic bacteria, a phenomenon that is proposed to have important roles in bac-
teria-host interactions, for example by camouflaging the bacterial surface from the host (272,346).
The X2 structure occurs in the lipo-oligosaccharide (LOS) of the Neisseria gonorrhoeae strain
F62 (347). Sialylation of lipo-oligosaccharide converts gonococci into serum resistant organ-
ism, reviewed in (273). So far only the sialylation of the LOS structure Galβ1-4GlcNAcβ1-
3Galβ1-4Glc by the neisserial sialyltransferase has been documented (273,348). However, Neis-
seria gonorrhoeae sialyltransferase has been shown to react with a GalNAc monosaccharide
derivative (349). It seems possible that Neisseria gonorrhoeae can sialylate its LOS structure
GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc, as well as Galβ1-4GlcNAcβ1-3Galβ1-4Glc, since
its sialyltransferase shows similar flexibility as the mammalian ST3Gal II described here.
6.4 Resistance towards Newcastle disease virus sialidase is not necessarily indicative of
α2,6-linked Neu5Ac (III)
Newcastle disease virus is widely used in structural analysis of oligosaccharides to differentiate
between α2,3- and α2,6-linked Neu5Ac, because it cleaves Neu5Acα2-3Gal bonds while leav-
ing Neu5Acα2-6Gal and Neu5Acα2-6GalNAc bonds intact (350). However, the data presented
in part III show that the Neu5Acα2-3GalNAc bond is resistant towards Newcastle disease virus
sialidase in conditions that completely cleave Neu5Acα2-3Gal bonds. Resistance towards
Newcastle disease virus sialidase has been used to identify Neu5Ac-GalNAc linkages as α2-6
(351-353). The results presented here show that when the sialic acid is linked to GalNAc, the
sialidase specificities that have been characterized using substrates where the sialic acid is linked
to galactose may not necessarily apply, and the results should be used with caution for structural
analysis. This demonstrates that there are certain pitfalls in the use of glycosidases to character-
ize novel oligosaccharide structures.
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7. SUMMARY
The carbohydrate structures that cover cell surfaces are involved in specific recognition events
in a wide variety of biological phenomena. The structural diversity of glycans is achieved through
the specific substrate requirements and  a well defined order of action of the glycosyltransferases
involved in their biosynthesis. The detailed acceptor specificities of the α1,3-fucosyltransferases
Fuc-TV and Fuc-TIX, and α2,3-sialyltransferase ST3Gal II were examined in the present study.
The acceptor- and site-specificity of α1,3-fucosyltransferase V (Fuc-TV) (I)
α1,3-Fucosyltransferases form the Lewis x epitope (Galβ1-4(Fucα1-3)GlcNAc). Six human α1,3-
fucosyltransferases have been cloned and characterized: Fuc-TIII-VII and Fuc-TIX. Distinct
acceptor specificity patterns are emerging among them. Fuc-TV is known to react with both type
1 (Galβ1-3GlcNAc, LNB) and type 2 (Galβ1-4GlcNAc, LN) lactosamines, although much more
efficiently with the latter. In the present study, Fuc-TV reacted very efficiently with N- and O-
glycan analogues where the acceptor LN unit is carried on the 6-branch, namely LNβ1-6Manα1-
OMe and Galβ1-3(LNβ1-6)GalNAc. Structures where the acceptor LN unit was β1,2- (LNβ1-
2Man), β1,3- (LNβ1-3Galβ1-OMe) or β1,4-linked (LNβ1-4GlcNAc) were much poorer accep-
tors for Fuc-TV, suggesting that structures in which the LN unit is attached to the C6 hydroxyl
fit better to the substrate binding site of Fuc-TV than those where the LN unit is linked to ring
hydroxyl. All sialylated acceptors were more efficiently fucosylated than the corresponding neu-
tral ones. When the site-specificity of Fuc-TV on polylactosamines containing multiple acceptor
sites was studied, it was noticed that Fuc-TV strongly prefers the reducing end LN units. While
the reactivity of the non-reducing end LN unit in LNβ1-3R type structures was significantly
lower than that of free LN, the reactivity of the LNB unit in LNBβ1-3R was essentially the same
as that of free LNB. These different reactivity patterns suggest that Fuc-TV may have two dis-
tinct acceptor substrate binding sites, one that preferably binds LN, and another that preferably
binds LNB.
The acceptor- and site-specificity of α1,3-fucosyltransferase IX (Fuc-TIX) (II)
Fuc-TIX is the most recent member of the α1,3-fucosyltransferase family. In part II of this thesis
the detailed acceptor specificity of Fuc-TIX, and its site-specificity on polylactosamines were
determined. Fuc-TIX reacted efficiently with LN and Fucα1-2LN, GalNAcβ1-4GlcNAc and 6-
sulfated LN, but not with LNB, lactose, Neu5Acα2-3LN or Neu5Acα2-6LN. It was found that
although Fuc-TIX preferentially fucosylates the distal, non-reducing end N-acetyllactosamine
unit of a polylactosamine chain, the addition of a single GlcNAcβ1-3 residue on the distal side
of the reacting unit does not significantly affect reactivity. Furthermore, on sialylated
polylactosamines the site-specificity was reversed: Fuc-TIX preferentially fucosylated the two
most reducing end lactosamine units of Neu5Acα2-3[Galβ1-4GlcNAcβ1-3]4. Therefore it can
be concluded that in addition to forming distal Lewis x epitopes, Fuc-TIX may have a role in the
biosynthesis of internally fucosylated polylactosamines. The emerging acceptor-  and site-speci-
ficity profile of Fuc-TIX is different from those of the other α1,3-fucosyltransferases studied so
far.
α2,3-Sialylation of N-acetylgalactosamine by ST3Gal II (III)
Glycan structures containing α2,3-sialylated GalNAc-residues have been characterized from
human tissues. However, enzymatic α2,3-sialylation of GalNAc has not been described previ-
ously. The known mammalian α2,3-sialyltransferases, ST3Gal I-VI, transfer sialic acid to the
galactose in Galβ1-4GlcNAc, Galβ1-3GlcNAc or Galβ1-3GalNAc, and show some promiscu-
ity among the three acceptor types, as well as overlapping acceptor specificities with each other.
To elucidate the biosynthetic route to the Neu5Acα2-3GalNAc linkage, commercial recombi-
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nant α2,3-sialyltransferases were tested for their ability to sialylate oligosaccharides containing
a terminal GalNAcβ1-3Gal determinant. ST3Gal II efficiently sialylated the X2 pentasaccharide
(GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc), globo-N-tetraose (GalNAcβ1-3Galα1-4Galβ1-
4Glc), and the disaccharide GalNAcβ1-3Gal. ST3Gal II has been thought to be specific for the
Galβ1-3GalNAc determinant. The present results show that ST3Gal II is multifunctional, and
could be renamed ST3Gal(NAc) II.
An understanding of the function, especially the substrate specificity, of glycosyltransferases is
essential for studying the regulation of the biological recognition events mediated by glycans.
The studies described above will help to understand the biosynthetic routes to biologically ac-
tive terminal oligosaccharide epitopes.
43
8. ACKNOWLEDGEMENTS
This study was carried out at the Laboratory of Carbohydrate Chemistry, Institute of Biotechnol-
ogy and Department of Biosciences, University of Helsinki, during 1999-2001, under the super-
vision of Prof. Emer. Ossi Renkonen. I wish to extend my warmest thanks to all the people who
contributed:
Prof. Emer. Ossi Renkonen for letting me work in his laboratory and supervising the work.
Director of the Institute of Biotechnology, Prof. Mart Saarma for providing the facilities, and
especially for giving me the opportunity to finish the thesis at the Institute.
Prof. Ilkka Mononen and Docent Jaakko Parkkinen for reviewing the manuscript.
Olli Aitio for outstanding NMR work.
Drs. John B. Lowe, Hisashi Narimatsu, Shoko Nishihara and Risto Renkonen for collaboration
with the fucosyltransferases. Risto is thanked also for invaluable help in getting the Fuc-TIX
manuscript written and published, and for reading through and giving helpful comments about
the manuscript of this thesis.
All the co-authors who worked on the colossal Fuc-TV project: Maria Pykäri, Jari Natunen,
Ritva Niemelä, Heidi Salminen, Minna Ekström, Pinja Parmanne, Mika Välimäki, Jocelyne
Alais and Claudine Augé.
Docent Jari Helin, Prof. Catherine E. Costello and Dr. Mark McComb for teaching me mass
spectrometry.
All the brilliant people who worked with me in the laboratory of carbohydrate chemistry: Hanna,
Heidi, Jari, Juha, Juho, Leena, Maria, Marjo, Minna, Olli, Pinja, Reko, Ritva, Tanja, and Tero.
What I miss the most is the friendly and enthusiastic atmosphere of the days when the lab was
full of people.
My mother, father and sister for all their love and support.
Jari who has been first my teacher, then my colleague, then my friend, and finally my boyfriend.
He has excelled at all these roles: by teaching me a tiny fragment of his vast knowledge of
glycobiology, by helping me out with all kinds of problems in and out of the lab, by encouraging
me when things were rough, and by loving me unconditionally even at the moments when I was
not that lovable.
The Graduate School of Bioorganic Chemistry, the Academy of Finland, Technology Develop-
ment Center (TEKES), and Emil Aaltonen Foundation for financial support.
Helsinki, May 2002
44
9. REFERENCES
1. Reuter, G., and Gabius, H.-J. (1999) Eukaryotic glycosylation: whim of nature or multipurpose tool Cell.
Mol. Life Sci. 55, 368-422
2. Varki, A., Cummings, R. D., Esko, J., Freeze, H., Hart, G., and Marth, J. D. eds. (1999) Essentials of
glycobiology, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
3. Hart, G. W. (1997) Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins Annu. Rev. Biochem.
66, 315-335
4. Harris, R. J., and Spellman, M. W. (1993) O-Linked fucose and other post-translational modifications
unique to EGF-modules Glycobiology 3, 219-224
5. Endo, M. (1999) O-Mannosyl glycans in mammals Biochim. Biophys. Acta 1473, 237-246
6. Järnefelt, J., Rush, J., Li, Y. T., Laine,  R. A. (1978) Erythroglycan, a high molecular weight glycopeptide
with the repeating structure (galactosyl-(1-4)-2-deoxy-2-acetamido-glucosyl(1-3)) comprising more than
one-third of protein-bound carbohydrate of human erythrocyte stroma J. Biol. Chem. 253, 8006-8009
7. Krusius, T., Finne, J., Rauvala, H. (1978) The poly(glycosyl) chains of glycoproteins. Characterisation of
a novel type of glycoprotein saccharides from human erythrocyte membrane Eur. J. Biochem. 92, 289-300
8. Svennerholm, L. (1963) Chromatographic separation of human brain gangliosides J. Neurochem. 10, 613-
623
9. Wang, Y., Shao, L., Shi, S., Harris, R. J., Spellman, M. W., Stanley, P., and Haltiwanger, R. S. (2001)
Modification of epidermal growth factor-like repeats with O-fucose. Molecular cloning and expression of
a novel GDP-fucose protein O-fucosyltransferase J. Biol. Chem. 276,40338-40345
10. Clarke, J. L., and Watkins, W. M. (1999) Expression of human α-L-fucosyltransferase gene homologs in
monkey kidney COS cells and modification of potential fucosyltransferase acceptor substrates by an en-
dogenous glycosidase Glycobiology 9, 191-202
11. Potvin, B., Kumar, R., Howard, D. R., and Stanley, P. (1990) Transfection of a human α-
(1,3)fucosyltransferase gene into Chinese hamster ovary cells. Complications arise from activation of en-
dogenous α-(1,3)fucosyltransferases J. Biol. Chem. 265, 1615-1622
12. Kukowska-Latallo, J. F., Larsen, R. D., Nair, R. P., and Lowe, J. B. (1990) A cloned human cDNA deter-
mines expression of a mouse stage-specific embryonic antigen and the Lewis blood group α(1,3/
1,4)fucosyltransferase Genes Dev. 4, 1288-1303
13. Mollicone, R., Gibaud, A., Francois, A., Ratcliffe, M., and Oriol, R. (1990) Acceptor specificity and tissue
distribution of three human α-3-fucosyltransferases Eur. J. Biochem. 191, 169-176
14. Chandrasekaran, E. V., Jain, R. K., Larsen, R. D., Wlasichuk, K., DiCioccio, R. A., and Matta, K. L. (1996)
Specificity analysis of three clonal and five non-clonal α1,3-L-fucosyltransferases with sulfated, sialylated,
or fucosylated synthetic carbohydrates as acceptors in relation to the assembly of 3'-sialyl-6'-sulfo Lewis x
(the L-selectin ligand) and related complex structures Biochemistry 35, 8925-8933
15. Weston, B. W., Nair, R. P., Larsen, R. D., and Lowe, J. B. (1992) Isolation of a novel human
α(1,3)fucosyltransferase gene and molecular comparison to the human Lewis blood group α(1,3/
1,4)fucosyltransferase gene. Synthetic, homologous, nonallelic genes encoding enzymes with distinct ac-
ceptor substrate specificities J. Biol. Chem. 267, 4152-4160
16. de Vries, T., Srnka, C. A., Palcic, M. M., Swiedler, S. J., van den Eijnden, D. H., and Macher, B. A. (1995)
Acceptor specificity of different length constructs of human recombinant α1,3/4-fucosyltransferases. Re-
placement of the stem region and the transmembrane domain of fucosyltransferase V by protein A results
in an enzyme with GDP-fucose hydrolyzing activity J. Biol. Chem. 270, 8712-8722
17. Gallet, P. F., Vaujour, H., Petit, J. M., Maftah, A., Oulmouden, A., Oriol, R., Le Narvor, C., Guilloton, M.,
and Julien, R. (1998) Heterologous expression of an engineered truncated form of human Lewis
fucosyltransferase (Fuc-TIII) by the methylotrophic yeast Pichia pastoris Glycobiology 8, 919-925
18. Sousa, V. L., Costa, M. T., Palma, A. S., Enguita, F., and Costa, J. (2001) Localization, purification and
specificity of the full-length membrane-bound form of human recombinant α1,3/4-fucosyltransferase from
BHK-21B cells Biochem. J. 357, 803-810
45
19. Costa, J., Grabenhorst, E., Nimtz, M., and Conradt, H. S. (1997) Stable expression of the Golgi form and
secretory variants of human fucosyltransferase III from BHK-21 cells. Purification and characterization of
an engineered truncated form from the culture medium J. Biol. Chem. 272, 11613-11621
20. Kimura, H., Shinya, N., Nishihara, S., Kaneko, M., Irimura, T., and Narimatsu, H. (1997) Distinct sub-
strate specificities of five human α-1,3-fucosyltransferases for in vivo synthesis of the sialyl Lewis x and
Lewis x epitopes Biochem. Biophys. Res. Commun. 237, 131-137
21. Grabenhorst, E., Nimtz, M., Costa, J., and Conradt, H. S. (1998) In vivo specificity of human α1,3/4-
fucosyltransferases III-VII in the biosynthesis of Lewisx and sialyl Lewisx motifs on complex-type N-
glycans. Coexpression studies from BHK-21 cells together with human β-trace protein J. Biol. Chem. 273,
30985-30994
22. Sueyoshi, S., Tsuboi, S., Sawada-Hirai, R., Dang, U. N., Lowe, J. B., and Fukuda, M. (1994) Expression of
distinct fucosylated oligosaccharides and carbohydrate-mediated adhesion efficiency directed by two dif-
ferent α1,3-fucosyltransferases. Comparison of E- and L-selectin-mediated adhesion J. Biol. Chem. 269,
32342-32350
23. Nishihara, S., Iwasaki, H., Kaneko, M., Tawada, A., Ito, M., and Narimatsu, H. (1999) α1,3-
Fucosyltransferase 9 (FUT9; Fuc-TIX) preferentially fucosylates the distal GlcNAc residue of
polylactosamine chain while the other four α1,3FUT members preferentially fucosylate the inner GlcNAc
residue FEBS Lett. 462, 289-294
24. Cameron, H. S., Szczepaniak, D., and Weston, B. W. (1995) Expression of human chromosome 19p α(1,3)-
fucosyltransferase genes in normal tissues. Alternative splicing, polyadenylation, and isoforms J. Biol.
Chem. 270, 20112-20122
25. Elmgren, A., Mollicone, R., Costache, M., Börjeson, C., Oriol, R., Harrington, J., and Larson, G. (1997)
Significance of individual point mutations, T202C and C314T, in the human Lewis (FUT3) gene for ex-
pression of Lewis antigens by the human α(1,3/1,4)-fucosyltransferase Fuc-TIII J. Biol. Chem. 272, 21994-
21998
26. Mollicone, R., Reguine, I., Kelly, R. J., Fletcher, A., Watt, J., Chatfield, S., Aziz, A., Cameron, H. S.,
Weston, B. W., Lowe, J. B., and Oriol, R. (1994) Molecular basis for Lewis α(1,3/1,4)-fucosyltransferase
gene deficiency (FUT3) found in Lewis negative Indonesian pedigrees J. Biol. Chem. 269, 20987-20994
27. Ellison, R. C., Zhang, Y., Myers, R. H., Swanson, J. L., Higgins, M., and Eckfeldt, J. (1999) Lewis blood
group phenotype as an independent risk factor for coronary heart disease (the NHLBI family heart study)
sup Am. J. Cardiol. 83, 345-348
28. Hein, H. O., Sorensen, H., Suadicani, P., and Gyntelberg, F. (1992) The Lewis blood group - a new genetic
marker of ischaemic heart disease J. Intern. Med. 232, 481-487
29. Goelz, S. E., Hession, C., Goff, D., Griffiths, B., Tizard, R., Newman, B., Chi-Rosso, G., and Lobb, R.
(1990) ELFT: A gene that directs the expression of an ELAM-1 ligand Cell 63, 1349-1356
30.  Kumar, R., Potvin, B., Muller, W. A., and Stanley, P. (1991) Cloning of a human α(1,3)-fucosyltransferase
gene that encodes ELFT but does not confer ELAM-1 recognition on Chinese hamster ovary cell transfectants
J. Biol. Chem. 266, 21777-21783
31. Lowe, J. B., Kukowska-Latallo, J. F., Nair, R. P., Larsen, R. D., Marks, R. M., Macher, B. A., Kelly, R. J.,
and Ernst, L. K. (1991) Molecular cloning of a human fucosyltransferase gene that determines expression
of the Lewis x and VIM-2 epitopes but not ELAM-1-dependent cell adhesion J. Biol. Chem. 266, 17467-
17477
32. Sherwood, A. L., and Holmes, E. H. (1999) Analysis of the expression and enzymatic properties of α1-
3fucosyltransferase from human lung carcinoma NCI-H69 and PC9 cells Glycobiology 9, 637-643
33. Clarke, J. L., and Watkins, W. M. (1996) α1,3-L-fucosyltransferase expression in developing human my-
eloid cells. Antigenic, enzymatic, and mRNA analyses J. Biol. Chem. 271, 10317-10328
34. Niemelä, R., Natunen, J., Majuri, M. L., Maaheimo, H., Helin, J., Lowe, J. B., Renkonen, O., and Renkonen,
R. (1998) Complementary acceptor and site specificities of Fuc-TIV and Fuc-TVII allow effective biosyn-
thesis of sialyl-triLex and related polylactosamines present on glycoprotein counterreceptors of selectins J.
Biol. Chem. 273, 4021-4026
35. Weston, B. W., Smith, P. L., Kelly, R. J., and Lowe, J. B. (1992) Molecular cloning of a fourth member of
a human α(1,3)fucosyltransferase gene family. Multiple homologous sequences that determine expression
of the Lewis x, sialyl Lewis x, and difucosyl sialyl Lewis x epitopes J. Biol. Chem. 267, 24575-24584
46
36. de Vries, T., Palcic, M. P., Schoenmakers, P. S., van den Eijnden, D. H., and Joziasse, D. H. (1997) Accep-
tor specificity of GDP-Fuc:Galβ1->4GlcNAc-R α3-fucosyltransferase VI (FucT VI) expressed in insect
cells as soluble, secreted enzyme Glycobiology 7, 921-927
37. Natunen, J., Aitio, O., Helin, J., Maaheimo, H., Niemelä, R., Heikkinen, S., and Renkonen, O. (2001)
Human α3-fucosyltransferases convert chitin oligosaccharides to products containing a GlcNAcβ1-4(Fucα1-
3)GlcNAcβ1-4R determinant at the nonreducing terminus Glycobiology 11, 209-216
38. Koszdin, K. L., and Bowen, B. R. (1992) The cloning and expression of a human α-1,3fucosyltransferase
capable of forming the E-selectin ligand Biochem. Biophys. Res. Commun. 187, 152-157
39. Brinkman-Van der Linden, E. C. M., Mollicone, R., Oriol, R., Larson, G., Van den Eijnden, D. H., and Van
Dijk, W. (1996) A missense mutation in the FUT6 gene results in total absence of α3-fucosylation of
human α1-acid glycoprotein J. Biol. Chem. 271, 14492-14495
40. Mollicone, R., Reguine, I., Fletcher, A., Aziz, A., Rustam, M., Weston, B. W., Kelly, R. J., Lowe, J. B., and
Oriol, R. (1994) Molecular basis for plasma α(1,3)-fucosyltransferase gene deficiency (FUT6) J. Biol.
Chem. 269, 12662-12671
41. Schnyder-Candrian, S., Borsig, L., Moser, R., and Berger, E. G. (2000) Localization of α1,3-
fucosyltransferase VI in Weibel-Palade bodies of human endothelial cells Proc. Natl. Acad. Sci. USA 97,
8369-8374
42. McCurley, R. S., Recinos, A., Olsen, A. S., Gingrich, J. C., Szczepaniak, D., Cameron, H. S., Krauss, R.,
and Weston, B. W. (1994) Physical maps of human α(1,3)fucosyltransferase genes FUT3-FUT6 on chro-
mosomes 19p13.3 and 11q21 Genomics 26, 142-146
43. Oulmouden, A., Wierinckx, A., Petit, J. M., Costache, M., Palcic, M. M., Mollicone, R., Oriol, R., and
Julien, R. (1997) Molecular cloning and expression of a bovine α(1,3)-fucosyltransferase gene homolo-
gous to a putative ancestor gene of the human FUT3-FUT5-FUT6 cluster J. Biol. Chem. 272, 8764-8773
44. Dupuy, F., Petit, J. M., Mollicone, R., Oriol, R., Julien, R., and Maftah, A. (1999) A single amino acid in
the hypervariable stem domain of vertebrate α1,3/1,4-fucosyltransferases determines the type 1/type 2
transfer. Characterization of acceptor substrate specificity of the Lewis enzyme by site-directed mutagen-
esis J. Biol. Chem. 274, 12257-12262
45. Legault, D. J., Kelly, R. J., Natsuka, Y., and Lowe, J. B. (1995) Human α(1,3/1,4)-fucosyltransferases
discriminate between different oligosaccharide acceptor substrates through a discrete peptide fragment J.
Biol. Chem. 270, 20987-20996
46. Nguyen, A. T., Holmes, E. H., Whitaker, J. M., Ho, S., Shetterly, S., and Macher, B. A. (1998) Human
α1,3/4-fucosyltransferases. I. Identification of amino acids involved in acceptor substrate binding by site-
directed mutagenesis J. Biol. Chem. 273, 25244-25249
47. Vo, L., Lee, S., Marcinko, M. C., Holmes, E. H., and Macher, B. A. (1998) Human α1,3/4-fucosyltransferases.
II. A single amino acid at the COOH terminus of FucT III and V alters their kinetic properties J. Biol.
Chem. 273, 25250-25255
48. Xu, Z., Vo, L., and Macher, B. A. (1996) Structure-function analysis of human α1,3-fucosyltransferase.
Amino acids involved in acceptor substrate specificity J. Biol. Chem. 271, 8818-8823
49. Natsuka, S., Gersten, K. M., Zenita, K., Kannagi, R., and Lowe, J. B. (1994) Molecular cloning of a cDNA
encoding a novel human leukocyte α-1,3-fucosyltransferase capable of synthesizing the sialyl Lewis x
determinant J. Biol. Chem. 269, 16789-16794
50. Sasaki, K., Kurata, K., Funayama, K., Nagata, M., Watanabe, E., Ohta, S., Hanai, N., and Nishi, T. (1994)
Expression cloning of a novel α1,3-fucosyltransferase that is involved in biosynthesis of the sialyl Lewis x
carbohydrate determinants in leukocytes J. Biol. Chem. 269, 14730-14737
51. Britten, C. J., van den Eijnden, D. H., McDowell, W., Kelly, V. A., Witham, S. J., Edbrooke, M. R., Bird,
M. I., de Vries, T., and Smithers, N. (1998) Acceptor specificity of the human leukocyte α3 fucosyltransferase:
role of FucT-VII in the generation of selectin ligands Glycobiology 8, 321-327
52. Maly, P., Thall, A. D., Petryniak, B., Rogers, C. E., Smith, P. L., Marks, R. M., Kelly, R. J., Gersten, K. M.,
Cheng, G., Saunders, T. L., Camper, S. A., Camphausen, R. T., Sullivan, F. X., Isogai, Y., Hindsgaul, O.,
von Andrian, U. H., and Lowe, J. B. (1996) The α(1,3)fucosyltrans-ferase Fuc-TVII controls leukocyte
trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis Cell 86, 643-653
53. Stroud, M. R., and Holmes, E. H. (1997) Fucosylation of complex glycosphingolipids by recombinant
fucosyltransferase-VII Biochem. Biophys. Res. Commun. 238, 165-168
47
54. Huang, M. C., Zöllner, O., Moll, T., Maly, P., Thall, A. D., Lowe, J. B., and Vestweber, D. (2000) P-selectin
Glycoprotein Ligand-1 and E-selectin Ligand-1 are differentially modified by fucosyltransferases Fuc-
TIV and Fuc-TVII in mouse neutrophils J. Biol. Chem. 275, 31353-31360
55. Weninger, W., Ulfman, L. H., Cheng, G., Souchkova, N., Quackenbush, E. J., Lowe, J. B., and von Andrian,
U. H. (2000) Specialized contributions by α(1,3)-fucosyltransferase-IV and FucT-VII during leukocyte
rolling in dermal microvessels Immunity 12, 665-676
56.  Homeister, J. W., Thall, A. D., Petryniak, B., Maly, P., Rogers, C. E., Smith, P. L., Kelly, R. J., Gersten, K.
M., Askari, S. W., Cheng, G., Smithson, G., Marks, R. M., Misra, A. K., Hindsgaul, O., von Andrian, U.
H., and Lowe, J. B. (2001) The α(1,3)fucosyltransferases FucT-IV and FucT-VII exert collaborative con-
trol over selectin-dependent leukocyte recruitment and lymphocyte homing Immunity 15, 115-126
57. Bengtson, P., Larson, C., Lundblad, A., Larson, G., and Påhlsson, P. (2001) Identification of a missense
mutation (G329A; Arg110-Gln) in the human FUT7 gene J. Biol. Chem. 276, 31575-31582
58. Kaneko, M., Kudo, T., Iwasaki, H., Ikehara, Y., Nishihara, S., Nakagawa, S., Sasaki, K., Shiina, T., Inoko,
H., Saitou, N., and Narimatsu, H. (1999) α1,3-Fucosyltransferase IX (Fuc-TIX) is very highly conserved
between human and mouse; molecular cloning, characterization and tissue specific distribution of human
Fuc-TIX FEBS Lett. 452, 237-242
59. Ikeda, N., Eguchi, H., Nishihara, S., Narimatsu, H., Kannagi, R., Irimura, T., Ohta, M., Matsuda, H.,
Taniguchi, N., and Honke, K. (2001) A remodelling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x
epitopes J. Biol. Chem. 276, 38588-38594
60. Cailleau-Thomas, A., Coullin, P., Candelier, J. J., Balanzino, L., Mennesson, B., Oriol, R., and Mollicone,
R. (2000) FUT4 and FUT9 genes are expressed early in human embryogenesis Glycobiology 10, 789-802
61. Baboval, T., Henion, T., Kinally, E., and Smith, F. I. (2000) Molecular cloning of rat α1,3-fucosyltransferase
IX (Fuc-TIX) and comparison of the expression of Fuc-TIV and Fuc-TIX genes during rat postnatal cer-
ebellum development J. Neurosci. Res. 62, 206-215
62. Kudo, T., Ikehara, Y., Togayachi, A., Kaneko, M., Hiraga, T., Sasaki, K., and Narimatsu, H. (1998) Ex-
pression cloning and characterization of a novel murine α1,3-fucosyltransferase, mFuc-TIX, that synthe-
sizes the Lewis x (CD15) epitope in brain and kidney J. Biol. Chem. 273, 26729-26738
63. Patnaik, S. K., Zhang, A., Shi, S., and Stanley, P. (2000) α(1,3)Fucosyltransferases expressed by the gain-
of-function Chinese hamster ovary glycosylation mutants LEC12, LEC29, and LEC30 Arch. Biochem.
Biophys. 375, 322-332
64. Shimoda, Y., Tajima, Y., Osanai, T., Katsume, A., Kohara, M., Kudo, T., Narimatsu, H., Takashima, N.,
Ishii, Y., Nakamura, S., Osumi, N., and Sanai, Y. (2002) Pax6 controls the expression of Lewis x epitope in
the embryonic forebrain by regulating α1,3-fucosyltransferase IX expression J. Biol. Chem. 277, 2033-
2039
65. Osanai, T., Chai, W., Tajima, Y., Shimoda, Y., Sanai, Y., and Yuen, C.-T. (2001) Expression of glycoconjugates
bearing the Lewis x epitope during neural differentiation of P19 EC cells FEBS Lett. 488, 23-28
66. Nakayama, F., Nishihara, S., Iwasaki, H., Kudo, T., Okubo, R., Kaneko, M., Nakamura, M., Karube, M.,
Sasaki, K., and Narimatsu, H. (2001) CD15 expression in mature granulocytes is determined by α1,3-
fucosyltransferase IX but in promyelocytes and monocytes by α1,3-fucosyltransferase IV J. Biol. Chem.
276, 16100-16106
67. Larsen, R. D., Ernst, L. K., Nair, R. P., and Lowe, J. B. (1990) Molecular cloning, sequence, and expres-
sion of a human GDP-L-fucose:β-D-galactoside 2-α-L-fucosyltransferase cDNA that can form the H blood
group antigen Proc. Natl. Acad. Sci. USA 87, 6674-6678
68. Kelly, R. J., Rouquier, S., Giorgi, D., Lennon, G. G., and Lowe, J. B. (1995) Sequence and expression of a
candidate for the human Secretor blood group α(1,2)fucosyltransferase gene (FUT2). Homozygosity for
an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype J. Biol.
Chem. 270, 4640-4649
69. Yanagidani, S., Uozumi, N., Ihara, Y., Miyoshi, E., Yamaguchi, N., and Taniguchi, N. (1997) Purification
and cDNA cloning of GDP-L-Fuc:N-acetyl-β-D-glucosaminide:α1-6 fucosyltransferase (α1-6 FucT) from
human gastric cancer MKN45 cells J. Biochem. 121, 626-632
48
70. Costache, M., Apoil, P. A., Cailleau, A., Elmgren, A., Larson, G., Henry, S., Blancher, A., Iordachescu, D.,
Oriol, R., and Mollicone, R. (1997) Evolution of fucosyltransferase genes in vertebrates J. Biol. Chem.
272, 29721-29728
71. Oriol, R., Mollicone, R., Cailleau, A., Balanzino, L., and Breton, C. (1999) Divergent evolution of
fucosyltransferase genes from vertebrates, invertebrates, and bacteria Glycobiology 9, 323-334
72. Datta, A. K., and Paulson, J. C. (1995) The sialyltransferase sialylmotif participates in binding the donor
substrate CMP-NeuAc J. Biol. Chem. 270, 1497-1500
73. Datta, A. K., Chammas, R., and Paulson, J. C. (2001) Conserved cysteines in the sialyltransferase sialylmotifs
form an essential disulfide bond J. Biol. Chem. 276, 15200-15207
74. Tsuji, S., Datta, A. K., and Paulson, J. C. (1996) Systematic nomenclature for sialyltransferases Glycobiology
6, v-vii
75. Chang, M. L., Eddy, R. L., Shows, T. B., and Lau, J. T. Y. (1995) Three genes that encode human β-
galactoside α2,3-sialyltransferases. Structural analysis and chromosomal mapping studies Glycobiology 5,
319-325
76. Kitagawa, H., and Paulson, J. C. (1994) Differential expression of five sialyltransferase genes in human
tissues J. Biol. Chem. 269, 17872-17878
77. Kitagawa, H., and Paulson, J. C. (1994) Cloning of a novel α2,3-sialyltransferase that sialylates glyco-
protein and glycolipid carbohydrate groups J. Biol. Chem. 269, 1394-1401
78. Kojima, N., Lee, Y. C., Hamamoto, T., Kurosawa, N., and Tsuji, S. (1994) Kinetic properties and acceptor
substrate preferences of two kinds of Galβ1,3GalNAc α2,3-sialyltransferases from mouse brain Biochem-
istry 33, 5772-5776
79. Burchell, J., Poulsom, R., Hanby, A., Whitehouse, C., Cooper, L., Clausen, H., Miles, D., and Taylor-
Papadimitriou, J. (1999) An α2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas
Glycobiology 9, 1307-1311
80. Dalziel, M., Whitehouse, C., McFarlane, I., Brockhausen, I., Gschmeissner, S., Schwientek, T., Clausen,
H., Burchell, J. M., and Taylor-Papadimitriou, J. (2001) The relative activities of the C2GnT1 and ST3Gal-
I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1
J. Biol. Chem. 276, 11007-11015
81. Priatel, J. J., Chui, D., Hiraoka, N., Simmons, C. J. T., Richardson, K. B., Page, D. M., Fukuda, M., Varki,
N. M., and Marth, J. D. (2000) The ST3Gal-I sialyltransferase controls CD8+ T lymphocyte homeostasis
by modulating O-glycan biosynthesis Immunity 12, 273-283
82. Piller, F., Piller, V., Fox, R. I., and Fukuda, M. (1988) Human T-lymphocyte activation is associated with
changes in O-glycan biosynthesis J. Biol. Chem. 263, 15146-15150
83. Giordanengo, V., Bannwarth, S., Laffont, C., Van Miegem, V., Harduin-Lepers, A., Delannoy, P., and
Lefebre, J. C. (1997) Cloning and expression of cDNA for a human Gal(β1-3)GalNAc α2,3-sialyltransferase
from the CEM T-cell line Eur. J. Biochem. 247, 558-566
84. Kim, Y.-J., Kim, K.-S., Kim, H.-S., Kim, C.-H., Ko, J. H., Choe, I.-S., Tsuji, S., and Lee, Y.-C. (1996)
Molecular cloning and expression of human Galβ1,3GalNAc α2,3-sialyltransferase (hST3Gal II) Biochem.
Biophys. Res. Commun. 228, 324-327
85. Lee, Y. C., Kojima, N., Wada, E., Kurosawa, N., Nakaoka, T., Hamamoto, T., and Tsuji, S. (1994) Cloning
and expression of cDNA for a new type of Galβ1,3GalNAc α2,3-sialyltransferase J. Biol. Chem. 269,
10028-10033
86. Chen, N., Soloway, P., and Lau, J. T. Y. (1998) Functional analysis of ST3Gal-2 by targeted mutagenesis
Glycobiology 8, A23
87. Kitagawa, H., and Paulson, J. C. (1993) Cloning and expression of human Galβ1,3(4)GlcNAc α2,3-
sialyltransferase Biochem. Biophys. Res. Commun. 194, 375-382
88. Chandrasekaran, E. V., Jain, R. K., Larsen, R. D., Wlasichuk, K., and Matta, K. L. (1995) Selectin ligands
and tumor-associated carbohydrate structures: specificities of α2,3-sialyltransferases in the assembly of 3'-
sialyl-6-sulfo/sialyl Lewis a and x, 3'-sialyl-6'-sulfo Lewis x and 3'-sialyl-6-sialyl/sulfo blood group T-
hapten Biochemistry 34, 2925-2936
49
89. Yeh, J. C. and Cummings, R. D. (1997) Differential recognition of glycoprotein acceptors by terminal
glycosyltransferases Glycobiology 7, 241-251
90. Damián-Matsumura, P., Zaga, V., Maldonado, A., Sánches-Hernándes, C., Timossi, C., and Ulloa-Aguirre,
A. (1999) Oestrogens regulate pituitary α2,3-sialyltransferase messenger ribonucleic acid levels in the
female rat J. Mol. Endocrinol. 23, 153-165
91. Burger, P. C., Lötscher, M., Streiff, M., Kleene, R., Kaissling, B., and Berger, E. G. (1998)
Immonocytochemical localization of α2,3(N)-sialyltransferase (ST3Gal III) in cell lines and rat kidney
tissue sections: evidence for Golgi and post-Golgi localization Glycobiology 8, 245-257
92. Sasaki, K., Watanabe, E., Kawashima, K., Sekine, S., Dohi, T., Oshima, M., Hanai, N., Nishi, T., and
Hasegawa, M. (1993) Expression cloning of a novel Galβ(1-3/1-4)GlcNAc α2,3-sialyltransferase using
lectin resistance selection J. Biol. Chem. 268, 22782-22787
93. Taniguchi, A., Hasegawa, Y., Higai, K., and Matsumoto, K. (1999) Down-regulation of human
Galβ1,3GalNAc/Galβ1,4GlcNAc α2,3-sialyltransferase (hST3Gal IV) gene during differentiation of the
HL-60 cell line Mol. Cell Biol. Res. Commun. 2, 197-201
94. Taniguchi, A., and Matsumoto, K. (1999) Epithelial-cell-specific transcriptional regulation of human
Galβ1,4GlcNAc α2,3-sialyltransferase (hST3Gal IV) gene Biochem. Biophys. Res. Commun. 257, 516-
522
95. Blander, J. M., Visintin, I., Janeway, C. A., and Medzhitov, R. (1999) α(1,3)-Fucosyltransferase VII and
α(2,3)-sialyltransferase IV are up-regulated in activated CD4 T-cells and maintained after their differen-
tiation into Th1 and migration into inflammatory sites J. Immunol. 163, 3746-3752
96. Okabe, A., Tawara, Y., Masa, T., Oka, T., Machida, A., Tanaka, T., Matsuhashi, H., Shiosaka, S., and Kato,
K. (2001) Differential expression of mRNAs for sialyltransferase isoenzymes induced in the hippocampus
of mouse following kindled seizures J. Neurochem. 77, 1185-1197
97. Ellies, L. G., Ditto, D., Varki, N., Page, D., Le, D., and Marth, J. D. (1999) The ST3Gal-IV sialyltransferase
function in hematopoiesis and hemostasis in vivo Glycobiology 9, 1099
98. Ishii, K., Ohta, M., Watanabe, Y., Matsuda, K., Ishiyama, K., Sakoe, K., Nakamura, M., Inokuchi, J. I.,
Sanai, Y., and Saito, M. (1998) Expression cloning and functional characterization of human cDNA for
ganglioside GM3 synthase J. Biol. Chem. 273, 31652-31655
99. Stern, C. A., and Tiemeyer, M. (2001) A ganglioside-specific sialyltransferase localizes to axons and non-
Golgi structures in neurons J. Neurosci. 21, 1434-1443
100. Okajima, T., Fukumoto, S., Miyazaki, H., Ishida, H., Kiso, M., Furukawa, K., Urano, T., and Furukawa, K.
(1999) Molecular cloning of a novel α2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine
structures on glycoproteins and glycolipids J. Biol. Chem. 274, 11479-11486
101. Fukumoto, S., Miyazaki, H., Goto, G., Urano, T., Furukawa, K., and Furukawa, K. (1999) Expression
cloning of mouse cDNA of CMP-NeuAc:lactosylceramide α2,3-sialyltransferase, an enzyme that initiates
the synthesis of gangliosides J. Biol. Chem. 274, 9271-9276
102. Grundman, U., Nerlich, C., Rein, T., and Zettlmeissl, G. (1990) Complete cDNA sequence encoding hu-
man β-galactoside α2,6-sialyltransferase Nucleic acids Res. 18, 667
103. Weinstein, J., Lee, E. U., McEntee, K., Lai, P.-H., and Paulson, J. C. (1987) Primary structure of β-galac-
toside α2,6-sialyltransferas. Conversion of membrane-bound enzyme to soluble forms by cleavage of the
NH2-terminal signal anchor J. Biol. Chem. 262, 17735-17743
104. Ikehara, Y., Kojima, N., Kurosawa, N., Kudo, T., Kono, M., Nishihara, S., Issiki, S., Morozumi, K., Itzkowitz,
S., Tsuda, T., Nishimura, S. I., Tsuji, S., and Narimatsu, H. (1999) Cloning and expression of a human gene
encoding an N-acetylgalactosamine-α2,6-sialyltransferase (ST6GalNAc I): a candicate for synthesis of
cancer-associated sialyl-Tn antigens Glycobiology 9, 1213-1224
105.  Kono, M., Tsuda, T., Ogata, S., Takashima, S., Liu, H., Hamamoto, T., Itzkowitz, S. H., Nishimura, S. I.,
and Tsuji, S. (2000) Redefined substrate specificity of ST6GalNAc II: A second candidate Sialyl-Tn syn-
thase Biochem. Biophys. Res. Commun. 272, 94-97
106. Kurosawa, N., Hamamoto, T., Lee, Y. C., Nakaoka, T., Kojima, N., and Tsuji, S. (1994) Molecular cloning
and expression of GalNAc α2,6-sialyltransferase J. Biol. Chem. 269, 1402-1409
50
107. Samyn-Petit, B., Krzewinski-Recchi, M. A., Steelant, W. F. A., Delannoy, P., and Harduin-Lepers, A.
(2000) Molecular cloning and functional expression of human ST6GalNAc II. Molecular expression in
various human cultured cells Biochim. Biophys. Acta 1474, 201-211
108. Lee, Y.-C., Kaufmann, M., Kitazume-Kawaguchi, S., Kono, M., Takashima, S., Kurosawa, N., Liu, H.,
Pircher, H., and Tsuji, S. (1999) Molecular cloning and functional expression of two members of mouse
NeuAcα2,3Galβ1,3GalNAc GalNAcα2,6-sialyltransferase family, ST6GalNAc III and IV J. Biol. Chem.
274, 11958-11967
109. Sjoberg, E. R., Kitagawa, H., Glushka, J., van Halbeek, H., and Paulson, J. C. (1996) Molecular cloning of
a developmentally regulated N-acetylgalactosamine α2,6-sialyltransferase specific for sialylated
glycoconjugates J. Biol. Chem. 271, 7450-7459
110. Harduin-Lepers, A., Stokes, D. C., Steelant, W. F. A., Samyn-Petit, B., Krzewinski-Recchi, M. A., Vallejo-
Ruiz, V., Zanetta, J. P., Augé, C., and Delannoy, P. (2000) Cloning, expression and gene organization of a
human Neu5Acα2-3Galβ1-3GalNAc α2,6-sialyltransferase: hST6GalNAc IV Biochem. J. 352, 37-48
111. Ikehara, Y., Shimizu, N., Kono, M., Nishihara, S., Nakanishi, H., Kitamura, T., Narimatsu, H., Tsuji, S.,
and Tatematsu, M. (1999) A novel glycosyltransferase with a polyglutamine repeat; a new candidate for
GD1α synthase (ST6GalNAc V) FEBS Lett. 463, 92-96
112. Okajima, T., Fukumoto, S., Ito, H., Kiso, M., Hirabayashi, Y., Urano, T., Furukawa, K., and Furukawa, K.
(1999) Molecular cloning of brain-specific GD1α synthase (ST6GalNAc V) containing CAG/glutamine
repeats J. Biol. Chem. 274, 30557-30562
113. Okajima, T., Chen, H. H., Ito, H., Kiso, M., Tai, T., Furukawa, K., Urano, T., and Furukawa, K. (2000)
Molecular cloning and expression of mouse GD1α/GTaα/GQ1bα synthase (ST6GalNAc VI) gene J. Biol.
Chem. 275, 6717-6723
114. Haraguchi, M., Yamashiro, S., Yamamoto, A., Furukawa, K., Takamiya, K., Lloyd, K. O., Shiku, H., and
Furukawa, K. (1994) Isolation of G
D3
 synthase gene by expression cloning of G
M3
 α-2,8-sialyltransferase
cDNA using anti-GD2 monoclonal antibody Proc. Natl. Acad. Sci. USA 91, 10455-10459
115. Nara, K., Watanabe, Y., Maruyama, K., Kasahara, K., Nagai, Y., and Sanai, Y. (1994) Expression cloning
of a CMP-NeuAc:NeuAcα2-3Galβ1-4Glcβ1-1Cer α2,8-sialyltransferase (GD3 synthase) from human
melanoma cells Proc. Natl. Acad. Sci. USA 91, 7952-7956
116. Sasaki, K., Kurata, K., Kojima, N., Kurosawa, N., Ohta, S., Hanai, N., Tsuji, S., and Nishi, T. (1994)
Expression cloning of GM3-specific α-2,8-sialyltransferase (GD3 synthase) J. Biol. Chem. 269, 15950-15956
117. Nakayama, J., Fukuda, M. N., Fredette, B., Ranscht, B., and Fukuda, M. (1995) Expression cloning of a
human polysialyltransferase that forms the polysialylated neural cell adhesion molecule present in embry-
onic brain Proc. Natl. Acad. Sci. USA 92, 7031-7035
118. Scheidegger, E. P., Sternberg, L. R., Roth, J., and Lowe, J. B. (1995) A human STX cDNA confers polysialic
acid expression in mammalian cells J. Biol. Chem. 270, 22685-22688
119. Lee, Y.-C., Kim, Y.-J., Lee, K.-Y., Kim, K.-S., Kim, B.-U., Kim, H.-N., Kim, C.-H., and Do, S.-I. (1998)
Cloning and expression of cDNA for a human Siaα2,3Galβ1,4GlcNA:α2,8-sialyltransferase (hST8Sia III)
Arch. Biochem. Biophys. 360, 41-46
120. Kim, Y.-J., Kim, K.-S., Do, S.-I., Kim, C.-H., Kim, S.-K., and Lee, Y.-C. (1997) Molecular cloning and
expression of human α2,8-sialyltransferase (hST8Sia V) Biochem. Biophys. Res. Commun. 235, 327-330
121. Lubke, T., Marquardt, T., Etzioni, A., Hartmann, E., von Figura, K., and Körner, C. (2001) Complementa-
tion cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose
transporter deficiency Nat. Genet. 28, 73-76
122. Etzioni, A., Frydman, M., Pollack, S., Avidor, I., Phillips, M. L., Paulson, J. C., and Gershoni-Baruch, R.
(1992) Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency N. Engl.
J. Med. 327, 1789-1792
123. Frydman, M., Etzioni, A., Eidlitz-Markus, T., Avidor, I., Varsano, I., Shechter, Y., Orlin, J. B., and Gershoni-
Baruch, R. (1992) Ramba-Hasharon syndrome of psychomotor retardation, short stature, defective neutro-
phil motility and Bombay phenotype Am. J. Med. Gen. 44, 297-302
124. Marquardt, T., Brune, T., Luhn, K., Zimmer, K.-P., Korner, C., Fabritz, L., van der Werft, N., Vormoor, J.,
Freeze, H. H., Louwen, F., Biermann, B., Harms, E., von Figura, K., Vestweber, D., and Koch, H. G.
(1999) Leukocyte adhesion deficiency II syndrome, a generalized defect in fucose metabolism J. Pediatr.
134, 681-688
51
125. Lasky, L. A. (1995) Selectin-carbohydrate interactions and the initiation of the inflammatory response
Annu. Rev. Biochem. 64, 113-139
126. Vestweber, D., and Blanks, J. E. (1999) Mechanisms that regulate the function of the selectins and their
ligands Physiol. Rev. 79, 181-213
127. Foxall, C., Watson, S. R., Dowbenko, D., Fennie, C., Lasky, L. A., Kiso, M., Hasegawa, A., Asa, D., and
Brandley, B. K. (1992) The three members of the selectin receptor family recognize a common carbohy-
drate epitope, the sialyl Lewis x oligosaccharide J. Cell Biol. 117, 895-902
128. Varki, A. (1997) Selectin ligands: Will the real ones please stand up? J. Clin. Invest. 99, 158-162
129. Hemmerich, S., Leffler, H., and Rosen, S. D. (1995) Structure of the O-glycans in GlyCAM-1, an endothe-
lial-derived ligand for L-selectin J. Biol. Chem. 270, 12035-12047
130. Ellies, L. G., Tsuboi, S., Petryniak, B., Lowe, J. B., Fukuda, M., and Marth, J. D. (1998) Core 2 oligosac-
charide biosynthesis distinguishes between selectin ligands essential for leukocyte homing and inflamma-
tion Immunity 9, 881-890
131. Yeh, J. C., Hiraoka, N., Petryniak, B., Nakayama, J., Ellies, L. G., Rabuka, D., Hindsgaul, O., Marth, J. D.,
Lowe, J. B., and Fukuda, M. (2001) Novel sulfated lymphocyte homing receptors and their control by a
core1 extension β1,3-N-acetylglucosaminyltransferase Cell 105, 957-969
132. Satomaa, T., Renkonen, O., Helin, J., Kirveskari, J., Mäkitie, A., and Renkonen, R. (2002) O-glycans on
human high endothelial CD34 putatively participating in L-selectin recognition Blood 99, 2609-2611
133. Wilkins, P. P., McEver, R. P., and Cummings, R. D. (1996) Structures of the O-glycans on P-selectin
glycoprotein ligand-1 from HL-60 cells J. Biol. Chem. 271, 18732-18742
134. Wilkins, P. P., Moore, K. L., McEver, R. P., and Cummings, R. D. (1995) Tyrosine sulfation of P-selectin
glycoprotein ligand-1 is required for high affinity binding to P-selectin J. Biol. Chem. 270, 22677-22680
135. Leppänen, A., White, S. P., Helin, J., McEver, R. P., and Cummings, R. D. (2000) Binding of
glycosulfopeptides to P-selectin requires stereospecific contributions of individual tyrosine sulfate and
sugar residues J. Biol. Chem. 275, 39569-39578
136. Somers, W. S., Tang, J., Shaw, G. D., and Camphausen, R. T. (2000) Insights into the molecular basis of
leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLex and PSGL-1 Cell
103, 467-479
137. Patel, T. P., Goelz, S. E., Lobb, R. R., and Parekh, R. B. (1994) Isolation and characterization of natural
protein-associated carbohydrate ligands for E-selectin Biochemistry 33, 14815-14824
138. Steegmaier, M., Levinovitz, A., Isenmann, S., Borges, E., Lenter, M., Kocher, H. P., Kleuser, B., and
Vestweber, D. (1995) The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor
Nature 373, 615-620
139. Handa, K., Stroud, M. R., and Hakomori, S.-I. (1997) Sialosyl-fucosyl poly-LacNac without the sialosyl-
Lex epitope as the physiological myeloid cell ligand in E-selectin-dependent adhesion: Studies under static
and dynamic flow conditions Biochemistry 36, 12412-12420
140. Kannagi, R., Fukushi, Y., Tachikawa, T., Noda, A., Shin, S., Shigeta, K., Hiraiwa, N., Fukuda, Y., Inamoto,
T., Hakomori, S.-I., and Imura, H. (1986) Quantitative and qualitative characterization of human cancer-
associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine
Cancer Res. 46, 2619-2626
141. Hakomori, S. I., Nudelman, E., Levery, S. B., and Kannagi, R. (1984) Novel fucolipids accumulating in
human adenocarcinoma  1. Glycolipids with di- or trifucosylated type 2 chain J. Biol. Chem. 259, 4672-
4680
142. Fukushima, K., Hirota, M., Terasaki, P. I., Wakisaka, A., Togashi, A., Chia, D., Suyama, N., Fukushi, Y.,
Nudelman, E., and Hakomori, S.-I. (1984) Characterization of sialosylated Lewisx as a new tumor-associ-
ated antigen Cancer Res. 44, 5279-5285
143. Fukushi, Y., Kannagi, R., Hakomori, S. I., Shepard, T., Kulander, B. G., and Singer, J. W. (1985) Location
and distribution of difucoganglioside (VI3NeuAcV3III3Fuc2nLc6) in normal and tumor tissues definied by
its monoclonal antibody FH6 Cancer Res. 45, 3711-3717
52
144. Abe, K., McKibbin, J. M., and Hakomori, S.-I. (1983) The monoclonal antibody directed to difucosylated
type 2 chain (Fucα1-2Galβ1-4[Fucα1-3]GlcNAc; Y determinant) J. Biol. Chem. 258, 11793-11797
145. Hakomori, S.-I., and Andrews, H. D. (1970) Sphingoglycolipids with Leb activity, and the co-presence of
Lea, Leb-glycolipids in human tumor tissue Biochim. Biophys. Acta 202, 225-228
146. Magnani, J. L., Nilsson, B., Brockhaus, M., Zopf, E., Steplewski, Z., Koprowski, H., and Ginsburg, V.
(1982) A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside
containing sialylated lacto-N-fucopentaose II J. Biol. Chem. 257, 14365-14369
147. Nilsson, O., Månsson, J.-E., Brezicka, T., Holmgren, J., Lindholm, L., Sörenson, S., Yngvason, F., and
Svennerholm, L. (1984) Fucosyl-GM1 - a ganglioside associated with small cell lung carcinomas
Glycoconjugate J. 1, 43-49
148. Kannagi, R., Levery, S. B., Ishigami, F., Hakomori, S. I., Shevinsky, L. H., Knowles, B. B., and Solter, D.
(1983) New globoseries glycosphingolipids in human teratocarcinoma reactive with the monoclonal anti-
body directed to a developmentally regulated antigen, stage-specific embryonic antigen 3 J. Biol. Chem.
258, 8934-8942
149. Aigner, S., Ramos, C. L., Hafezi-Moghadam, A., Lawrence, M. B., Friederichs, J., Altevogt, P., and Ley,
K. (1998) CD24 mediates rolling of breast carcinoma cells on P-selectin FASEB J. 12, 1241-1251
150. Majuri, M.-L., Mattila, P., and Renkonen, R. (1992) Recombinant E-selectin-protein mediates tumor cell
adhesion via sialyl-Lea and sialyl-Lex Biochem. Biophys. Res. Commun. 182, 1376-1382
151. Matsushita, Y., Cleary, K. R., Ota, D. M., Hoff, S. D., and Irimura, T. (1990) Sialyl-dimeric Lewis-X
antigen expressed on mucin-like glycoproteins in colorectal cancer metastases Lab. Invest. 63, 780-791
152. Nakamori, S., Kameyama, M., Imaoka, S., Furukawa, H., Ishikawa, O., Sasaki, Y., Kabuto, T., Iwanaga,
T., Matsushita, Y., and Irimura, T. (1993) Increased expression of sialyl Lewisx antigen correlates with
poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study
Cancer Res. 53, 3632-3637
153. Renkonen, J., Paavonen, T., and Renkonen, R. (1997) Endothelial and epithelial expression of sialyl Lewisx
and sialyl Lewisa in lesions of breast carcinoma Int. J. Cancer 74, 296-300
154. Wassarman, P. M. (1999) Mammalian fertilization: molecular aspects of gamete adhesion, exocytosis and
fusion Cell 96, 175-183
155. Johnston, D. S., Wright, W. W., Shaper, J. H., Hokke, C. H., Van den Eijnden, D. H., and Joziasse, D. H.
(1998) Murine sperm-zona binding, a fucosyl residue is required for a high affinity sperm-binding ligand.
A second site on sperm binds a nonfucosylated, β-galactosyl-capped oligosaccharide J. Biol. Chem. 273,
1888-1895
156. Oehninger, S., Patankar, M., Seppälä, M., and Clark, F. (1998) Involvement of selectin-like carbohydrate
binding specificity in human gamete interaction Andrologia 30, 269-274
157. Muramatsu, T. (1988) Developmentally regulated expression of cell surface carbohydrates during mouse
embryogenesis J. Cell. Biochem. 36, 1-14
158. Solter, D., and Knowles, B. B. (1978) Monoclonal antibody defining a stage-specific mouse embryonic
antigen (SSEA-1) Proc. Natl. Acad. Sci. USA 75, 5565-5569
159. Eggens, I., Fenderson, B., Toyokuni, T., Dean, B., Stroud, M., and Hakomori, S.-I. (1989) Specific interac-
tion between Lex and Lex determinants. A possible basis for cell recognition in preimplantation embryos
and in embryonal carcinoma cells J. Biol. Chem. 264, 9476-9484
160. Fenderson, B. A., Zehavi, U., and Hakomori, S.-I. (1984) A multivalent lacto-N-fucopentaose III-lysyllysine
conjugate decompacts preimplantation mouse embryos, while the free oligosaccharide is ineffective J.
Exp. Med. 160, 1591-1596
161. Allendoerfer, K. L., Durairaj, A., Matthews, G. A., and Patterson, P. H. (1999) Morphological domains of
Lewis-X/FORSE-1 immunolabeling in the embryonic neural tube are due to developmental regulation of
cell surface carbohydrate expression Dev. Biol. 211, 208-219
162. Ashwell, K. W. S., and Mai, J. K. (1997) Developmental expression of the CD15 epitope in the hippocam-
pus of the mouse Cell Tissue Res. 289, 17-23
163. Mai, J. K., Andressen, C., and Ashwell, K. W. S. (1998) Demarcation of prosencephalic regions by CD15-
positive radial glia Eur. J. Neurosci. 10, 746-751
53
164. Sajdel-Sulkowska, E. M. (1998) Immunofluorescent detection of CD15-fucosylated glycoconjugates in
primary cerebellar cultures and their function in glial-neuronal adhesion in the central nervous system Acta
Biochim. Pol. 45, 781-790
165. Götz, M., Wizenmann, A., Reinhardt, S., Lumsden, A., and Price, J. (1996) Selective adhesion of cells
from different telencephalic regions Neuron 16, 551-564
166. Cao, Z., Zhao, Z., Mohan, R., Alroy, J., Stanley, P., and Panjwani, N. (2001) Role of the Lewisx glycan
determinant in corneal epithelial cell adhesion and differentiation J. Biol. Chem. 276, 21714-21723
167. Tuo, X.-H., Itai, S., Nishikata, J., Mori, T., Tanaka, O., and Kannagi, R. (1992) Stage-specific expression
of cancer-associated type 1 and type 2 chain polylactosamine antigens in the developing pancreas of hu-
man embryos Cancer Res. 52, 5744-5751
168. Candelier, J. J., Mollicone, R., Mennesson, B., Bergemer, A.-M., Henry, S., Coullin, P., and Oriol, R.
(1993) α-3-Fucosyltransferases and their glycoconjugate antigen products in the developing human kidney
Lab. Invest. 69, 449-459
169. Miyake, M., Zenita, K., Tanaka, O., Okada, Y., and Kannagi, R. (1988) Stage-specific expression of SSEA-
1-related antigens in the developing lung of human embryos and its relation to the distribution of these
antigens in lung cancers Cancer Res. 48, 7150-7158
170. Marker, P. C., Stephan, J. P., Lee, J., Bald, L., Mather, J. P., and Cunha, G. R. (2001) fucosyltransferase1
and H-type complex carbohydrates modulate epithelial cell proliferation during prostate branching mor-
phogenesis Dev. Biol. 233, 95-108
171. Artavanis-Tsakonas, S., Rand, M. D., and Lake, R. J. (1999) Notch signalling: cell fate control and signal
integration in development Science 284, 770-776
172. Moloney, D. J., Panin, V. M., Johnston, S. H., J., Chen, J., Shao, L., Wilson, R., Wang, Y., Stanley, P.,
Irvine, K. D., Haltiwanger, R. S., and Vogt, T. F. (2000) Fringe is a glycosyltransferase that modifies Notch
Nature 406, 369-375
173. Rabbani, S. A., Mazar, A. P., Bernier, S. M., Haq, M., Bolivar, I., Henkin, J., and Goltzman, D. (1992)
Structural requirements for the growth factor activity of the amino terminal domain of urokinase J. Biol.
Chem. 267, 14151-14156
174. Schiffer, S. G., Foley, S., Kaffashan, A., Hronowski, X., Zichittella, A. E., Yeo, C. Y., Miatkowski, K.,
Adkins, H. B., Damon, B., Whitman, M., Salomon, D., Sanicola, M., and Williams, K. P. (2001) Fucosylation
of Cripto is required for its ability to facilitate nodal signaling J. Biol. Chem. 276, 37769-37778
175. Gagneux, P., and Varki, A. (1999) Evolutionary considerations in relating oligosaccharide diversity to
biological function Glycobiology 9, 747-755
176. Ilver, D., Arnqvist, A., Ögren, J., Frick, I.-M., Kersulyte, D., Incecik, E. T., Berg, D. E., Covacci, A.,
Engstrand, L., and Borén, T. (1998) Helicobacter pylori adhesin binding fucosylated histo-blood group
antigens revealed by retagging Science 279, 373-377
177. Herron, M. J., Nelson, C. M., Larson, J., Snapp, K. R., Kansas, G. S., and Goodman, J. L. (2000) Intracel-
lular parasitism by the human granulocytic erlichiosis bacterium through the P-selectin ligand, PSGL-1
Science 288, 1653-1656
178. Newburg, D. S. (1997) Do the binding properties of oligosaccharides in milk protect human infants from
gastrointestinal bacteria? J. Nutr. 127, 980S-948S
179. Nguyen, M., Strubel, N. A., and Bischoff, J. (1993) A role for sialyl Lewis-X/A glycoconjugates in capil-
lary morphogenesis Nature 365, 267-269
180. Koch, A. E., Halloran, M. M., Haskell, C. J., Shah, M. R., and Polverini, P. J. (1995) Angiogenesis medi-
ated by soluble forms of E-selectin and vascular cell adhesion molecule-1 Nature 376, 517-519
181. Ferrara, N. (1995) Leukocyte adhesion: missing link in angiogenesis Nature 376, 467
182. Halloran, M. M., Carley, W. W., Polverini, P. J., Haskell, C. J., Phan, S., Anderson, B. J., Woods, J. M.,
Campbell, P. L., Volin, M. V., Bäcker, A. E., and Koch, A. E. (2000) Ley/H: An endothelial-selective,
cytokine-inducible, angiogenic mediator J. Immunol. 164, 4868-4877
183. Crocker, P. R., Clark, E. A., Filbin, M., Gordon, S., Jones, Y., Kehrl, J. H., Kelm, S., Le Douarin, N.,
Powell, L., Roder, J., Schnaar, R. L., Sgroi, D. C., Stamenkovic, I., Schauer, R., Schachner, M., van den
54
Berg, T. K., van den Merwe, P. A., Watt, S. M., and Varki, A. (1998) Siglecs: a family of sialic-acid binding
lectins Glycobiology 8, v-vi
184. Crocker, P. R., and Varki, A. (2001) Siglecs, sialic acids and innate immunity Trends Immunol. 22, 337-
342
185. Crocker, P. R., Mucklow, S., Bouckson, V., McWilliam, A., Willis, A. C., Gordon, S., Milon, G., Kelm, S.,
and Bradfield, P. (1994) Sialoadhesin, a macrophage sialic acid binding receptor for haemopoietic cells
with 17 immunoglobulin-like domains EMBO J. 13, 4490-4503
186. Erickson, L. D., Tygrett, L. T., Bhatia, S. K., Grabstein, K. H., and Waldschmidt, T. J. (1996) Differential
expression of CD22 (Lyb8) on murine B cells Int. Immunol. 8, 1121-1129
187. Sgroi, D., Varki, A., Braesch-Andersen, S., and Stamenkovic, I. (1993) CD22, a B cell specific immuno-
globulin superfamily member, is a sialic acid-binding lectin J. Biol. Chem. 268, 7011-7018
188. Simmons, D., and Seed, B. (1988) Isolation of a cDNA encoding CD33, a differentiation antigen of my-
eloid progenitor cells J. Immunol. 141, 2797-2800
189. Brinkman-Van der Linden, E. C. M., and Varki, A. (2000) New aspects of Siglec binding specificities,
including the significance of fucosylation and of the sialyl-Tn epitope J. Biol. Chem. 275, 8625-8632
190. Powell, L. D., Jain, R. K., Matta, K. L., Sabesan, S., and Varki, A. (1995) Characterization of
sialyloligosaccharide binding by recombinant soluble and native cell-associated CD22. Evidence for a
minimum structural recognition motif and the potential importance of multisite binding J. Biol. Chem. 270,
7523-7532
191. Schadee-Eestermans, I. L., Hoefsmit, E. C. M., van de Ende, M., Crocker, P. R., and van den Berg, T. K.
(2000) Ultrastructural localisation of sialoadhesin (Siglec-1) on macrophages in rodent lymphoid tissues
Immunobiology 202, 309-325
192. van den Berg, T. K., Brevé, J. J. P., Damoiseaux, J. G. M. C., Döpp, E. A., Kelm, S., Crocker, P. R.,
Dijkstra, C. D., and Kraal, G. (1992) Sialoadhesin on macrophages: its identification as a lymphocyte
adhesion molecule J. Exp. Med. 176, 647-655
193. Tuscano, J., Engel, P., Tedder, T. F., and Kehrl, J. H. (1996) Engagement of the adhesion receptor CD22
triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell
proliferation Blood 87, 4723-4730
194. Nitschke, L., Floyd, H., Ferguson, D. J. P., and Crocker, P. R. (1999) Identification of CD22 ligands on
bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells J.
Exp. Med. 189, 1513-1518
195. OKeefe, T. L., Williams, G. T., Davies, S. L., and Neuberger, M. S. (1996) Hyperresponsive B cells in
CD22-deficient mice Science 274, 798-801
196. Otipoby, K. L., Andersson, K. B., Draves, K. E., Klaus, S. J., Farr, A. G., Kerner, J. D., Perlmutter, R. M.,
Law, C.-L., and Clark, E. A. (1996) CD22 regulates thymus-independent responses and the lifespan of B
cells Nature 384, 634-637
197. Hennet, T., Chui, D., Paulson, J. C., and Marth, J. D. (1998) Immune regulation by the ST6Gal
sialyltransferase Proc. Natl. Acad. Sci. USA 95, 4504-4509
198. Vitale, C., Romagnani, C., Falco, M., Ponte, M., Vitale, M., Moretta, A., Bacigalupo, A., Moretta, L., and
Mingari, M. C. (1999) Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leuke-
mic myeloid cells Proc. Natl. Acad. Sci. USA 96, 15091-15096
199. Ferlazzo, G., Spaggiari, G. M., Semino, C., Melioli, G., and Moretta, L. (2000) Engagement of CD33
surface molecules prevents the generation of dendritic cells from both monocytes and CD34+ myeloid
precursors Eur. J. Immunol. 30, 827-833
200. Sternberger, N. H., Quarles, R. H., Itoyama, Y., and Webster, H. (1979) Myelin-associated glycoprotein
demonstrated immunocytochemically in myelin and myelin-forming cells of developing rat Proc. Natl.
Acad. Sci. USA 76, 1510-1514
201. Trapp, B. D., Andrews, S. B., Cootauco, C., and Quarles, R. (1989) The myelin-associated glycoprotein is
enriched in multivesicular bodies and periaxonal membranes of actively myelinating oligodendrocytes J.
Cell Biol. 109, 2417-2426
55
202. Yang, L. J.-S., Zeller, C. B., Shaper, N. L., Kiso, M., Hasegawa, A., Shapiro, R. E., and Schnaar, R. L.
(1996) Gangliosides are neuronal ligands for myelin-associated glycoprotein Proc. Natl. Acad. Sci. USA
93, 814-818
203. Collins, B. E., Ito, H., Sawada, N., Ishida, H., Kiso, M., and Schnaar, R. L. (1999) Enhanced binding of the
neural Siglecs, myelin-associated glycoprotein and Schwann cell myelin protein, to Chol-1 (α-series) gan-
gliosides and novel sulfated Chol-1 analogs J. Biol. Chem. 274, 37637-37643
204. DeBellard, M. E., Tang, S., Mukhopadhyay, G., Shen, Y. J., and Filbin, M. T. (1996) Myelin-associated
glycoprotein inhibits axonal regeneration from a variety of neurons via interaction with a sialoglycoprotein
Mol. Cell. Neurosci. 7, 89-101
205. Strenge, K., Schauer, R., and Kelm, S. (1999) Binding partners for the myelin-associated glycoprotein of
N2A neuroblastoma cells FEBS Lett. 444, 59-64
206. Li, C., Tropak, M. B., Gerlai, R., Clapoff, S., Abramow-Newerly, W., Trapp, B., Peterson, A., and Roder,
J. (1994) Myelination in the absence of myelin-associated glycoprotein Nature 369, 747-750
207. Montag, D., Giese, K. P., Bartsch, U., Martini, R., Lang, Y., Blüthmann, H., Karthigasan, J., Kirschner, D.
A., Wintergerst, E. S., Nave, K.-A., Zielasek, J., Toyka, K. V., Lipp, H.-P., and Schachner, M. (1994) Mice
deficient for the myelin-associated glycoprotein show subtle abnormalities in myelin Neuron 13, 229-246
208. Fruttiger, M., Montag, D., Schachner, M., and Martini, R. (1995) Crucial role for the myelin-associated
glycoprotein in the maintenance of axon-myelin integrity Eur. J. Neurosci. 7, 511-515
209. Mukhopadhyay, G., Doherty, P., Walsh, F. S., Crocker, P. R., and Filbin, M. T. (1994) A novel role for
myelin-associated glycoprotein as an inhibitor of axonal regeneration Neuron 13, 757-767
210. Vinson, M., Strijbos, P. J. L. M., Rowles, A., Facci, L., Moore, S. E., Simmons, D. L., and Walsh, F. S.
(2001) Myelin-associated glycoprotein interacts with ganglioside GT1b. A mechanism for neurite out-
growth inhibition J. Biol. Chem. 276, 20280-20285
211. Cornish, A. L., Freeman, S., Forbes, G., Ni, J., Zhang, M., Cepeda, M., Gentz, R., Augustus, M., Carter, K.
C., and Crocker, P. R. (1998) Characterization of Siglec-5, a novel glycoprotein expressed on myeloid cells
related to CD33 Blood 92, 2123-2132
212. Patel, N., Brinkman-Van der Linden, E. C. M., Altmann, S. W., Gish, K., Balasubramanian, S., Timans, J.
C., Peterson, D., Bell, M. P., Bazan, J. F., Varki, A., and Kastelein, R. A. (1999) OB-BP1/Siglec-6. A
leptin- and sialic acid-binding protein of the immunoglobulin superfamily J. Biol. Chem. 274, 22729-
22738
213.  Angata, T., and Varki, A. (2000) Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamily
Glycobiology 10, 431-438
214. Falco, M., Biassoni, R., Bottino, C., Vitale, M., Sivori, S., Augugliaro, R., Moretta, L., and Moretta, A.
(1999) Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family
that functions as an inhibitory receptor in human natural killer cells J. Exp. Med. 190, 793-801
215. Ito, A., Handa, K., Withers, D. A., Satoh, M., and Hakomori, S.-I. (2001) Binding specificity of siglec7 to
disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression FEBS
Lett. 498, 116-120
216. Yamaji, T., Teranishi, T., Alphey, M. S., Crocker, P. R., and Hashimoto, Y. (2002) A small region of the
natural killer cell receptor, Siglec-7, is responsible for its preferred binding to α2,8-disialyl and branched
α2,6-sialyl residues. A comparison with Siglec-9 J. Biol. Chem. 277, 6324-6332
217. Angata, T., and Varki, A. (2000) Cloning, characterization, and phylogenetic analysis of Siglec-9, a new
member of the CD33-related group of Siglecs. Evidence for co-evolution with sialic acid synthesis path-
ways J. Biol. Chem. 275, 22127-22135
218. Floyd, H., Ni, J., Cornish, A. L., Zeng, Z., Liu, D., Carter, K. C., Steel, J., and Crocker, P. R. (2000) Siglec
8. A novel eosinophil-specific member of the immunoglobulin superfamily J. Biol. Chem. 275, 861-866
219. Munday, J., Kerr, S., Ni, J., Cornish, A. L., Zhang, J. Q., Nicoll, G., Floyd, H., Mattei, M. G., Moore, P.,
Liu, D., and Crocker, P. R. (2001) Identification, characterization and leucocyte expression of Siglec-10, a
novel human sialic acid-binding receptor Biochem. J. 355, 489-497
220. Angata, T., Varki, N. M., and Varki, A. (2001) A second uniquely human mutation affecting sialic acid
biology J. Biol. Chem. 276, 40282-40287
56
221. Yu, Z., Lai, C. M., Maoui, M., Banville, D., and Shen, S. H. (2001) Identification and characterization of
S2V, a novel putative Siglec that contains two V set Ig-like domains and recruits protein-tyrosine phos-
phatases SHPs J. Biol. Chem. 276, 23816-23824
222. Hakomori, S.-I. (1990) Bifunctional role of glycosphingolipids. Modulators for transmembrane signaling
and mediators for cellular interactions J. Biol. Chem. 265, 18713-18716
223. Lloyd, K. O., and Furukawa, K. (1998) Biosynthesis and functions of gangliosides: recent advances
Glycoconjugate J. 15, 627-636
224. Hakomori, S.-I. (2002) The glycosynapse Proc. Natl. Acad. Sci. USA 99, 225-232
225. Li, R., Manela, J., Kong, Y., and Ladisch, S. (2000) Cellular gangliosides promote growth factor-induced
proliferation of fibroblasts J. Biol. Chem. 275, 34213-34223
226. Saqr, H. E., Lee, M. C., Burkman, A. M., and Yates, A. J. (1995) Gangliosides have a bimodal effect on
DNA synthesis in U-1242 MG human glioma cells J. Neurosci. Res. 41, 491-500
227. Cannella, M. S., Oderfeld-Nowak, B., Gradkowska, M., Skup, M., Garofalo, L., Cuello, A. C., and Ledeen,
R. W. (1990) Derivatives of ganglioside GM1 as neuronotrophic agents: comparison of in vivo and in vitro
effects Brain Research 513, 286-294
228. Facci, L., Leon, A., Toffano, G., Sonnino, S., Ghidoni, R., and Tettamanti, G. (1984) Promotion of
neuritogenesis in mouse neuroblastoma cells by exogenous gangliosides. Relationship between the effect
and the cell association of ganglioside GM1 J. Neurochem. 42, 299-305
229. Sabel, B. A., Slavin, M. D., and Stein, D. G. (1984) Ganglioside treatment facilitates behavioral recovery
from bilateral brain damage Science 225, 340-341
230. Mutoh, T., Tokuda, A., Miyadai, T., Hamaguchi, M., and Fujiki, N. (1995) Ganglioside GM1 binds to the
Trk protein and regulates receptor function Proc. Natl. Acad. Sci. USA 92, 5087-5091
231. Mutoh, T., Tokuda, A., Inokuchi, J., and Kuriyama, M. (1998) Glucosylceramide synthase inhibitor inhib-
its the action of nerve growth factor in PC12 cells J. Biol. Chem. 273, 26001-26007
232. Bremer, E. G., Schlessinger, J., and Hakomori, S.-I. (1986) Ganglioside-mediated modulation of cell growth.
Specific effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor J. Biol. Chem.
261, 2434-2440
233. Weis, F. M. B., and Davis, R. J. (1990) Regulation of epidermal growth factor receptor signal transduction.
Role of gangliosides J. Biol. Chem. 265, 12059-12066
234. Meuillet, E. J., Kroes, R., Yamamoto, H., Warner, T. G., Ferrari, J., Mania-Farnell, B., George, D., Rebbaa,
A., Moskal, J. R., and Bremer, E. G. (1999) Sialidase gene transfection enhances epidermal growth factor
receptor activity in an epidermal carcinoma cell line, A431 Cancer Res. 59, 234-240
235. Hynds, D. L., Summers, M., Van Brocklyn, J., ODorisio, M. S., and Yates, A. J. (1995) Gangliosides
inhibit platelet-derived growth factor-stimulated growth, receptor phosphorylation, and dimerization in
neuroblastoma SH-SY5Y cells J. Neurochem. 65, 2251-2258
236. Zhao, J., Furukawa, K., Fukumoto, S., Okada, M., Furugen, R., Miyazaki, H., Takamiya, K., Aizawa, S.,
Shiku, H., Matsuyama, T., and Furukawa, K. (1999) Attenuation of interleukin 2 signal in the spleen cells
of complex ganglioside-lacking mice J. Biol. Chem. 274, 13744-13747
237. Rusnati, M., Tanghetti, E., Urbinati, C., Tulipano, G., Marchesini, S., Ziche, E., and Presta, M. (1999)
Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and
biological consequences in endothelial cell cultures Mol. Biol. Cell 10, 313-327
238. Nojiri, H., Stroud, M., and Hakomori, S.-I. (1991) A specific type of ganglioside as a modulator of insulin-
dependent cell growth and insulin receptor tyrosine kinase activity. Possible association of ganglioside-
induced inhibition of insulin receptor function and monocytic differentiation induction in HL-60 cells J.
Biol. Chem. 266, 4531-4537
239. Lang, Z., Guerrera, M., Li, R., and Ladisch, S. (2001) Ganglioside GD1a enhances VEGF-induced endot-
helial cell proliferation and migration Biochem. Biophys. Res. Commun. 282, 1031-1037
240. Wu, W., Harley, P. H., Punt, J. A., Sharrow, S. O., and Kearse, K. P. (1996) Identification of CD8 as a
peanut agglutinin (PNA) receptor molecule on immature thymocytes J. Exp. Med. 184, 759-764
57
241. Gillespie, W., Paulson, J. C., Kelm, S., Pang, M., and Baum, L. G. (1993) Regulation of α2,3-sialyltransferase
expression correlates with conversion of peanut agglutinin (PNA)+ to PNA- phenotype in developing thy-
mocytes J. Biol. Chem. 268, 3801-3804
242. Daniels, M. A., Devine, L., Miller, J. D., Moser, J. M., Lukacher, A. E., Altman, J. D., Kavathas, P.,
Hogquist, K. A., and Jameson, S. C. (2001) CD8 binding to MCH class I molecules is influenced by T cell
maturation and glycosylation Immunity 15, 1051-1061
243. Moody, A. M., Chui, D., Reche, P. A., Priatel, J. J., Marth, J. D., and Reinherz, E. L. (2001) Developmen-
tally regulated glycosylation of the CD8αβ coreceptor stalk modulates ligand binding Cell 107, 501-512
244. Galvan, M., Tsuboi, S., Fukuda, M., and Baum, L. G. (2000) Expression of a specific glycosyltransferase
enzyme regulates T cell death mediated by galectin-1 J. Biol. Chem. 275, 16730-16737
245. Perillo, N. L., Uittenbogaart, C. H., Nguyen, J. T., and Baum, L. G. (1997) Galectin-1, an endogeneous
lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes J. Exp. Med. 185, 1851-
1858
246. Chiba, A., Matsumura, K., Yamada, H., Inazu, T., Shimizu, T., Kusunoki, S., Kanazawa, I., Kobata, A., and
Endo, T. (1997) Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve α-dystroglycan.
The role of a novel O-mannosyl-type oligosaccharide in the binding of α-dystroglycan with laminin J.
Biol. Chem. 272, 2156-2162
247. Smalheiser, N. R., Haslam, S. M., Sutton-Smith, M., Morris, H. R., and Dell, A. (1998) Structural analysis
of sequences O-linked to mannose reveals  novel Lewis X structure in cranin (dystroglycan) purified from
sheep brain J. Biol. Chem. 273, 23698-23703
248. Yoshida, A., Kobayashi, K., Manya, H., Taniguchi, K., Kano, H., Mizuno, M., Inazu, T., Mitsuhashi, H.,
Takahashi, S., Takeuchi, M., Herrmann, R., Straub, V., Talim, B., Voit, T., Topaloglu, H., Toda, T., and
Endo, T. (2001) Muscular dystrophy and neuronal migration disorder caused by mutations in a
glycosyltransferase, POMGnT1 Dev. Cell 1, 717-724
249. Eidels, L., Proia, R. L., and Hart, D. A. (1983) Membrane receptors for bacterial toxins Microbiol. Rev. 47,
596-620
250. Karlsson, K. A. (1995) Microbial recognition of target-cell glycoconjugates Curr. Opin. Struct. Biol. 5,
622-635
251. Varki, A. (1997) Sialic acids as ligands in recognition phenomena FASEB J. 11, 248-255
252. Evans, D. G., Evans, D. J., Moulds, J. J., and Graham, D. Y. (1988) N-acetylneuraminyllactose-binding
fibrillar hemagglutinin of Campylobacter pylori: a putative colonization factor antigen Infect. Immun. 56,
2896-2906
253. Johansson, L., and Karlsson, K. A. (1998) Selective binding by Helicobacter pylori of leucocyte ganglio-
sides with 3-linked sialic acid, as identified by a new approach of linkage analysis Glycoconjugate J. 15,
713-721
254. Johansson, L., Johansson, P., and Miller-Podraza, H. (1999) Neu5Acα3Gal is part of the Helicobacter
pylori binding epitope in polyglycosylceramides of human erythrocytes Eur. J. Biochem. 266, 559-565
255. Miller-Podraza, H., Bergström, J., Milh, M. A., and Karlsson, K. A. (1997) Recognition of glycoconjugates
by Helicobacter pylori. Comparison of two sialic acid-dependent specificities based on hemagglutination
and binding to human erythrocyte glycoconjugates Glycoconjugate J. 14, 467-471
256. Roche, N., Larsson, T., Ångström, J., and Teneberg, S. (2001) Helicobacter pylori-binding gangliosides of
human gastric adenocarcinoma Glycobiology 11, 935-944
257. Parkkinen, J., Rogers, G. N., Korhonen, T., Dahr, W., and Finne, J. (1986) Identification of the O-linked
sialyloligosaccharides of glycophorin A as the erythrocyte receptors for S-fimbriated Escherichia coli
Infect. Immun. 54, 37-42
258. Liukkonen, J., Haataja, S., Tikkanen, K., Kelm, S., and Finne, J. (1992) Identification of N-acetylneuraminyl
α2-3 poly-N-acetyllactosamine glycans as the receptors of sialic acid-binding Streptococcus suis strains J.
Biol. Chem. 267, 21105-21111
259. Fakih, M. G., Murphy, T. F., Pattoli, M. A., and Berenson, C. S. (1997) Specific binding of Haemophilus
influenzae to minor gangliosides of human respiratory epithelial cells Infect. Immun. 65, 1695-1700
58
260. Loomes, L. M., Uemura, K., Childs, R. A., Paulson, J. C., Rogers, G. N., Scudder, P. R., Michalski, J. C.,
Hounsell, E. F., Taylor-Robinson, D., and Feizi, T. (1984) Erythrocyte receptors for Mycoplasma pneumoniae
are sialylated oligosaccharides of Ii antigen type Nature 307, 560-563
261. Ångström, J., Teneberg, S., and Karlsson, K. A. (1994) Delineation and comparison of ganglioside-bind-
ing epitopes for the toxins of Vibrio cholerae, Escherichia coli, and Clostridium tetani: Evidence for
overlapping epitopes Proc. Natl. Acad. Sci. USA 91, 11859-11863
262. Nishiki, T., Tokuyama, Y., Kamata, Y., Nemoto, Y., Yoshida, A., Sato, K., Sekiguchi, M., Takahashi, M.,
and Kozaki, S. (1996) The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin
II associated with gangliosides GT1b/GD1a FEBS Lett. 378, 253-257
263. Brennan, M. J., David, J. L., Kenimer, J. G., and Manclark, C. R. (1988) Lectin-like binding of pertussis
toxin to a 165-kilodalton Chinese hamster ovary cell glycoprotein J. Biol. Chem. 263, 4895-4899
264. Stein, P. E., Boodhoo, A., Armstrong, G. D., Heerze, L. D., Cockle, S. A., Klein, M. H., and Read, R. J.
(1994) Structure of pertussis toxin-sugar complex as a model for receptor binding Nat. Struct. Biol. 1, 591-
596
265. Connor, R. J., Kawaoka, Y., Webster, R. G., and Paulson, J. C. (1994) Receptor specificity in human, avian
and equine H2 and H3 influenza virus isolates Virology 205, 17-23
266. Rogers, G. N., and Paulson, J. C. (1983) Receptor determinants of human and animal influenza virus
isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin Virology
127, 361-373
267. Ha, Y., Stevens, D. J., Skehel, J. J., and Wiley, D. C. (2001) X-ray structures of H5 avian and H9 swine
influenza virus hemagglutinins bound to avian and human receptor analogs Proc. Natl. Acad. Sci. USA 98,
11181-11186
268. Miller-Podraza, H., Johansson, L., Johansson, P., Larsson, T., Matrosovich, M., and Karlsson, K. A. (2000)
A strain of human influenza A virus binds to extended but not short gangliosides as assayed by thin-layer
chromatography overlay Glycobiology 10, 975-982
269. Markwell, M. A. K., Svennerholm, L., and Paulson, J. C. (1981) Specific gangliosides function as host cell
receptors for Sendai virus Proc. Natl. Acad. Sci. USA 78, 5406-5410
270. Fried, H., Cahan, L. D., and Paulson, J. C. (1981) Polyoma virus recognizes specific sialyloligosaccharide
receptors on host cells Virology 109, 188-192
271. Liu, C. K., Wei, G., and Atwood, W. J. (1998) Infection of glial cells by human polyomavirus JC is medi-
ated by an N-linked glycoprotein containing terminal α(2-6)-linked sialic acids J. Virol. 72, 4643-4749
272. Finne, J. (1985) Polysialic acid - a glycoprotein involved in neural adhesion and bacterial meningitis
Trends Biochem. Sci. 10, 129-133
273. Smith, H., Parsons, N. J., and Cole, J. A. (1995) Sialylation of neisserial lipopolysaccharide: a major
influence on pathogenicity Microb. Pathog. 19, 365-377
274. Pearlstein, E., Salk, P. L., Yogeeswaran, G., and Karpatkin, S. (1980) Correlation between spontaneous
metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10
metastatic-variant derivatives of a rat renal sarcoma cell line Proc. Natl. Acad. Sci. USA 77, 4336-4339
275. Yogeeswaran, G., and Salk, P. L. (1981) Metastatic potential is positively correlated with cell surface
sialylation of cultured murine tumor cell lines Science 212, 1514-1516
276. Nudelman, E., Hakomori, S.-I., Kannagi, R., Levery, S. B., Yeh, M. Y., Hellström, K. E., and Hellström, I.
(1982) Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal
antibody, 4.2 J. Biol. Chem. 257, 12752-12756
277. Berra, B., Gaini, S. M., and Riboni, L. (1985) Correlation between ganglioside distribution and histologi-
cal grading of human astrocytomas Int. J. Cancer 36, 363-366
278. Ravindranath, M. H., Tsuchida, T., Morton, D. L., and Irie, R. F. (1991) Ganglioside GM3:GD3 ratio as an
index for the management of melanoma Cancer 67, 3029-3035
279. Zeng, G., Gao, L., Birklé, S., and Yu, R. K. (2000) Suppression of ganglioside GD3 expression in a rat F-
11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production
Cancer Res. 60, 6670-6676
59
280. Zeng, G., Gao, L., and Yu, R. K. (2000) Reduced cell migration, tumor growth and experimental metastasis
of rat F-11 cells whose expression of CD3-synthase is suppressed Int. J. Cancer 88, 53-57
281. Watanabe, T., Pukel, C. S., Takeyama, H., Lloyd, K. O., Shiku, H., Li, L. T. C., Travassos, L. R., Oettgen,
H. F., and Old, L. J. (1982) Human melanoma antigen AH is an autoantigenic ganglioside related to GD2 J.
Exp. Med. 156, 1884-1889
282. Hamilton, W. B., Helling, F., Lloyd, K. O., and Livingston, P. O. (1993) Ganglioside expression on human
malignant melanoma assessed by quantitative immune thin-layer chromatography Int. J. Cancer 53, 566-
573
283. Tai, T., Paulson, J. C., Cahan, L. D., and Irie, R. F. (1983) Ganglioside GM3 as a human tumor antigen
(OFA-I-1) Proc. Natl. Acad. Sci. USA 80, 5392-5396
284. Fukuda, M. N., Bothner, B., Lloyd, K. O., Rettig, W. J., Tiller, P. R., and Dell, A. (1986) Structures of
glycosphingolipids isolated from human embryonal carcinoma cells. The presence of mono- and disialosyl
glycolipids with blood group type 1 sequence J. Biol. Chem. 261, 5145-5153
285. Fukushi, Y., Nudelman, E., Levery, S. B., Higuchi, T., and Hakomori, S.-I. (1986) A novel disialoganglioside
(IV3NeuAcIII6NeuAcLc4) of human adenocarcinoma and the monoclonal antibody (FH9) defining this
disialosyl structure Biochemistry 25, 2859-2866
286. Ito, A., Levery, S. B., Saito, S., Satoh, M., and Hakomori, S.-I. (2001) A novel ganglioside isolated from
renal cell carcinoma J. Biol. Chem. 276, 16695-16703
287. Ladisch, S., Gillard, B., Wong, C., and Ulsh, L. (1983) Shedding and immunoregulatory activity of YAC-
1 lymphoma cell gangliosides Cancer Res. 43, 3808-3813
288. Portoukalian, J., David, M. J., Gain, P., and Richard, M. (1993) Shedding of GD2 ganglioside in patients
with retinoblastoma Int. J. Cancer 53, 948-951
289. Hachida, M., Uwabe, K., Nonoyama, M., Imamaki, M., Nemoto, S., Hoshi, H., Katsumata, T., Endo, M.,
and Koyanagi, H. (1993) The significant immunosuppressive effect of ganglioside GM3 in heart transplan-
tation Transplantation 56, 479-482
290. Ladisch, S., Hasegawa, A., Li, R., and Kiso, M. (1995) Immunosuppressive activity of chemically synthe-
sized gangliosides Biochemistry 34, 1197-1202
291. Li, R., Villacreses, N., and Ladisch, S. (1995) Human tumor gangliosides inhibit murine immune responses
in vivo Cancer Res. 55, 211-214
292. Lloyd, K. O., Burchell, J., Kudryashov, V., Yin, B. W. T., and Taylor-Papadimitriou, J. (1996) Comparison
of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carci-
noma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells J. Biol. Chem. 271,
33325-33334
293. Itzkowitz, S. H., Yuan, M., Montgomery, C. K., Kjeldsen, T., Takahashi, H. K., Bigbee, W. L., and Kim, Y.
S. (1989) Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer Cancer Res. 49, 197-204
294. Terasawa, K., Furumoto, H., Kamada, M., and Aono, T. (1996) Expression of Tn and sialyl-Tn antigens in
the neoplastic transformation of uterine cervical epithelial cells Cancer Res. 56, 2229-2232
295. Brockhausen, I. (1999) Pathways of O-glycan biosynthesis in cancer cells Biochim. Biophys. Acta 1473,
67-95
296. Takamatsu, K., Auerbach, B., Gerardy-Schahn, R., Eckhardt, M., Jaques, G., and Madry, N. (1994) Char-
acterization of tumor-associated neural cell adhesion molecule in human serum Cancer Res. 54, 2598-
2603
297. Tanaka, F., Otake, Y., Nakagawa, T., Kawano, Y., Miyahara, R., Li, M., Yanagihara, K., Nakayama, J.,
Fujimoto, I., Ikenaka, K., and Wada, H. (2000) Expression of polysialic acid and STX, a human
polysialyltransferase, is correlated with tumor progression in non-small cell lung cancer Cancer Res.  60,
3072-3080
298. Malykh, Y. N., Schauer, R., and Shaw, L. (2001) N-Glycolylneuraminic acid in human tumours Biochimie
83, 623-634
299. Rutishauser, U. (1996) Polysialic acid and the regulation of cell interactions Curr. Opin. Cell Biol. 8, 679-
684
60
300. Zuber, C., Lackie, P. M., Catterall, W. A., and Roth, J. (1992) Polysialic acid is associated with sodium
channels and the neural cell adhesion molecule N-CAM in adult rat brain J. Biol. Chem. 267, 9965-9971
301. Close, B. E., and Colley, K. J. (1998) In vivo autopolysialylation and localization of the polysialyltransferases
PST and STX J. Biol. Chem. 273, 34586-34593
302. Nadanaka, S., Sato, C., Kitajima, K., Katagiri, K., Irie, S., and Yamagata, T. (2001) Occurrence of oligosialic
acids on integrin α5 subunit and their involvement in cell adhesion to fibronectin. J. Biol. Chem. 276,
33657-33664
303. Varki, A. (1992) Diversity in the sialic acids Glycobiology 2, 25-40
304. Irie, A., Koyama, S., Kozutsumi, Y., Kawasaki, T., and Suzuki, A. (1998) The molecular basis for the
absence of N-glycolylneuraminic acid in humans J. Biol. Chem. 273, 15866-15871
305. Cheresh, D. A., Varki, A. P., Varki, N. M., Stallcup, W. B., Levine, J., and Reisfeld, R. A. (1984) A
monoclonal antibody recognizes an O-acetylated sialic acid in a human melanoma-associated ganglioside
J. Biol. Chem. 259, 7453-7459
306. Toba, S., Tenno, M., and Kurosaka, A. (2000) An O-acetylated sialyl-Tn is involved in ovarian cancer-
associated antigenicity Biochem. Biophys. Res. Commun. 271, 281-286
307. Herrler, G., and Klenk, H. D. (1987) The surface receptor is a major determinant of the cell tropism of
influenza C virus Virology 159, 102-108
308. Higa, H. H., Rogers, G. N., and Paulson, J. C. (1985) Influenza virus hemagglutins differentiate between
receptor determinants bearing N-acetyl-, N-glycolyl- and N,O-diacetylneuraminic acids Virology 144, 279-
282
309. Shi, W. X., Chammas, R., Varki, N. M., Powell, L., and Varki, A. (1996) Sialic acid 9-O-acetylation on
murine erythroleukemia cells affects complement activation, binding to I-type lectins, and tissue homing J.
Biol. Chem. 271, 31526-31532
310. Sjoberg, E. R., Powell, L. D., Klein, A., and Varki, A. (1994) Natural ligands of the B cell adhesion
molecule CD22β can be masked by 9-O-acetylation of sialic acids J. Cell Biol. 126, 549-562
311. Brew, K., Vanaman, T. C., and Hill, R. L. (1968) The role of α-lactalbumin and the A protein in lactose
synthetase: A unique mechanism for the control of a biological reaction Proc. Natl. Acad. Sci. USA 59,
491-497
312. Palcic, M. M., and Hindsgaul, O. (1991) Flexibility in the donor substrate specificity of β1,4-
galactosyltransferase: application in the synthesis of complex carbohydrates Glycobiology 1, 205-209
313. Leppänen, A., Salminen, H., Zhu, Y., Maaheimo, H., Helin, J., Costello, C. E., and Renkonen, O. (1997) In
vitro biosynthesis of a decasaccharide prototype of multiply branched polylactosaminoglycan backbones
Biochemistry 36, 7026-7036
314. Maaheimo, H., Renkonen, R., Turunen, J. P., Penttilä, L., and Renkonen, O. (1995) Synthesis of a divalent
sialyl Lewis x O-glycan, a potent inhibitor of lymphocyte-endothelium adhesion. Evidence that multivalency
enhances the saccharide binding to L-selectin Eur. J. Biochem. 234, 616-625
315. Renkonen, O., Helin, J., Vainio, A., Niemelä, R., Penttilä, L., and Hilden, P. (1990) Escherichia coli β-
galactosidase unexpectedly cleaves the hexasaccharide Galβ1-4GlcNAcβ1-3(Galβ1-4GlcNAcβ1-6)Galβ1-
4GlcNAc without branch specificity Biochem. Cell Biol. 68, 1032-1036
316. Niemelä, R., Räbinä, J., Leppänen, A., Maaheimo, H., Costello, C. E., and Renkonen, O. (1995) Site-
directed enzymatic α−(1,3)-L-fucosylation of the tetrasaccharide Galβ(1-4)GlcNAcβ(1-3)Galβ(1-4)GlcNAc
at the distal N-acetyllactosamine unit Carbohydr. Res. 279, 331-338
317. Niemelä, R., Natunen, J., Penttilä, L., Salminen, H., Helin, J., Maaheimo, H., Costello, C. E., and Renkonen,
O. (1999) Isolation and characterization of linear polylactosamines containing one and two site-specifi-
cally positioned Lewis x determinants: WGA agarose chromatography in fractionation of mixtures gener-
ated by random, partial enzymatic α3-fucosylation of pure polylactosamines Glycobiology 9, 517-526
318. Räbinä, J., Natunen, J., Niemelä, R., Salminen, H., Ilves, K., Aitio, O., Maaheimo, H., Helin, J., and
Renkonen, O. (1998) Enzymatic synthesis of site-specifically (α1-3)-fucosylated polylactosamines con-
taining either a sialyl Lewis x, a VIM-2, or a sialylated and internally difucosylated sequence Carbohydr.
Res. 305, 491-499
61
319. Alais, J., and Veyrières, A. (1990) Syntheses of linear tetra-, hexa-, and octa-saccharide fragments of the i-
blood group active poly-(N-acetyl-lactosamine) series. Blockwise methods for the synthesis of repetitive
oligosaccharide sequences Carbohydr. Res. 207, 11-31
320. Takeya, A., Hosomi, O., Shimoda, N., and Yazawa, S. (1992) Biosynthesis of the blood group P antigen-
like GalNAcβ1-3Galβ1-4GlcNAc/Glc structure. A novel N-acetylgalactosaminyltransferase in human blood
plasma J. Biochem. 112, 389-395
321. Yates, A. D., and Watkins, W. M. (1983) Enzymes involved in the biosynthesis of glycoconjugates. A
UDP-2-acetamido-2-deoxy-D-glucose: β-D-galactopyranosyl-(1-4)-saccharide (1-3)-2-acetamido-2-deoxy-
β-D-glucopyranosyltransferase in human serum Carbohydr. Res. 120, 251-268
322. Niemelä, R., Natunen, J., Brotherus, E., Saarikangas, A., and Renkonen, O. (1995) α1,3-Fucosylation of
branched blood group I-type oligo-(N-acetyllactosamino)glycans by human milk transferases is restricted
to distal N-acetyllactosamine units: The resulting isomers are separated by WGA-agarose chromatography
Glycoconjugate J. 12, 36-44
323. Natunen, J., Seppo, A., Helin, J., Reinhold, B. B., Räbinä, J., Costello, C. E., and Renkonen, O. (1997)
Enzymatic transfer of a β1,6-linked N-acetylglucosamine to the α-galactose of globo-N-tetraose: in vitro
synthesis of a novel hybrid pentasaccharide of lacto-globo type Glycobiology 7, 711-718
324. Renkonen, O., Penttilä, L., Niemelä, R., and Leppänen, A. (1991) Single mid-chain GlcNAcβ1-6Galβ1-
4R sequences of linear oligosaccharides are resistant to endo-β-galactosidase of Bacteroides fragilis
Glycoconjugate J. 8, 376-380
325. Seppo, A., Turunen, J. P., Penttilä, L., Keane, A., Renkonen, O., and Renkonen, R. (1996) Synthesis of a
tetravalent sialyl Lewis x glycan, a high-affinity inhibitor of L-selectin-mediated lymphocyte binding to
endothelium Glycobiology 6, 65-71
326. Renkonen, O., Penttilä, L., Makkonen, A., Niemelä, R., Leppänen, A., Helin, J., and Vainio, A. (1989) The
linear tetrasaccharide, Galβ1-4GlcNAcβ1-6Galβ1-4GlcNAc, isolated from radiolabeled teratocarcinoma
poly-N-acetyllactosaminoglycan resists the action of E. freundii endo-β-galactosidase Glycoconjugate J.
6, 129-140
327. Hård, K., van Zadelhoff, G., Moonen, P., Kamerling, J. P., and Vliegenthart, J. F. G. (1992) The Asn-linked
carbohydrate chains of human Tamm-Horsfall Glycoprotein of one male. Novel sulfated and novel N-
acetylgalactosamine-containing N-linked carbohydrate chains. Eur. J. Biochem. 209, 895-915
328. Maaheimo, H., Räbinä, J., and Renkonen, O. (1997) 1H and 13C NMR analysis of the pentasaccharide
Galβ(1-4)GlcNAcβ(1-3)[GlcNAcβ(1-6)]Galβ(1-4)GlcNAc synthesized by the mid-chain β-(1-6)-D-N-
acetylglucosaminyltransferase of rat serum Carbohydr. Res. 297, 145-151
329. Davis, A. L., Keeler, J., Laue, E. D., and Moskau, D. (1992) Experiments for recording pure-absorption
heteronuclear correlation spectra using pulsed field gradients J. Magn. Reson. 98, 207-216
330. Bax, A., and Summers, M. F. (1986) 1H and 13C assignments from sensitivity-enhanced detection of
heteronuclear multiple-bond connectivity by 2D multiple quantum NMR J. Am. Chem. Soc. 108, 2093-
2094
331. Hurd, R. E., and John, B. K. (1991) Gradient-enhanced proton-detected heteronuclear multiple-quantum
cohorence spectroscopy J. Magn. Reson. 91, 648-653
332. Nyman, T. A., Kalkkinen, N., Tölö, H., and Helin, J. (1998) Structural characterization of N-linked and O-
linked oligosaccharides derived from interferon-α2b and interferon-α14c produced by Sendai-virus in-
duced human peripheral blood leukocytes Eur. J. Biochem. 253, 485-493
333. Papac, D. I., Wong, A., and Jones, A. J. S. (1996) Analysis of acidic oligosaccharides and glycopeptides by
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry Anal. Chem. 68, 3215-3223
334. Brown, G. M., Huckerby, T. N., Morris, H. G., Abram, B. L., and Nieduszynski, I. A. (1994) Oligosaccha-
rides derived from bovine articular cartilage keratan sulfates after keratanase II digestion: Implications for
keratan sulfate structural fingerprinting Biochemistry 33, 4836-4846
335. Tai, G. H., Huckerby, T. N., and Nieduszynski, I. A. (1993) N.m.r. spectroscopic studies of fucose-contain-
ing oligosaccharides derived from keratanase digestion of articular cartilage keratan sulfates. Influence of
fucose residues on keratanase cleavage Biochem. J. 291, 889-894
336. Chai, W., Yuen, C.-T., Kogelberg, H., Carruthers, R. A., Margolis, R. U., Feizi, T., and Lawson, A. M.
(1999) High prevalence of 2-mono and 2,6-di-substituted Manol-terminating sequences among O-glycans
released from brain glycopeptides by reductive alkaline hydrolysis Eur. J. Biochem. 263, 879-888
62
337. Kono, M., Ohyama, Y., Lee, Y.-C., Hamamoto, T., Kojima, N., and Tsuji, S. (1997) Mouse β-galactoside
α2,3-sialyltransferases: comparison of in vitro substrate specificities and tissue specific expression
Glycobiology 7, 469-479
338. Kundu, S. K., Harati, Y., and Misra, L. K. (1984) Sialosylglobotetraosylceramide: a marker for amyotropic
lateral sclerosis Biochem. Biophys. Res. Commun. 118, 82-89
339. Schwarting, G. A., Carroll, P. G., and DeWolf, W. C. (1983) Fucosyl-globoside and sialosyl-globoside are
new glycolipids isolated from human teratocarcinoma cells Biochem. Biophys. Res. Commun. 112, 935-
940
340. Thorn, J. J., Levery, S. B., Salyan, M. E. K., Stroud, M. R., Cedergren, B., Nilsson, B., Hakomori, S.-I., and
Clausen, H. (1992) Structural characterization of x2 glycosphingolipid, its extended form, and its sialosyl
derivatives: accumulation associated with the rare blood group p phenotype Biochemistry 31, 6509-6517
341. Zhou, D., Henion, T. R., Jungalwala, F. B., Berger, E. G., and Hennet, T. (2000) The β1,3-
galactosyltransferase β3GalT-V is a stage-specific embryonic antigen-3 (SSEA-3) synthase J. Biol. Chem.
275, 22631-22634
342. Schwientek, T., Nomoto, M., Levery, S. B., Merkx, G., van Kessel, A. G., Bennett, E. P., Hollingsworth,
M. A., and Clausen, H. (1999) Control of O-glycan branch formation. Molecular cloning of human cDNA
encoding a novel β1,6-N-acetylglucosaminyltransferase forming core 2 and core 4 J. Biol. Chem. 274,
4504-4512
343. Yeh, J. C., Ong, E., and Fukuda, M. (1999) Molecular cloning and expression of a novel β-1,6-N-
acetylglucosaminyltransferase that forms core 2, core 4, and I branches J. Biol. Chem. 274, 3215-3221
344. Nemansky, M., and van den Eijnden, D. H. (1992) Bovine colostrum CMP-NeuAc:Galβ(1-4)GlcNAc-R
α(2-6)-sialyltransferase is involved in the synthesis of the terminal NeuAcα(2-6)GalNAcβ(1-4)GlcNAc
sequence occuring on N-linked glycans of bovine milk glycoproteins Biochem. J. 287, 311-316
345. Teneberg, S., Lönnroth, I., Torres Lopez, J. F., Galili, U., Ölwegård Halvarsson, M., Ångström, J., and
Karlsson, K. A. (1996) Molecular mimicry in the recognition of glycosphingolipids by
Galα3Galβ4GlcNAcβ-binding Clostridium difficile toxin A, human natural anti α-galactosyl IgG, and the
monoclonal antibody Gal-13: characterization of a binding-active human glycosphingolipid, non-identical
with the animal receptor Glycobiology 6, 599-609
346. Moran, A. P., Prendergast, M. M., and Appelmelk, B. J. (1996) Molecular mimicry of host structures by
bacterial lipopolysaccharides and its contribution to disease FEMS Immunol. Med. Microbiol. 16, 105-115
347. Yamasaki, R., Bacon, B. E., Nasholds, W., Schneider, H., and Griffiss, J. M. (1991) Structural determina-
tion of oligosaccharides derived from lipooligosaccharide of Neisseria gonorrhoeae F62 by chemical,
enzymatic, and two-dimensional NMR methods Biochemistry 30, 10566-10575
348. Gilbert, M., Watson, D. C., Cunningham, A., Jennings, M. P., Young, N. M., and Wakarchuk, W. W. (1996)
Cloning of the lipooligosaccharide α-2,3-sialyltransferase from the bacterial pathogens Neisseria
meningitidis and Neisseria gonorrhoeae J. Biol. Chem. 271, 28271-28276
349. Izumi, M., Shen, G. J., Wacowich-Sgarbi, S., Nakatani, T., Plettenburg, O., and Wong, C. H. (2001) Micro-
bial glycosyltransferases for carbohydrate synthesis: α-2,3-sialyltransferase from Neisseria gonorrheae J.
Am. Chem. Soc. 123, 10909-10918
350. Paulson, J. C., Weinstein, J., Dorland, L., van Halbeek, H., and Vliegenthart, J. F. G. (1982) Newcastle
disease virus contains a linkage specific glycoprotein sialidase. Application to the localization of sialic
acid residues in N-linked oligosaccharides of α1-acid glycoprotein J. Biol. Chem. 257, 12734-12738
351. Ervasti, J. M., Burwell, A. L., and Geissler, A. L. (1997) Tissue-specific heterogeneity in α-dystroglycan
sialoglycosylation. Skeletal muscle α-dystroglycan is a latent receptor for Vicia villosa agglutinin B4 masked
by sialic acid modification J. Biol. Chem. 272, 22315-22321
352. Green, E. D., and Baenziger, J. U. (1988) Asparagine-linked oligosaccharides on lutropin, follitropin, and
thyrotropin. 1. Structural elucidation of the sulfated and sialylated oligosaccharides on bovine, ovine, and
human pituitary glycoprotein hormones J. Biol. Chem. 263, 25-35
353. Manzella, S. M., Dharmesh, S. M., Cohick, C. B., Soares, M. J., and Baenziger, J. U. (1997) Developmen-
tal regulation of a pregnancy-specific oligosaccharide structure, NeuAcα2,6GalNAcβ1,4GlcNAc, on se-
lect members of the rat placental prolactin family J. Biol. Chem. 272, 4775-4782
